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Bone defects caused by trauma, tumor resection or disease present a significant 
clinical problem. Failures in ‘high risk’ fractures and large bone defects have been 
reported to be as high as 30-50%. The drawbacks associated with current bone grafting 
procedures have stimulated the search for improved techniques for bone repair. Tissue 
engineering/regenerative medicine approaches promote tissue repair by providing a 
combination of physical and biological cues through structural scaffolds and bioactive 
agents. Though they have demonstrated significant promise for bone regeneration, very 
little has been translated to clinical practice. 
The goal of this thesis was to investigate the potential of electrospun nanofiber 
mesh scaffolds for bone regeneration. Nanofiber meshes were utilized in a three-pronged 
approach. First, we validated their ability to robustly support osteogenic cell functions, 
including proliferation and matrix mineralization. We also demonstrated their efficacy as 
a cell delivery vehicle. Second, we investigated the effects of modulating nanofiber 
bioactivity and orientation on stem cell programming. Our results indicate that 
functionalization of nanofiber meshes with a collagen-mimetic peptide enhanced the 
migration, proliferation and osteogenic differentiation of cells. Fiber alignment improved 
cell migration along the direction of fiber orientation. Finally, a nanofiber mesh based 
hybrid system for growth factor delivery was developed for bone repair and tested in a 
challenging animal model. The delivery of bone morphogenetic protein (BMP) via this 
system resulted in the functional restoration of limb function, and in fact proved more 
efficacious than the current clinical standard for BMP delivery.  
The studies performed in this thesis have suggested novel techniques for 
improving the repair of clinically challenging bone defects. They indicate that delivery of 
BMP via the hybrid system may reduce the dose and side effects of BMP, thereby 
 xxi
broadening the use of BMP based bone augmentation procedures. Therefore, this 
nanofiber mesh based system has the potential to become the standard of care for 




CHAPTER 1  
SPECIFIC AIMS 
Introduction 
 The treatment of bone defects remains a challenging problem. The well known 
limitations of autografts and allografts have driven efforts to develop alternative 
therapeutic strategies for bone repair. Tissue engineering/regenerative medicine (TE/RM) 
research has focused on developing therapeutic strategies involving the delivery of 
biological agents along with biodegradable scaffolds. Both two- and three-dimensional 
scaffolds have been designed to provide a template for bone regeneration. The focus of 
bone regeneration strategies has been to create three-dimensional scaffolds having 
adequate strength to support in vivo loading. However, such scaffolds usually do not 
provide an optimal environment for cellular function and take a long time to degrade. 
Moreover, exogenous cells delivered in vivo at the center of these scaffolds may not 
survive due to the initial lack of vascularity at the defect. Thin, two-dimensional 
membranes have also been used for bone repair by placing them along the periosteal 
surface on the defect boundary. Though this technique (called guided bone/tissue 
regeneration) has been highly successful in the dental field for bone regeneration, it has 
not been quantitatively evaluated for the case of long bone defects. Over the last decade, 
recombinant human bone morphogenetic protein-2 (rhBMP-2) and rhBMP-7 have been 
approved by the U.S. Food and Drug Administration for spinal fusion, oral-maxillofacial 
applications and the treatment of certain fractures. However, challenges remain due to the 
suboptimal delivery systems, which have resulted in the use of supraphysiologic 
concentrations for generating a substantial healing response. 
 Electrospun nanofiber meshes have recently emerged as a new generation of 
scaffold membranes, possessing a number of features suitable for tissue regeneration. 
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They have fibers in the same size-scale of extracellular matrix (ECM) components and a 
large surface area, which improves cellular attachment, morphology and function. 
Nanofiber meshes can also be modified to add further design elements to enhance cellular 
interaction and elicit specific cellular responses. Due to these unique properties, they may 
therefore prove efficacious as a membrane for bone regeneration by guiding cell 
migration into bone defects and facilitating mineral deposition. In addition, nanofiber 
meshes may be useful for the delivery of osteogenic growth factors. The overall objective 
of this project is to employ electrospun nanofiber meshes for the functional repair of 
large diaphyseal bone defects. Our central hypothesis is that nanofiber meshes are 
effective in directing stem cell proliferation, migration and differentiation in vitro, 
and thereby improve bone regeneration in vivo. To this end, we propose the following 
specific aims: 
Specific Aim I 
Establish techniques for nanofiber mesh fabrication, and characterize stem cell 
colonization and osteogenic differentiation on nanofiber meshes. 
 The objectives of this aim were to develop protocols for nanofiber mesh 
fabrication, and to investigate the ability of nanofiber meshes to support osteogenic cell 
function and delivery. Our working hypothesis was that nanofiber meshes would support 
robust cell colonization and osteogenic differentiation in vitro. To accomplish this aim, 
we first developed techniques for electrospinning nanofiber meshes and nanofiber 
characterization. Next, we investigated the attachment, colonization and osteogenic 
differentiation of human mesenchymal stem cells (hMSCs) and human amniotic fluid 
stem (hAFS) cells on nanofiber meshes. We also compared the behavior of the stem cells 
on nanofiber meshes to that on tissue culture plastic. Finally, the ability of cell-seeded 
nanofiber meshes to serve as a cell delivery vehicle was investigated by studying its 
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effectiveness in colonizing three-dimensional scaffolds in vitro. The outcomes of this 
Aim are discussed in Chapter 3. 
Specific Aim II 
Analyze effects of nanofiber orientation and surface functionalization on stem cell 
infiltration and differentiation and on bone regeneration. 
 The objectives of this aim were to identify conditions that best support progenitor 
cells bridging bone defects and test the optimal design in vivo. Our working hypothesis 
was that presentation of a collagen-mimetic peptide on the nanofiber mesh surface and 
aligning nanofiber orientation will modulate cellular behavior in vitro, and enhance bone 
regeneration in vivo. Nanofiber meshes were coated with a triple-helical, type I collagen-
mimetic peptide, containing the glycine-phenylalanine-hydroxyproline-glycine-
glutamate-arginine (GFOGER) motif, to improve cell adhesion and osteogenic 
differentiation. An oriented topography was obtained by electrospinning aligned 
nanofibers in order to enhance cellular migration. We developed an in vitro model to 
examine hMSC infiltration on nanofiber meshes, and isolated the contribution of cell 
proliferation versus migration. The individual and combined effects of nanofiber 
functionalization and orientation on hMSC function were investigated. In addition, we 
assessed the efficacy of GFOGER coating to improve nanofiber mesh based repair of 
critically-sized segmental bone defects in vivo. The results of this Aim are discussed in 
Chapter 4. 
Specific Aim III 
Evaluate the potential of a nanofiber mesh based protein delivery system to 
functionally repair challenging bone defects. 
 The objectives of this aim were to develop and test a nanofiber mesh based 
system for the delivery of growth factors in vivo. Our working hypothesis was that 
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delivery of an osteoinductive growth factor within a nanofiber mesh/hydrogel system 
would enhance the functional repair of challenging bone defects, compared to hydrogel 
delivery and collagen matrix delivery. We first developed a hybrid protein delivery 
system that utilizes an electrospun nanofiber mesh tube and injectable alginate hydrogel. 
We tested the ability of this system to functionally heal segmental bone defects by the 
delivery of rhBMP-2. The effect of a perforated nanofiber mesh design on bone repair 
was also investigated. The nanofiber mesh/alginate BMP delivery technique was 
compared with the clinical standard of BMP delivery on collagen matrix. Finally, the role 
of the nanofiber mesh tube as a spatial constraint was investigated. The outcomes of this 
Aim are discussed in Chapters 5 and 6. 
Significance 
 Musculoskeletal injuries remain a significant challenge for orthopaedic surgeons. 
Of the approximately 10 million fractures that are reported annually in the US, 5-10% do 
not heal spontaneously and require clinical intervention. Challenging injuries such as 
open tibial fractures and large bone defects have an even higher failure rate, estimated to 
be around 50%. These injuries result in severe pain, limited mobility and psychological 
distress, and therefore significantly impact the patient’s quality of life. Current bone 
grafting procedures are moderately successful in repairing damaged bone, but lead to 
numerous secondary complications. Even BMP based bone augmentation procedures 
have experienced limited acceptance due to the large doses required. Thus, due to the 
limitations of the current procedures, more effective bone repair techniques are urgently 
needed. This work is significant because it has suggested novel approaches to improve 
the repair of clinically challenging bone defects by the employment of electrospun 
nanofiber meshes. We have developed innovative strategies for promoting bone 
regeneration by the delivery of biomolecular stimuli on biodegradable nanofiber meshes. 
In addition to thorough in vitro characterization of cell behavior on nanofiber meshes, we 
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tested their efficacy in vivo in a challenging animal model. Using quantitative tools for 
analyzing bone regeneration, we have demonstrated that a nanofiber mesh based system 
for rhBMP-2 delivery results in the functional repair of critically-sized segmental bone 
defects. In fact, our system proved superior to the current clinical standard of rhBMP-2 
delivery on collagen sponge. This study suggests that nanofiber mesh based techniques 
for bone repair have the potential to advance the clinical treatment of bone defects. As the 
delivery of bioactive factors on biodegradable scaffolds is a central concept in the 
regeneration of injured or diseased tissues, the strategies developed in this study may 
contribute to the treatment of other musculoskeletal defects, such as those in cartilage, 
tendons and ligaments. 
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CHAPTER 2  
LITERATURE REVIEW 
Bone Structure and Function 
Introduction 
 Knowledge of the complex, dynamic structure of bone and an understanding of its 
physiological functions are essential for the treatment of injuries of the musculoskeletal 
system. Bone performs several functions in the human body [1, 2]. Bone serves as a 
reservoir of several essential ions, such as calcium and phosphate. The exchange of these 
ions with the extracellular fluids maintains a tight control of their fluid concentrations, 
which is necessary for critical physiological functions. In addition, trabecular bone and 
marrow cavities are host to the haematopoietic marrow, which supplies the body with 
nutrient-carrying red blood cells, infection-fighting white blood cells, and tissue-forming 
progenitor and stem cells. Finally, as the main constituent of the adult skeletal system, 
bone supports and provides structure to tissues, protects vital organs and provides 
attachment sites for muscles that are essential for body movements. Unlike other 
functions, this mechanical function of bone occurs at a local level, and if lost due to 
injury to the tissue, has to be regained to maintain skeletal continuity. This restoration of 
bone function drives the development of clinical strategies for bone repair.   
Short, flat and long bones 
 Bone can be described in a number of ways, depending on the structural level of 
interest. On the basis of general shape, bones can be classified as short, flat and long [3]. 
Short bones, such as vertebral bodies and tarsals, are approximately the same size in all 
dimensions. On the other hand, cranial bones are examples of flat bones, which are 
shorter along one direction. Long bones, such as the femur and tibia, are cylindrical in 
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shape with wider ends, and are the larger bones in the body. They are described by three 
regions: diaphysis, metaphysis and epiphysis, based on the location with respect to the 
‘physis’ or growth plate [1]. The growth plate is the region near the end of long bones 
from which bone grows during development. The diaphysis (‘between the physis’) is the 
central tubular region of a long bone. The metaphysis (‘next to the physis’) refers to the 
transitional region between the diaphysis and the flared ends. The epiphysis (‘upon the 
physis’) is the portion of long bones beyond the growth plate, towards the ends. 
Cortical and trabecular bone 
 The next hierarchical level of structure, which can be observed from gross 
examinations of bone cross section, divides the bone into cortical (compact) and 
trabecular (cancellous) bone [2]. Cortical bone correspond to dense areas without cavities 
(approximately 10% porosity), while trabecular bone corresponds to spongy areas with 
numerous interconnecting cavities (50-90% porosity) [3]. This difference in structure 
results in cortical bone possessing a much higher compressive strength than trabecular 
bone. In contrast, the high surface area of the trabecular network permits greater 
deformation and energy absorption. The cortical bone is responsible for the supportive 
and protective functions of the skeleton, whereas the trabecular bone represents the 
primary site of bone’s metabolic functions. It should, however, be noted that both cortical 
and trabecular bone have the same microstructure and matrix composition; the 
differences arise due to the distinct arrangement of the microstructure. Mature cortical 
bone consists of a repeating set of concentric layers (lamellae) of tissue called a haversian 
system or osteon (described below). The much less dense trabecular bone is comprised of 
an array of plates and rods connected to form a porous structure. In long bones, the 
epiphysis is composed of trabecular bone in the interior surrounded by a thin layer of 
cortical bone on the outside. On the other hand, the diaphysis is almost exclusively 
composed of compact bone. 
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Bone matrix 
 As mentioned previously, at the ultrastructural level, bone tissue is composed of 
the same bone matrix. The extracellular matrix (ECM) of bone is a composite material 
consisting of an inorganic and an organic component. The inorganic and organic matters 
contribute approximately 65% and 20%, respectively, to the wet weight of bone. The 
remaining weight is accounted by water [3]. The inorganic component of bone is 
comprised of mineral crystals containing mainly calcium and phosphorus. In addition, the 
crystals include sodium and magnesium to a lesser extent. Significant quantities of 
amorphous calcium phosphate are also present in the organic matrix. It was thought that 
the mineral crystals were composed purely of calcium and phosphorus based 
hydroxyapatite (Ca10[PO4]6[OH]2). However, recent studies have shown that they contain 
both carbonate and acid phosphate groups [4, 5]. The organic component consists of 
predominantly of type I collagen, making up approximately 90% of this component. The 
other 10% consists of non-collageneous glycoproteins and bone-specific proteoglycans, 
which includes osteocalcin, osteopontin and bone sialoprotein. These non-collageneous 
proteins are thought to influence the organization and mineralization of the bone matrix. 
Bone matrix also contains growth factors that regulate bone cell function, such as bone 
morphogenetic proteins (BMPs), insulin-like growth factor-1 (IGF-1) and members of the 
transforming growth factor-β (TGF-β) family. The organic matter gives bone its form and 
tensile strength, while the inorganic component provides the compressive strength. 
However, it is the association of the mineral phase with the collagen fibers that is 
responsible for the unique combination of hardness and toughness that the bone tissue 




Woven and lamellar bone 
 Another classification of bone tissue is based on the organization of the bone 
matrix. According to this classification, there are two types of bone tissue: woven 
(immature; primary) and lamellar (mature; secondary) bone [2]. In woven bone, the 
collagen bundles are randomly placed, whereas those in lamellar bone are positioned in 
tightly organized parallel sheets, forming distinct lamellae having a thickness of 4-12-µm 
[3, 6]. Woven bone is the first bony tissue that is deposited during embryogenesis and 
repair. It is replaced by lamellar bone after the remodeling process, and found only in 
small amounts in adults. Woven bone also has a much higher concentration of cells than 
lamellar bone. The collagen lamellae in lamellar bone are parallel to each other or 
organized concentrically around a vascular canal. The entire complex of concentric 
lamellae surrounding a canal containing blood vessels, nerves and loose connective tissue 
is called a haversian system or osteon [2]. Due to the variation in matrix organization 
between the two bone tissue types, woven bone is weaker but more flexible than lamellar 
bone. 
Bone cells and functions 
 The unique self-healing capacity of bone can be partly attributed to the presence 
of diverse cell types. The three main cell types in bone tissue are osteoblasts, osteocytes 
and osteoclasts [2, 3]. The osteoblasts are located on the surfaces of bone tissue, and pack 
tightly against adjacent osteoblasts. They are responsible for the synthesis and secretion 
of the organic matrix of bone. In addition, they influence mineralization and remodeling 
of bone matrix. When osteoblasts are active in matrix synthesis, they have a cuboidal to 
columnar shape and demonstrate high alkaline phosphatase activity. In this phase, they 
also contain abundant endoplasmic reticulum, Golgi membranes and mitochondria. As 
the osteoblasts secrete matrix in their surrounding region, they become embedded in the 
tissue and turn into osteocytes. Some osteoblasts remain on the surface of bone with 
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reduced activity, and some are removed from the region by an as yet unknown 
mechanism [3].    
 The osteocytes are involved in the maintenance of the bone matrix. They are 
surrounded by bone matrix, and therefore appear to lie in cavities called lacunae. In 
lamellar bone, osteocytes are found in lacunae that are located between and occasionally 
within lamellae. The osteocytes extend long, branching cytoplasmic processes through 
canaliculi that make contact with adjacent cells via gap junctions. It is through these 
connections that flow of small molecules and ions occur. These connections are essential 
not only for nutrient and metabolite transport, but also for intercellular signaling, which is 
required for bone maintenance and adaptation. 
 The osteoclasts are large, extensively branched, multinucleated cells that are 
involved in the resorption and remodeling of bone tissue. Unlike other bone cells, they 
are derived from the hematopoietic lineage and share similarities with monocytes. When 
activated for the resorption of bone, the osteoclasts bind to the surface of bone, creating a 
sealed space. The osteoclast membrane facing bone matrix is extensively folded to trap 
small particles and increase resorptive area. Transmembranous proton pumps transport 
protons into the sealed space, creating an acidic environment that solubilizes the bone 
mineral [7]. The osteocytes secrete acid proteases to degrade the remaining organic 
matrix.  
 In addition to the three main cell types, bone-lining cells that lie directly against 
the bone matrix have been identified [3]. They appear to have a role in attracting 
osteoclasts and stimulating them to form bone. Also, undifferentiated mesenchymal cells 
with the potential to differentiate into osteoblasts reside in the bone marrow, blood 




Periosteum and endosteum 
 The external and internal surfaces of bone are called periosteum and endosteum, 
respectively. These surfaces are covered with thin tissue bilayers, comprising of cells and 
connective tissue. The periosteum, especially, has been demonstrated to possess 
considerable mechanical and biological importance. It consists of two layers: an outer 
dense layer of collagen fibers and fibroblasts, and an inner layer that contains progenitor 
cells and blood vessels. The periosteum provides an important part of the blood supply to 
the bone, and therefore is essential for its viability. The progenitor cells of the inner layer 
have been demonstrated to play an important role in bone growth and repair [9, 10]. In 
fact, they are thought to drive the callus formation and subsequent remodeling during 
fracture healing [11]. The periosteal cells have also been isolated and utilized for bone 
tissue engineering [12]. 
Bone Morphogenesis and Repair 
Bone formation and remodeling 
 Developmentally, there are two paths of forming bone: intramembranous 
ossification and endochondral ossification, though both share the same mechanism of 
matrix development [13]. The common mechanism of bone matrix formation involves the 
differentiation of progenitor mesenchymal cells into osteoblasts, which then secrete the 
specialized bone matrix. As this matrix mineralizes, the osteoblasts are encapsulated in 
the matrix, and become osteocytes. The initial bone that is deposited is an immature 
woven bone, which is then remodeled into mature lamellar bone. Bone remodeling results 
from osteoclast resorption and osteoblast deposition of bone, through a sequence of 
tightly coordinated events [13]. 
In intramembranous ossification, the matrix formation is initiated by the 
aggregation of the progenitor mesenchymal cells into layers or membranes at discrete 
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locations. Several such locations arise simultaneously and then fuse to impart a 
trabecular-like structure to the developing bone. Numerous such ossification centers 
occur within the bone tissue, which grow radially and merge together to form the whole 
bone. Most flat bones of the human body, like the frontal and parietal bones of the skull, 
are formed by intramembranous ossification. 
Unlike intramembranous ossification, endochondral ossification occurs within a 
cartilaginous tissue that is first formed from mesenchymal tissue. This type of 
ossification is primarily responsible for the formation of long bones like the femur and 
tibia. It begins with the aggregation of undifferentiated mesenchymal cells that 
differentiate into chondrocytes and secrete a cartilaginous matrix. This hyaline cartilage 
tissue takes the shape of the bone that is to be formed. Next, part of the cartilage matrix is 
calcified, and the chondrocytes die after undergoing hypertrophy. An osteogenic bud, 
consisting of osteoprogenitor cells and blood capillaries invades the cartilage. The 
osteoprogenitor cells differentiate into osteoblasts, and bone formation progresses on the 
remnants of the calcified cartilage matrix. 
In addition to the deposition of bone matrix with the necessary composition, 
normal mechanical function of the musculoskeletal system requires the formation of 
bones of appropriate shape and size. Long bones develop from cartilaginous models 
through the endochondral ossification process. However the process is preceded by the 
formation of a bone collar in the perichondrium by means of intramembranous 
ossification [2]. As the endochondral ossification progresses, the calcified cartilage 
matrix is resorbed by chondroclasts. This process first occurs in the diaphysis, in what is 
known as the primary ossification center. Bone grows longitudinally from the primary 
ossification center, with resorption of the bone at the center, creating the hollow tubular 
structure, characteristic of long bones. Secondary ossification centers arise at the center 
of each epiphysis, and grow radially. The diaphysis and epiphysis are separated by the 
epiphyseal cartilage, also called the growth plate. Long bones grow longitudinally by the 
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replacement of the epiphyseal cartilage by bone tissue on the diaphyseal side. The 
enlargement of the width of long bones occurs by appositional growth of the bone collar, 
in which osteoblasts synthesize new bone matrix on an existing bone surface. 
Fracture healing 
 Bone is one of the few adult tissues with the capacity for true self-healing. Unlike 
soft tissue injuries, which generally result in the formation of scar tissue, bone healing 
concludes with the actual reconstitution of the injured tissue, including the biochemical 
and biomechanical properties. Bone fracture healing involves both intramembranous and 
endochondral ossification pathways, in a process that recapitulates embryonic bone 
formation to a large degree [14].  
  When bone fractures, the following events occur sequentially: hematoma 
formation, acute inflammation, cartilaginous callus formation and calcification, 
neovascularization, callus mineralization, and remodeling [15, 16]. The cascade starts 
with the leakage of blood from the damaged blood vessels and a hematoma is formed. 
Platelets in the hematoma release vasoactive mediators and growth factors [1]. Acute 
inflammation follows, and the damaged cells and tissue are removed by macrophages. 
The ends of the bone do not participate in the healing response, and are in fact dead [17]. 
Progenitor and stem cells, first from the periosteum and later from adjacent sites, are 
mobilized and ultimately form a callus tissue, which surrounds the fracture and occupies 
the space between the fracture ends. In addition to a mainly cartilaginous matrix, the 
fracture callus consists of osteoblasts and woven bone deposited by intramembranous 
ossification. The callus bridges the fracture and achieves stabilization of the fracture 
fragments. Once cartilage is calcified, it is invaded by blood vessels, bringing 
osteoprogenitor cells with them. The cartilage is resorbed by chondroclasts, and 
immature woven bone is deposited by differentiated osteoblasts, much like what occurs 
in embryonic long bone development. Once the callus is mainly composed of woven 
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bone and unites the fracture ends with bony tissue, the woven bone undergoes chronic 
remodeling into lamellar bone and the native bone structure is restored. 
 Fracture healing is influenced by numerous internal and external factors. For 
example, growth factors from the BMP family have been investigated extensively for the 
induction of osteogenesis at fracture sites, and are used clinically for the treatment of  
challenging fractures [18]. The BMPs have been shown to induce a cascade of 
chemotaxis, mitosis and osteogenic differentiation of undifferentiated mesenchymal cells 
[19]. In addition, they have been characterized for their ability to couple angiogenesis and 
bone formation [20, 21]. The fixation technique used for fracture stabilization also has a 
profound effect on the healing response [22, 23]. In less stabilized fractures, the 
endochondral route of ossification dominates, and results in the classical fracture healing 
cascade, as outlined above [23]. In fact, the periosteal response to fracture is enhanced by 
moderate motion and inhibited by rigid fixation [17]. Conversely, fractures are healed 
predominantly by intramembranous ossification only when the bone ends are rigidly 
fixated with respect to each other. It should, however, be noted that excessive motion at 
the fracture site inhibits vascularization and prolongs the cartilaginous callus phase [22, 
24]. 
BMPs in skeletal development and fracture healing 
 In 1965, Marshal R. Urist made the key discovery that when dimineralized bone 
matrix from rabbits was implanted in an intramuscular pouch in rats, it lead to the 
formation of new bone [25]. He later identified a protein responsible for this effect, which 
was termed bone morphogenetic protein. In 1988, Wozney et al. identified the genetic 
sequence of the protein, which made the production of BMPs possible by recombinant 
DNA technology [26].  
BMPs, which are part of the TGF-β superfamily, are one of the most potent 
agents known for bone induction. More than 15 members of the BMP family have been 
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currently identified, which are essential during the embryogenesis of bones, brain, eyes, 
heart, kidneys and teeth [19, 27, 28]. Mice deficient in BMP-2, -4, and -7 die either 
during embryonic development or soon after birth [29]. The deficiency of BMP-2 in mice 
has been associated with developmental abnormalities of skull, hindlimb, and kidney 
[30]. In addition, BMP-2, 4 and 7 are known to play a critical role in bone healing in 
adults [29, 31]. Currently, recombinant BMP-2 and -7 have been approved by the Food 
and Drug Administration (Rockville, MD) for certain clinical bone repair therapies. 
 BMPs are pleiotropic regulators of cell function, and have been demonstrated to 
play a pivotal role in the growth and differentiation of numerous cell types [30, 32]. Bone 
marrow derived mesenchymal stem cells (MSCs) and osteoprogenitor cells undergo 
osteogenic differentiation to a mineralizing phenotype in response to BMPs [33-36]. For 
example, Lecanda et al. reported that incubation of human MSCs and osteoblasts with 
BMP-2 inhibited proliferation, and induced matrix mineralization and upregulation of 
osteopontin, bone sialoprotein and osteocalcin [36]. In addition, BMPs stimulate cell 
chemotaxis of MSCs, which is especially important in recruiting endogenous cells for 
tissue repair [37-39]. BMPs are dimeric molecules, and trigger intracellular effects by 
binding to serine/threonine kinase receptors. The binding of BMPs to their receptors 
triggers the activation of intracellular signaling proteins called SMADs, which then enter 
the nucleus and modulate the expression of transcription factors [32].  
 BMPs are also known to be essential for the inherent fracture healing response 
[32]. In fact, fractures in BMP-2 deficient mice do not resolve spontaneously [31]. The 
individual BMPs play important yet distinct roles during fracture repair [40]. Studies 
have shown that the expression of BMP-2 and -4 is upregulated in MSCs that migrate to a 
fracture site, while BMP-2, -4 and -7 are present in the newly formed woven bone [41, 
42]. For instance, Bostrom et al. characterized the temporal and spatial distribution of 
BMP-2 and -4 in fracture healing using a monoclonal antibody specific to these BMPs 
[41]. They reported that the BMP levels were high in the inner layer of the periosteum 
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immediately after fracture, in the chondroprogenitor cells and in the osteoblasts that lined 
the calcified cartilage matrix. Conversely, BMP expression went down as the lamellar 
bone replaced the woven bone. 
Bone Regeneration and Clinical Therapies 
Clinical need for bone regeneration 
The need for bone regeneration occurs in cases of bone loss due to trauma, tumor 
resection or disease. In addition, bony tissue formation is needed for joint arthrodesis 
such as spinal fusion. The frequency and success rate of bone augmentation procedures 
obtained at one clinical center is listed in Table 2.1. Joint arthrodesis is the most common 
procedure performed at this center, followed by fracture repair. On the other hand, 
fracture nonunions and large bone defects have been reported less commonly. Overall, 
most of the conditions have been treated with high success rates at this center, other than 
the notable exception of large bone defects. However, it should be kept in mind that 
successful treatments include bone grafting procedures, which are associated with 
numerous secondary disadvantages. Moreover, it should be noted that in addition to large 
bone defects, the treatment of nonunions and certain cases of fractures has proved to be 
challenging. Failures in ‘high risk’ fractures have been reported to be as high as 30% 
[18]. For example, open tibial fractures remain a persistent problem. A recent clinical 
trial on open tibial fracture treatment showed that one year after injury, more than half of 
the patients managed with the standard of care had treatment failure [43]. Another study 
demonstrated that seven years after surgery, half of the patients still reported appreciable 
disability [44].  
Impaired fracture and bone defect healing are associated with pain and stiffness of 
surrounding joints, leading frequently to patient disability [45]. In addition, high rates of 
psychological distress have been reported after trauma [46]. This places a considerable 
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economic burden on the patient and society. The cost of bone grafting procedures alone is 
estimated to be currently $2.5 billion per year [47]. Long-term rehabilitation and the 
indirect cost of lost wages add to the economic burden to the healthcare system. There is 
therefore a significant clinical need for improving bone regeneration, especially in the 
cases where the current techniques are not adequate. 
 
Clinical techniques for bone repair 
Traditional orthopaedic practice relies on the ability of the surgeon to drill, cut 
ream and realign bone [3]. The success of these procedures requires technical skill and 
well-designed hardware. In a majority of cases, this is sufficient for healing, thanks to the 
remarkable capacity of bone for self-regeneration. However, certain fractures and bone 
defects require additional bone augmentation, as noted above. The current procedures for 
bone augmentation include autologous and allogeneic bone grafting, and more recently 
ceramic and composite substitutes for bone grafts [45, 48, 49]. Approximately 500,000 
bone grafting procedures are performed in the U.S. and 2.2 million worldwide [50, 51]. 







Defects (>2 cm) 3% <50%
Table 2.1. The frequency and success rate of bone augmentation procedures at the
Cleveland Clinic (Cleveland, OH). Data courtesy Dr. George Muschler 
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The clinical gold standard for bone regeneration has been autologous bone grafting as it 
provides osteogenic cells and osteoinductive factors for bone healing [49]. Though it has 
been successful in many cases, it has significant disadvantages including limited graft 
material and morbidity of the donor site [52, 53]. These limitations have led to increased 
use of allograft bone as a substitute for autologous bone. However, allograft bone is 
inferior to autologous bone due to reduced biological activity after processing, and is 
associated with a high rate of complications and late fractures as well as a risk of disease 
transmission. The high failure rate of allografts is associated with their lack of ability to 
revascularize and remodel [54-56]. Ceramic and polymer based bone graft substitutes 
have recently been introduced, and are being used frequently. But ceramics tend to be 
brittle, whereas polymers suffer from limited bioactivity and strength, and may need to be 
supplemented with osteogenic cells and growth factors [51]. These limitations of the 
grafting procedures have stimulated the search for improved techniques for bone repair.  
BMPs in clinical practice 
In the last decade, recombinant human BMP-2 (rhBMP-2) and -7 (rhBMP-7) have 
been approved for clinical use. In addition to spinal applications, rhBMP-2 delivered on a 
type I collagen sponge is approved for open tibial fractures [43, 57]. The use of rhBMP-7 
(also known as osteogenic protein-1 (OP-1)) on a type I collagen carrier is allowed for 
the treatment of tibial nonunions and in limited cases of spinal fusion [58, 59]. A 
prospective, controlled, randomized clinical trial was performed to investigate the 
efficacy of rhBMP-2 for treatment of open tibial fractures along with intramedullary nail 
fixation [43]. It was reported that rhMBP-2 treatment resulted in a 29% reduction in 
nonunion and a 41% reduction in secondary intervention, compared to intramedullary 
nail alone. 
 Although BMPs have been quite successful in fracture healing, high doses (3.5-12 
mg) are required. In the 2002 BMP-2 clinical trial, only a 1.5 mg/mL dose, and not a 0.75 
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mg/mL dose was found to be superior to the standard of care. The need for such large 
doses is probably related to the inefficient delivery of the growth factor on collagen 
sponge. The high doses have resulted in complications due to the diffusion of the BMP 
away from the application site [60, 61]. BMP usage is also considered expensive due to 
the high doses required, and surgeons typically avoid using it until other treatment 
options have been exhausted [62]. Garrison and coworkers have performed a cost 
effectiveness study of BMPs in orthopaedic practice in the U.K [63]. They reported that 
the incremental cost of BMP for open tibial fractures was about £3.5 million per year. 
The cost effectiveness ratio was found to be sensitive to the price of BMP and severity of 
the fracture. They concluded that the cost effectiveness of BMP may be improved if its 
price is reduced or if it is mainly used in severe cases. Therefore, delivery systems that 
can reduce BMP dose by enhancing delivery efficiency are urgently needed to improve 
the cost effectiveness of BMP therapy. 
Research Strategies for Bone Repair 
Tissue engineering/regenerative medicine (TE/RM) 
Though bone grafting remains the standard for clinical bone regeneration, there is 
a clear need for effective bone repair techniques. The basic elements required for 
successful bone repair include an extracellular matrix, cells, osteoinductive factors and a 
vascular supply. TE/RM approaches attempt to provide one or more of the above to 
mimic the natural process of bone regeneration [64, 65]. Historically, tissue engineering 
was defined as the development of biological substitutes for damaged tissues and organs 
[66]. Tissue substitutes are created in vitro by the culture of cells on scaffolds in an 
appropriate environment, with the goal of using for transplantation in vivo. As the tissue 
is primarily created in vitro in this approach, this can be termed as in vitro tissue 
engineering [67]. The pioneering tissue-engineered products were skin substitutes 
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produced using this method [68]. This approach has been found to be suitable for thin 
tissues with low vascularity and low regenerative potential, such as cartilage [69, 70]. On 
the other hand, the creation and post-implant viability of large vascularized tissues, such 
as bone, remain a significant challenge because of mass transport limitations in the 
absence of a vascular supply [71]. Fortunately, for bone and other tissues with high 
healing potential, strategies that promote the activation of endogenous repair mechanisms 
with minimal in vitro processing have been successful [72-74]. This could involve, for 
example, delivery of growth factors that stimulate the endogenous cells to migrate to the 
injury site and initiate repair. This approach, termed in vivo tissue engineering, has the 
significant advantages of requiring less processing and culture time, and therefore 
presents a more viable method for regulatory approval and commercialization.  
The current definition of tissue engineering encompasses both the in vitro and in 
vivo approaches, and has come to mean the replacement, repair and/or regeneration of 
tissues and organs [75]. In addition, regenerative medicine, which has been synonymous 
with stem cell technology, has been added to the definition due to its complementary 
relationship with tissue engineering, and the entire field is now called TE/RM [76]. 
TE/RM strategies for bone repair encompass a broad set of approaches typically 
involving a scaffold and a biological component [64, 65, 77]. The biological factor 
includes cells, proteins, peptides or genes, or a combination of these [77-83]. 
Scaffolds 
Scaffolds are the central concept in TE/RM as they provide the template for tissue 
regeneration. In addition to their structural role, advances in the field of biomaterials have 
resulted in bioactive scaffolds capable of influencing cell behavior [84, 85]. Scaffolds for 
tissue regeneration have been manufactured from techniques such as rapid prototyping, 
salt leaching, self-assembly, phase separation, gas foaming and electrospinning [65, 86-
90]. The most frequently used scaffolds in bone TE/RM research are three-dimensional 
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structural scaffolds having large pore sizes  [74, 87, 91]. They are typically made from 
synthetic polymers like poly(ε-caprolactone) (PCL) and poly(L,DL, lactide) (PLDL), or 
ceramics like hydroxyapatite and calcium phosphate. Though successful for promoting 
bone formation, structural scaffolds usually do not provide an optimal environment for 
cellular function and typically suffer from slow resorption kinetics, thereby impeding 
functional restoration of the damaged tissue. Oest et al. reported that PLDL scaffolds 
infused with rhBMP-2 promoted bone ingrowth but failed to fully restore the mechanical 
properties of long bone defects [74]. They hypothesized that minimal degradation of the 
material at 16 weeks resulted in confining the bone formation to the pores and the 
periphery of the scaffold [74]. In contrast to the three-dimensional structural scaffolds, 
two-dimensional membranes have been used to promote bone repair by placing them 
along the periosteal surface in a process termed guided bone regeneration (GBR) [92-95]. 
Due to their placement on the edge of the defect, the space inside the defect is available 
for tissue deposition, which may lead to the complete restoration of the bone. Nanofiber 
meshes, made by electrospinning, are scaffold membranes with the potential of being 
efficacious in GBR. Their nanometer range fibers mimic the structural characteristic of 
ECM and improve cell attachment and function [96-98]. Nanofiber meshes will be 
discussed in detail in a later section. Another class of scaffolds of interest is the hydrogel, 
which has gel-like consistency [99, 100]. Though their mechanical properties are much 
lower than bone tissue, they can be injected using minimally invasive procedures, and 
permit cell migration and remodeling. In addition to functioning as scaffolds, they can be 
used for delivering biologics to the defect site. Hydrogels will be discussed further below. 
Growth factors and peptides 
Growth factors are signaling proteins secreted by cells that act on target cells to 
modulate cell functions like migration, proliferation and differentiation [29]. After 
binding to receptors on the target cells, they induce an intracellular signal transduction 
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cascade that produces a biological response. The growth factors most frequently utilized 
for bone formation are from the BMP family, which have been successfully translated to 
the clinical setting [30, 101]. In addition to the BMPs, other members of the TGF-β 
superfamily have also been investigated for their potential to enhance bone repair. 
Critchlow et al. evaluated the effect of exogenous TGF-β2 on the healing of rabbit tibial 
fractures [102]. They reported that a higher dose of TGF-β2 (600-ng), in the presence of 
stable mechanical fixation, resulted in abundant callus formation but no increase in bone 
content in the callus. The angiogenic growth factor, vascular endothelial growth factor 
(VEGF), has been demonstrated to enhance mineralization and callus maturation in 
murine fractures [103]. Finally, platelet derived growth factor (PDGF), insulin-like 
growth factors (IGF) and fibroblast growth factors (FGF) have also been investigated for 
bone repair, with mixed results [29, 104]. As bone repair is regulated by a complex set of 
growth factors, combination of the above growth factors have also been attempted. A 
synergistic effect of TGF-β3 and BMP-2 delivery on bone formation was seen by 
Simmons et al. in an ectopic murine model [105]. Co-delivery of angiogenic and 
osteogenic factors have also been demonstrated to promote bone repair subcutaneously 
[106]; however, this effect was not seen in an orthotopic model [107]. 
An alternative to full-length proteins, including growth factors, are peptides that 
mimic specific regions of these proteins. Whole proteins suffer from purification and 
processing issues, and can result in a host immunogenic response [108-111]. On the other 
hand, short-length peptides can be made synthetically to avoid these issues, and 
furthermore would cost much less. Saito and coworkers have developed a novel peptide 
corresponding to residues 73-92 of BMP-2 [112]. They demonstrated that this peptide 
promotes osteogenic differentiation of progenitor cells and induces mineralization in vivo 
[113, 114]. As opposed to being presented in soluble form, peptides can also be coated 
onto biomaterial surfaces. These ECM-mimetic material surfaces present adhesion motifs 
to engage the signal transduction machinery of cells for directing cellular response and 
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tissue repair [115, 116]. A further advantage of using peptides over a full-length ECM 
protein in such a scenario is that they can be designed to mimic individual domains of 
proteins, resulting in the engagement of specific cellular receptors, and therefore 
generating a concerted cellular response. One such peptide that has been identified from 
the type I collagen molecule is a triple-helical peptide that contains the glycine-
phenylalanine-hydroxyproline-glycine-glutamate-arginine (GFOGER) motif. The 
GFOGER motif has been identified as the major site of interaction between the type I 
collagen molecule with the α2β1 integrin receptor. This interaction has been found to be 
the key signal for the osteogenic differentiation of cells [117-119]. Recently, Reyes and 
coworkers demonstrated that coating surfaces with GFOGER enhanced the osteogenic 
differentiation of osteoblasts and MSCs, and improved osseointegration of titanium 
implants [120, 121]. 
Cell sourcing and delivery 
Although acellular approaches to bone reconstruction using scaffolds and BMPs 
have shown moderate clinical success, the delivery of osteogenic cells may be required 
for patients with a reduced local supply of responsive osteoprogenitor cells. This includes 
older patients, smokers, patients receiving chemotherapy or radiation, and patients with 
severely damaged wounds or metabolic diseases [122]. For a cell based therapy to be 
successful in regenerating bone it is necessary to identify an appropriate cell source that 
is easily accessible, can be expanded to large numbers, and has osteogenic potential [123, 
124]. Of the numerous cells types studied for bone tissue engineering, mesenchymal stem 
cells (MSCs) derived from the bone marrow have been extensively investigated, and have 
been shown to promote repair of critically-sized defects in pre-clinical animal studies 
[125-127]. However bone marrow MSCs have limitations to the extent of their self 
renewal capacity [128, 129], and have also shown loss of differentiation abilities with age 
of the donor [130, 131]. Recently pluripotent cells have been isolated from the human 
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and rodent amniotic fluid [132] that express c-Kit , which is the receptor for stem cell 
factor. These cells, termed amniotic fluid-derived stem (AFS) cells, have shown 
remarkable ability to differentiate into cells of all three embryonic germ layers. In 
addition AFS cells proliferate rapidly without feeder cells and have not shown 
tumorigenicity, thus making them an exciting new source of regenerative cells. Our lab 
has recently developed protocols to differentiate them along the osteogenic and 
chondrogenic lineages [133, 134]. 
 It is well known that static in vitro culture of three-dimensional tissue-engineered 
constructs greater than 1 mm usually results in a thin shell of viable cells and tissue on 
the periphery [135-138]. It is thought that this effect is due to the limited mass transport 
of vital nutrients to the center of the construct. Similarly in the case of segmental bone 
defects, the lack of initial vascularity limits the transport of nutrients to and waste 
products from the center of the defect. Typically, when cellular constructs are used in 
vivo, the cells are seeded throughout a 3-D scaffold and placed at the injury site. 
However, due to the reasons mentioned above, cells located at the center of the scaffold 
may not survive [139, 140]. An alternative method may be to deliver cells within a tissue-
engineered periosteum, on the periphery of the defect, where the presence of a 
neighboring vasculature may enhance cell survival. With time, as a continuous 
vasculature is established at the center, the cells may migrate towards the center due to 
the improved transport environment. Recently Zhang reported that engraftment of BMP-2 
producing BMSCs using gelfoam wrapped around nonvital allografts improved allograft 
incorporation and repair [141]. Due to their unique structural properties, electrospun 
nanofiber meshes promote cellular attachment and proliferation, and therefore may be 




Growth factor delivery systems for tissue regeneration 
Due to their important role in regulating tissue formation and maintenance, 
growth factors have the potential to be clinically successful in repairing injured tissues 
[142]. The direct injection of growth factors in a bolus dose is generally not effective due 
to the short protein half-life in vivo and the rapid protein diffusion through vascular 
networks [143]. Multiple injections to the injury site are not feasible due to the high cost 
of growth factors and repeated hospital visits. In addition, protein diffusion of osteogenic 
growth factors like BMPs into non-bony tissues may result in an unwanted and 
uncontrolled ectopic bone formation [60, 144]. For instance, when rhBMP-2 solution is 
soaked on a collagen sponge, the retention at defect site is prolonged compared to bolus 
delivery [145]. In one study, an extremely high dose of 80-µg rhBMP-2 was required in a 
rat femoral fracture model with a percutaneous injection [146]. For these reasons, protein 
delivery systems that can provide controlled release and local retention are required for 
the efficacy of growth factor based therapies [143, 147]. 
There are several considerations in designing delivery systems for tissue 
regeneration [143]. A unique aspect of drug delivery for tissue repair is the need of a 
structural template for guiding the repair process. Therefore, drug delivery vehicles 
should have the ability to be configured as scaffolds, or at least be able to be loaded onto 
scaffolds. The scaffolds should have the structural and biological properties to support 
robust cell and tissue infiltration. The delivery vehicle must be biodegradable, 
biotolerant, and protect against protein degradation and denaturation in vivo. The delivery 
system should achieve spatiotemporal release of the protein, including an appropriate 
protein release rate and retention of the growth factor within the injury site. The proteins 
are typically released from the delivery vehicle due to a combination of protein diffusion 
and matrix degradation. Finally, in order to minimize protein denaturation, the methods 
of fabrication should not involve harsh solvents or high temperatures. 
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A variety of growth factor delivery systems have been developed with the above 
design criteria in mind (for a review see [148]). Based on composition, the major 
categories of growth factor delivery systems being currently investigated for bone repair 
are [149, 150]: (1) Natural materials, (2) Inorganic materials, (3) Synthetic materials, and 
composites of the above. Natural materials include collagen, hyaluronans, chitosan, 
fibrin, agarose and alginate [151-153]. These typically exhibit good biotolerance and 
biodegradation profiles, and can be manufactured in numerous formulations. Inorganic 
systems, made from bioglass or ceramics such as hydroxyapatite, calcium phosphate and 
calcium sulfate, are being investigated for protein delivery [91, 154]. These materials 
have demonstrated osteoconductivity in numerous animal models, and are used clinically 
as bone graft substitutes. Synthetic materials include the homo- and copolymers of lactide 
and glycolide (PLA, PGA, PLGA), polyethylene glycol (PEG), polyketals and 
poly(propylene) fumarate (PPF), and are attractive because of their well-controlled and 
reproducible chemical, physical and structural properties [155-158]. Protein delivery 
systems can also be classified according to the structure and the formulation of the 
delivery system as three dimensional scaffolds, electrospun nanofiber meshes, 
micro/nano-particles, hydrogels or composites [148].  
Collagen scaffolds with a spongy structure are clinically used for rhBMP-2 
delivery. Winn et al. reported that collagen sponges loaded with rhBMP-2 exhibited a 
continuous release for 2 weeks in vivo, with a half life of 3-5 days in a rat ectopic model 
[159]. However, the long term release was not investigated, and it is likely that the 
protein is not retained at later time points. This system also results in significant initial 
burst release, in the range of 40-90% [160]. It is perhaps due to these reasons that large 
rhBMP-2 doses (3.5 – 12 mg) are required for efficacy in humans. In addition, the risk of 
an immunogenic reaction to collagen or pathogen transmission to the host cannot be 
eliminated, and concerns also persist regarding the heterogeneity of the product [161, 
162]. Despite these drawbacks, collagen still remains the standard for rhBMP-2 delivery 
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due to its acceptable delivery performance, its long history of clinical use, and because 
the risk of adverse reactions is generally considered low. 
Ceramic materials are commonly for bone regeneration. Chu and coworkers 
delivered rhBMP-2 to a rat segmental defect in dicalcium phosphate dehydrate within a 
composite ceramic/polymer scaffold, and reported that this system was able to restore the 
mechanical properties of the rat femurs [91]. However, the scaffold density was reduced 
by less than 10% in 15 weeks of implantation. The typical problems with ceramics are 
their brittle nature, uncontrolled degradation and lack of macroporosity. Porous ceramic 
blocks have been fabricated to mimic the structure of trabecular bone [163]. The 
disadvantage of this system is that due to the high-temperature sintering process, BMPs 
can only be surface coated after fabrication, thus limiting the protein dose that can be 
delivered. 
Hydrogels are a class of highly hydrated materials that are composed of 
hydrophilic polymer chains [164]. Though their low mechanical stiffness necessitates the 
use of fixation devices for fracture stabilization, they can be deployed using minimally 
invasive procedures, conform to the shape of the defect and be manipulated by cells 
during tissue regeneration [165]. In addition, they are require mild processing conditions 
and can be designed for sustained delivery. For these reasons, hydrogels are attractive for 
the delivery of growth factors for tissue regeneration. Eckardt et al. used a hyaluronic 
acid-based hydrogel to deliver rhBMP-2 to rabbit tibial osteotomies, and reported 
substantial bone formation [166]. Tabata and coworkers have demonstrated that the co-
delivery of TGF-β and MSCs within gelatin microspheres achieved the closure of rabbit 
cranial defects [167, 168]. The importance of protein release from hydrogels and their 
degradation rate was highlighted in a study by Rizzi et al [169]. They reported that the 
physical linkage of rhBMP-2 to a recombinant protein-poly(ethylene glycol) hydrogel 
prevented optimal bone healing of murine cranial defects, due to lack of chemotactic 
signaling and insufficient degradation of the hydrogel matrix. 
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Alginates are well-characterized polysaccharides isolated from brown algae found 
in coastal waters. Hydrogels made from alginate have been established as a scaffolding 
material [105] and a spatiotemporal delivery vehicle for a wide range of proteins [170-
172]. This is due to their biocompatibility, low toxicity, relatively low cost, and simple 
gelation with divalent cations like Ca2+ and Mg2+ [99]. Alginates can be covalently 
coupled with adhesion peptides to promote cellular attachment, and their degradation rate 
can be increased by Gamma-irradiation [173]. These modified alginates have been 
demonstrated to be better suited for tissue regeneration by allowing faster ingrowth of 
cells and tissue [105, 174]. 
In summary, the current clinical delivery systems may require further 
optimization, and there is a tremendous need for improving protein delivery for tissue 
regeneration applications [148]. It is also unlikely that one of the above delivery systems 
will be ideal for all clinical therapies. The optimal design of the delivery system will 
depend on the protein to be delivered, the tissue and injury to be repaired, and the 
vasculature and weight bearing requirements. 
Guided bone regeneration 
Guided bone regeneration refers to the use of membranes to repair bone defects 
by placing them along the periosteal surface to demarcate the osseous from the non-
osseous region. This technique has been used successfully in the dental field to regenerate 
lost alveolar bone following chronic periodontitis [175-178]. A few groups have 
investigated the efficacy of this technique for healing diaphyseal bone defects in animal 
models [92, 179, 180]. Gogolewski and co-workers used polylactide membranes formed 
into tubes to conform to a 10 mm diaphyseal defect in the radius of rabbits. The 
membranes were 0.12-0.25 mm thick and had pore sizes that varied from less than 5 µm 
in microporous membranes to 200 µm in large pore membranes. Based on histologic and 
radiographic evidence, they concluded that by 8 weeks, the defects had been bridged by 
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bony tissue when membranes were used, and that microporous membranes had the most 
intensive bone formation [181, 182]. When they used the technique with larger defects in 
the sheep model, they observed similar bridging, but required an additional bone graft or 
vascularized osteoperiosteal flap for effective bone healing. They also made perforations 
in the membrane to enhance the vascular supply to the defect [183]. Giardino et al. 
reported that the average thickness of regenerated bone was significantly increased when 
they used a poly-DL-lactide tubular chamber with MSCs and demineralized bone matrix 
(DBM) compared to just MSCs and DBM [94]. It is hypothesized that the mechanism by 
which the membranes heal defects is by protecting the defect from infiltration by soft 
tissue cells, guiding the osteogenic cells and containing the osteogenic factors within the 
defect site [182]. Woven bone formation, supported by migration of osteoprogenitor cells 
from the periosteum and bone marrow, is thought to start at the periphery and proceed 
inwards within the defect site [92]. Despite the numerous studies on guided bone 
regeneration, the quantification of bone formation in diaphyseal defects and the 
evaluation of restoration of limb function remains to be performed [179, 181, 184]. 
Electrospun Nanofiber Meshes 
Nanofiber mesh: an ECM-mimetic scaffold 
 Numerous biodegradable scaffolds have been designed to function as a temporary 
matrix for cellular attachment, proliferation and extracellular matrix deposition. By 
providing a template for tissue regeneration, scaffolds are an essential component of the 
TE/RM strategy. Scaffolds are typically designed to possess a set of properties that 
enhances cell survival, signaling, growth and phenotype expression [185]. A major focus 
of researchers has been to create scaffolds that mimic the ECM. An important component 
of this strategy is to design structural features on the scaffold that are similar to the ECM. 
Electrospinning, though a process known for decades, has recently emerged as a 
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technique to produce scaffolds with fiber diameters ranging from tens of nanometers to as 
large as 10 µm, thus closely resembling the size scale of ECM components [186-188]. 
Electrospinning can generate nanofiber meshes with high porosities and large surface 
area-to-volume ratios, and therefore is an attractive technique for the production of 
scaffolds. The nanofiber mesh structure allows for greater cellular attachment and 
enhanced cell spreading. Numerous in vitro studies have shown that nanofiber meshes are 
able to support the attachment, proliferation and metabolism of numerous cells types 
including osteoblasts, MSCs, endothelial cells, and fibroblasts [189-192]. Xin and 
coworkers seeded hMSCs on PLGA nanofiber meshes, and separately induced their 
chondrogenic and osteogenic differentiation [191]. They reported that the cells remained 
viable on the meshes, and after 2 weeks, the deposited matrix stained for markers of 
cartilage and bone. However, quantitative analysis of the matrix was missing. In contrast 
to the numerous in vitro publications, there is limited in vivo data available on nanofiber 
meshes. A few studies have explored their use in calvarial defect models in vivo [96, 
193]. However, their efficacy in guiding long bone regeneration remains to be 
investigated. 
 Electrospun meshes are frequently fabricated from synthetic polymers due to their 
relative ease of processing and ready availability. However, synthetic meshes lack the 
necessary biofunctionality that is important in the scaffold’s interactions with cells. In an 
attempt to further mimic the ECM, researchers have used natural materials to electrospin 
nanofiber meshes. These natural materials including collagen (types I-IV), gelatin, 
fibrinogen, silk, and chitosan [187, 194-198]. Despite the improved bioactivity, nanofiber 
meshes composed entirely of natural materials have limited strength and may be 
impractical for many applications. The structural integrity of collagen meshes may be 
improved by cross linking the collagen [199], but still falls short of synthetic meshes. For 
this reason, composite meshes containing both synthetic and natural materials may 
possess an optimum combination of strength and bioactivity. A few studies have 
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observed enhanced cellular responses on collagen-containing composite meshes [189, 
200, 201], but further work needs to be done to understand their efficacy in promoting 
osteogenic differentiation. 
Electrospinning setup 
Electrospinning is a relatively simple process, and has been employed for over 
four decades to produce various industrial products [202-205]. The electrospinning 
apparatus consists of (a) high voltage power supply, (b) syringe pump, (c) syringe, (d) 
stainless steel needle, and (e) metal collector plate. The whole setup is enclosed in a 
plastic chamber to provide electrical shielding. A polymer solution is loaded into a 
syringe attached with a metallic needle, which is then placed on the syringe pump set to 
infuse the solution. The positive electrode of the high voltage power supply is connected 
to the needle. This creates a strong electrostatic field between the polymer solution and 
the grounded collector plate. When the electrostatic forces exceed the surface tension 
holding the polymer solution at the needle tip, the polymer solution is ejected as a jet. As 
the jet moves towards the collector plate, the solvent evaporates and the jet is split into 
ultra-fine fibers due to charge repulsion. Ultimately, the fibers are collected on the metal 
plate, with fiber diameters typically in the nanometers to a few micrometers range. 
Nanofiber mesh: a 2-D or a 3-D scaffold? 
 Though electrospun nanofiber meshes have high porosity (usually 70-90%), the 
pore size is much less than 10 µm [196, 206]. Since this is lower than the size of a typical 
mammalian cell, cells seeded on a nanofiber mesh remain primarily on the surface of the 
mesh with minimal penetration into the interior (Figure 2.1). This is distinctly different 
than what occurs in a typical TE/RM scaffold. Traditional TE/RM scaffolds are 3-D in 
structure, designed with a pore size of 200-900 µm to encourage cell penetration [65]. 
The pore size in nanofiber meshes is directly related to and controlled by the fiber 
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diameter, and therefore cell infiltration can be improved to a certain extent by increasing 
the fiber diameter [186, 207]. However, some studies have found that larger micrometer-
scale fibers hinder cell attachment and spreading [186, 190, 192]. In addition to the 
limited cell penetration, electrospun nanofiber meshes are also relatively thin. Meshes 
can be manufactured with a maximum thickness of around a few millimeters, even after 
many hours of electrospinning [208]. This is much less than the dimensions of large bone 
defects (2-6 cm). Thus, impaired cellular infiltration and limited thickness are major 
drawbacks in the use of nanofiber meshes as a 3-D scaffold for regenerating thick tissues 
like bone. However, the ability to control cellular penetration may be advantageous for 
regenerating bone via GBR by preventing fibrous tissue infiltration into bone defects 
[183]. 
 
Figure 2.1. Histologic cross section of a cell-seeded electrospun nanofiber mesh. Due to
the small pore size, cells seeded on a nanofiber mesh form a cell layer on the mesh
surface after 2 weeks. There is no evidence of cell infiltration into the center. 
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CHAPTER 3  
COLONIZATION AND OSTEOGENIC DIFFERENTIATION OF 
DIFFERENT STEM CELL SOURCES ON ELECTROSPUN 
NANOFIBER MESHES 
Introduction 
 Bone is one of the few adult tissues with the capacity to regenerate. However, 
large, unstable, or infected bone defects remain a challenging clinical problem [50]. 
Tissue engineering strategies that deliver cells, growth factors and genetic material on 
scaffolds have demonstrated considerable potential in developing bone graft substitutes 
[64, 65]. Delivery of exogenous cells capable of forming bony tissue may be especially 
important to repair bone defects in patients with a limited endogenous progenitor cell 
supply, such as older patients, smokers, or patients with certain diseases [122]. The 
success of cell-based therapies for bone regeneration has been limited, in part, by the 
inadequate availability of large quantities of osteogenic cells and an effective cell 
delivery system. 
The identification of a cell source that may be easily harvested, expanded to large 
numbers, and controllably differentiated may be tremendously beneficial clinically for 
the reconstruction of damaged tissues. Bone marrow derived mesenchymal stem cells 
(MSCs) have demonstrated a strong potential for differentiation into bone forming cells, 
and have been shown to promote repair of critically-sized bone defects in pre-clinical 
animal studies [125-127]. These cells are well suited for autologous transplantation, 
making them a feasible cell source for clinical deployment due to the lack of 
immunogenic issues associated with this transplantation modality. However, MSCs are 
associated with reduced mineralization capacity in older donors and following expansion 
to achieve therapeutic cell numbers [128, 130]. 
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 Amniotic fluid-derived stem (AFS) cells are c-Kit expressing cells isolated from 
amniotic fluid that have demonstrated a high self-renewal capacity and the ability to 
differentiate into a diverse range of cell types, including those from the adipose, muscle, 
neuronal, cartilage and bone lineages [132, 134, 209, 210]. Recently, our lab has 
demonstrated that these cells can produce robust mineralization in 3-D constructs in vitro 
and in vivo [211, 212]. Importantly, AFS cells have also shown a lack of senescence 
through 250 population doublings and display an absence of tumorigenicity in vivo [132]. 
However, not much is known of their osteogenic potential compared to MSCs. A critical 
step towards clinical translation is the quantitative comparison of the proliferation and 
bone-forming capacity of different cell sources. 
The delivery of stem cells to the site of injury, either through systemic 
introduction or local delivery, is another critical consideration for the success of cell-
based therapies. Site-specific delivery has the advantage of being able to deliver large 
numbers of cells directly to the required area. In tissue-engineering strategies, this 
typically involves placing cells on a three-dimensional (3-D) scaffold, followed by 
implantation at the injury site. However, the lack of initial vascularity at the center of a 3-
D scaffold limits the transport of nutrients to, and waste products from, the cells. This 
presents a very harsh environment that makes cell survival extremely difficult [139, 140]. 
An alternative is to deliver cells to the periphery of the defect via a thin membrane or 
scaffold. This delivery strategy may enhance cell survival by positioning the cells in close 
proximity to the surrounding highly vascularized tissues, and thereby providing for 
nourishment and clearance of waste products. 
Electrospinning has recently emerged as a technique to produce polymeric 
scaffolds for tissue engineering, with fiber diameters ranging from tens of nanometers to 
as large as 10 µm [186-188]. The nanofiber mesh obtained by this process is a unique 
scaffold membrane that possesses structural features with a size scale similar to 
extracellular matrix (ECM) components, high porosity and large surface area to volume 
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ratios. These properties allow for enhanced cellular attachment and spreading [90, 98]. 
and therefore nanofiber meshes may serve as an effective delivery vehicle for cells to a 
defect site in vivo. However, it is important to first evaluate their efficacy in supporting 
cell function and as a cell delivery vehicle in vitro. Though a few studies have 
investigated the osteogenic differentiation of progenitor cells on nanofiber meshes, more 
thorough analyses are needed to characterize the differentiation and mineralization 
process, and to quantify mineral deposition [191, 213, 214]. In addition, nanofiber 
meshes may be utilized as an ECM-mimetic surface for evaluating cell behavior, and 
therefore serve as an improved in vitro cell culture system, compared to flat tissue culture 
plates [215]. 
The purpose of this study was to investigate the attachment, colonization and 
osteogenic differentiation of human MSCs (hMSCs) and human AFS (hAFS) cells on 
electrospun nanofiber meshes. We demonstrate that electrospun meshes are able to 
robustly support these functions for both cell types. Compared to tissue culture plastic, 
there is delayed initial attachment and proliferation, but enhanced mineralization at a later 
time point. Differences in the kinetics of osteogenic differentiation were observed 
between hMSCs and hAFS cells. Cell-seeded nanofiber meshes were also effective in 
colonizing three dimensional scaffolds in an in vitro model. These results provide support 
for the use of the nanofiber mesh as a cell delivery vehicle for the repair of bone defects 
in vivo. 
Materials and Methods 
Fabrication of nanofiber meshes 
A polymer solution was made by dissolving 13% (w/v) poly (ε-caprolactone) 
(PCL) (Sigma-Aldrich, St. Louis, MO) in a 40:60 volume ratio of dichloromethane 
(DCM):dimethylformamide (DMF) (Sigma-Aldrich). PCL pellets were added to the 
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solvent mixture, and gently stirred for 16-24 hours. The polymer solution was loaded in a 
3 mL syringe (Becton-Dickinson, Franklin Lakes, NJ), and a 22 gauge blunt stainless 
steel needle (Jensen Global Inc., Santa Barbara, CA) was attached to the syringe end. The 
syringe was mounted on a syringe pump (Harvard Apparatus, Holliston, MA), and the 
pump was set to infuse at a rate of 0.75 mL/hr. A flat, 6 6 inch copper plate (McMaster-
Carr, Atlanta, GA) covered with aluminum foil was used to collect the fibers, and placed 
at a distance of 20 cm from the needle end. Fibers were electrospun for 50 minutes at a 
voltage of 14 kV, supplied by a high voltage power supply (Gamma High Voltage 
Research, Ormond Beach, FL), to obtain a thin sheet of nanofiber mesh. To remove any 
residual solvent, the meshes were placed in a dessicator for at least one day before further 
use.  
Nanofiber mesh morphology 
The morphology of the nanofiber meshes was examined using a Scanning 
Electron Microscope (SEM). A small piece of the dry nanofiber mesh was cut and 
mounted on a metal stub using double-sided adhesive tape. A thin layer of gold was then 
deposited on the mesh sample for 80 seconds using a sputter coater (Quorum 
Technologies, East Granby, CT). The gold-coated sample was then viewed under a 
Hitachi S-800 Field Emission SEM (Hitachi HTA, Pleasanton, CA) with 10kV 
accelerating voltage. The diameters of the fibers were quantified by analyzing the SEM 
images (at 7000  magnification) using a custom MATLAB® (MATLAB® 7.0 R14, The 
MathWorks Inc., Natick, MA) program. A total of at least 75 distinct fibers were 
measured from four randomly chosen locations. 
Culture of AFS cells and MSCs 
Human AFS cells were kindly provided by Dr. Anthony Atala and Dr. Shay Soker 
at the Wake Forest Institute for Regenerative Medicine (Winston-Salem, NC). The 
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isolation method and culture protocols have been described previously [132, 134]. 
Briefly, back-up human amniocentesis cultures were harvested by trypsinization, and 
subjected to c-kit immunoselection. hAFS cells were subcultured routinely at a dilution 
of 1:4 to 1:8, and not permitted to expand beyond 70% confluence. The hAFS cells were 
passaged in αMEM (Minimum Essential Medium Alpha) supplemented with 16% fetal 
bovine serum (ES Cell-qualified FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, 2 
mM L-glutamine (Invitrogen, Carlsbad, CA), 18% Chang B and 2% Chang C (Irvine 
Scientific, Santa Ana, CA). In all experiments, cells were used at passages 16-17. 
Human MSCs derived from the bone marrow were obtained from the Tulane 
University Center for Gene Therapy (New Orleans, LA) at passage 1. Cells were isolated 
using bone marrow aspirates from the iliac crest of normal adult donors as previously 
described [216]. For expansion, these cells were plated at a density of 50 cells/cm2, and 
cultured in hMSC growth media. The hMSC growth media consisted of αMEM 
(Invitrogen) supplemented with 16% FBS (Atlanta Biologicals, Atlanta, GA), 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine (Invitrogen). The cells were 
subcultured once they reached a confluency of ~70%. Passage 2-3 hMSCs were then used 
for all experiments. 
Cell culture on nanofiber fiber meshes 
Square 15 mm samples were cut from nanofiber mesh sheets using scissors. 
Samples were placed in 24-well culture plates, submerged in 200 proof ethanol (Sigma-
Aldrich), and sterilized by allowing the ethanol to evaporate overnight. After the samples 
had dried completely, they were pre-wetted with sterile 70% ethanol for 30 minutes. The 
70% ethanol was then aspirated, and sterile dead weights were placed around the samples 
to prevent them from floating. The mesh samples were next rinsed three times with 
excess sterile PBS (Mediatech Inc., Manassas, VA). An 800 µL volume of media was 
placed in each well containing the samples. The control groups received hMSC growth 
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media, whereas the osteogenic groups were further supplemented with 10 nM 
dexamethasone, 6 mM β-glycerol phosphate, 50 µg/ml ascorbic acid 2-phosphate and 50 
ng/ml L-thyroxine (Sigma-Aldrich). hMSCs and hAFS cells were then seeded onto 
nanofiber meshes in approximately 200 µL of hMSC media such that the density of cells 
was 20,000 cells/cm2. Cells were also cultured in tissue culture treated 24-well plates at 
the same density for comparison. Media was changed every 3-4 days, and the constructs 
were cultured for up to 4 weeks. 
Cell viability 
On days 1, 7, 14 and 28, the viability of the cells in the constructs was assessed 
using the Live/Dead® staining kit (Molecular Probes, Invitrogen). Harvested constructs 
were rinsed in PBS and incubated in 4 µM calcein-AM and 4 µM ethidium homodimer-1 
for 45 minutes at room temperature. The samples were again rinsed in PBS, and images 
were obtained on a Zeiss LSM 510 confocal microscope (Carl Zeiss, Thornwood, NY). 
Green fluorescence of calcein-AM was detected by using a 488-nm Argon ion laser and a 
band pass 505-550 filter. Red fluorescence of ethidium homodimer-1 was detected by 
using a 543-nm Helium-Neon laser and a long pass 560 filter. 
DNA content 
Samples were harvested after 1, 7, 14 and 28 days to evaluate the construct 
cellularity, which was assessed by determining the DNA content. The cells were first 
lysed by freeze-thawing the constructs three times in 0.05% Triton X-100 (Sigma-
Aldrich) with vigorous vortexing. To freeze the samples, they were placed in dry ice 
cooled methanol (Sigma-Aldrich) for 5 minutes. Samples were then thawed in a room 
temperature water bath. The DNA amount in the lysate was quantified using the 
PicoGreen® dsDNA Quantitation Kit (Molecular Probes, Eugene, OR), and standardized 
using Lambda DNA solutions of known concentrations. A working solution of the 
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PicoGreen® reagent was made following the manufacturer’s protocol, and incubated with 
experimental samples in the dark for 5 minutes at room temperature. The fluorescence 
was measured on a plate reader (HTS 7000, Perkins-Elmer, Waltham, MA) at an 
excitation of 485-nm and emission of 535-nm. All samples were run in triplicate, and the 
DNA content was normalized to the culture surface area of the samples. 
Alkaline Phosphatase (ALP) activity 
To determine the osteogenic differentiation of the cells on nanofiber meshes, the 
ALP activity assay was performed. In this assay, the release of p-nitrophenol from p-
nitrophenyl phosphate by the ALP enzyme is measured [217]. The same lysate solution 
that was used to determine DNA content was used for this purpose. The ALP substrate 
working solution was made by mixing equal parts of 20 mM p-nitrophenyl phosphate, 1.5 
M 2-Amino-2-Methyl-1-Propanol (pH 10.25) and 10 mM MgCl2. The experimental 
samples were mixed with the freshly made substrate working solution, and incubated for 
1 hour at 37° C. The reaction was stopped by adding 1N NaOH, and the absorbance was 
measured at 405 nm on a plate reader (PowerWave XS, Biotek, VT). All samples were 
run in triplicate and compared to p-nitrophenol standards. The ALP activity was 
normalized by the incubation time and the amount of DNA obtained from the PicoGreen® 
assay. 
Calcium content 
To quantify matrix mineralization, the calcium deposited by cells on nanofiber 
meshes after 28 days was determined using the Arsenazo III dye [218]. Samples were 
vortexed with 1 N acetic acid overnight to extract the calcium into solution. The extract 
was mixed with the Arsenazo III reagent (Diagnostic Chemicals Limited, Oxford, CT), 
incubated for 30 seconds at room temperature, and the absorbance read at 650 nm on a 
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plate reader (PowerWave XS, Biotek). The samples were assayed in triplicate and 
compared to Calcium Chloride (CaCl2) standards. 
Calcein staining and quantification 
For visualization of the mineral deposited by the cells, the samples were stained 
using calcein on day 28 [219, 220]. Briefly, a stock solution of 100 µg/ml calcein 
(Sigma-Aldrich) in PBS (pH 7.4) was added to the media on top of the samples, such that 
the final concentration of calcein was 10 µg/ml. The samples were incubated in the 
calcein solution for 4 hours in the incubator. After rinsing twice with PBS and fixing with 
10% neutral buffered formalin (EMD Chemicals, Gibbstown, NJ), samples were rinsed 
with excess of DI water. The fluorescence of the samples was read on a fluorescence 
plate reader (HTS 7000, Perkins-Elmer) at an excitation of 485-nm and emission of 535-
nm. Following this, the same samples were imaged using an inverted microscope (Axio 
Observer.Z1, Carl Zeiss) and a FITC filter. 
Fourier Transform Infrared (FTIR) Spectroscopy 
On day 28, constructs were also harvested for analyzing the chemical composition 
of the mineral deposited on the nanofiber meshes. Samples were dehydrated in 100% 
ethanol and dried at 50° C overnight. Acellular PCL nanofiber mesh was used as a 
negative control. After dehydration, the samples were cut into small pieces, mixed with 
potassium bromide (Sigma-Aldrich), and pressed into pellets using a custom built 
apparatus. Samples were analyzed with a Nicolet Nexus 470 FTIR spectrometer 
(Thermo-Nicolet, Madison, MI). Sixty four scans were acquired at 4 cm-1 resolution 
under nitrogen purge. 
Cell delivery by nanofiber mesh in vitro 
The ability of a cell seeded nanofiber mesh to serve as a cell delivery vehicle was 
studied using an in vitro model. AFS cells were seeded on to nanofiber mesh samples 
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(15 10 mm) at a density of 200,000 cells/cm2. The cells were allowed to attach to the 
mesh overnight. On the following day, each cell seeded mesh was wrapped around a 
cylindrical collagen scaffold (dry dimensions: 4 mm diameter and 9 mm length) 
aseptically, such that the cells were facing the scaffold (Figure 3.7A). The scaffolds were 
punched from a fibrous collagen sheet (average pore size 61.7 µm, 93.7% pore volume, 
Kensey Nash, Exton, PA). The mesh was held in position by placing two interrupted silk 
sutures through the mesh and scaffold at the two ends of the scaffold. For comparison, we 
also seeded 300,000 cells throughout collagen scaffolds by pipetting the cell suspension 
directly in the scaffolds. There was no nanofiber mesh in this control group. The 
constructs were statically cultured in hAFS cell growth media. After two weeks, the mesh 
was taken off, following which the mesh and scaffold were stained with the Live/Dead® 
staining kit (Molecular Probes, Invitrogen) to visualize the cell migration into the 
scaffold. A confocal microscope (Zeiss LSM 510, Carl Zeiss) was used to take serial 
images to create three dimensional images. 
Data analysis 
Results are presented as mean + standard error of the mean (SEM). Analysis of 
variance (ANOVA) was performed on data, with pairwise comparisons done using the 
Tukey multiple comparison procedure. A p-value < 0.05 was considered significant. 
Residuals were used for diagnosing the appropriateness of the model by analyzing the 
constancy of error variance and normality of error terms [221]. Wherever required, 
remedial measures were taken by transforming the data according to the Box-Cox 
procedure [222], or by using weighted least squares to make the error variance constant 
and the error distribution normal [221, 223]. Minitab® 15 (Minitab Inc., State College, 




Morphology of nanofiber meshes 
PCL nanofiber meshes were electrospun on a flat collector plate. The mesh 
formed a circular area of approximately 8 cm diameter. The thickness of the mesh was 
found to vary with location, with the central areas thicker than the edges. The thin mesh 
samples from the edges were discarded and not used for cell culture. Fibers appeared to 
be smooth and uniform, with minimal bead formation (Figure 3.1 A and B). The 
quantification of the fiber diameter using a custom MATLAB® program demonstrated 
that the mean fiber diameter was 591 nm with a standard deviation of 199 nm. The fiber 
diameter histogram revealed that most of the fibers were between 300-900 nm, with the 
highest frequency occurring in the 500-600 nm range (Figure 3.1 C). 
Viability and colonization of hMSCs and hAFS cells over time 
hMSCs and hAFS cells were seeded on electrospun nanofiber meshes and tissue 
culture plates, and cultured in osteogenic media for up to 28 days. The viability of the 
cells on the meshes was assessed on days 1, 7, 14 and 28 by the Live/Dead® staining kit. 
The live cells are stained green, whereas the dead cells appear red. At the same time 
points, DNA from the samples was extracted and quantified to estimate the number of 
cells on the meshes, as well as in the culture wells. The Live/Dead images (Figure 3.2) 
illustrate that both cell types attached to the nanofiber meshes by day 1 and were able to 
spread out by day 7. During days 7-14 the number of cells increased considerably, and by 
day 28, the cells were confluent on the meshes. The viability of both cell types on the 
meshes was found to be high, as seen by the extensive green stain, though a few dead 
cells were detected. No differences were observed in the viability and colonization 
between the two cell types. 
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The DNA quantification over the four week culture period was used to compare 
the colonization kinetics of the two cell types on tissue culture plates and nanofiber 
meshes, respectively (Figure 3.3). There was significant increase in DNA with time for 
both cell types, on plates as well as meshes, indicating cellular proliferation. On plates, 
the number of hAFS cells increased between days 1-7 but did not change significantly 
after that, suggesting rapid initial proliferation and confluency around day 7 (Figure 3.3 
A). On the other hand, hMSCs increased in numbers between both days 1-7 and days 14-
28. However, this result is an artifact of hMSC culture on the plates, as the hMSCs were 
found to lift off the plate after confluence around day 7 to form a pellet, and then 
repopulate the plate. This pelleting behavior was not seen with the hAFS cells for up to 
28 days, though the hAFS cells do ultimately lift off the plate. The hMSC repopulation 
explains the increase in hMSC cell number between days 14-28 and the differences seen 
between hMSCs and hAFS cells on days 14 and 28. There were also significantly more 
hAFS cells than hMSCs on day 1, suggesting a higher initial attachment and/or 
proliferation rate. 
The pelleting phenomenon does not occur on the nanofiber meshes, even at a later 
time points. There was a significant increase in DNA for both cell types between days 1-
7, and an even higher increase between days 7-14, corresponding to the Live/Dead 
images (Figure 3.3 B). The number of cells did not change significantly after that, 
suggesting confluency of the cells on the nanofiber meshes. There were no significant 
differences in the DNA between hMSCs and hAFS cells at any time point. 
We also compared the colonization kinetics of hAFS cells on the nanofiber 
meshes with that on the tissue culture plates (Figure 3.3 C and D). On days 1, there was 
significantly less DNA on the mesh compared to plates, suggesting that not all cells 
attach to the nanofibers within the first 24 hours. The same trend was seen on day 7. 
However, by day 14, there was no significant difference between meshes and plates. On 
day 28, there was again no significant difference, though the lines crossed over. Although 
 44
the hMSCs pellet in the plates and repopulate the culture surface by day 28, the amount 

























Figure 3.1. Nanofiber mesh morphology. Nanofiber meshes were electrospun from a 13%
(w/v) poly (ε-caprolactone) (PCL) solution made in 40:60 dichloromethane
(DCM):dimethylformamide (DMF). A Scanning Electron Microscope (SEM) was used to
examine the morphology of the nanofibers. (A) SEM image at low (1000X)
magnification. (B) SEM image at high (7000X) magnification. (C) The diameter of the
fibers was quantified using a custom MATLAB® program and the diameter distribution
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Figure 3.2. Live/dead staining. Human mesenchymal stem cells (hMSCs) and human
amniotic fluid stem (hAFS) cells were seeded on nanofiber meshes and cultured in
osteogenic media. On days 1, 7, 14 and 28 , the viability of the cells on the meshes was
assessed by imaging the constructs with a confocal microscope after staining with the
Live/Dead® stain. Live cells: green; dead cells: red. Images were taken at 10X
magnification. Scale bar indicates 200 µm and applies to all images. Both cell types were
able to attach, proliferate and become confluent on the mesh. 
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Figure 3.3. DNA content. In order to evaluate sample cellularity, the DNA content was
determined after cell lysis using the PicoGreen® reagent. Cells were cultured on (A)
tissue culture plates and (B) nanofiber meshes. To compare the cellularity on nanofiber
meshes with that on tissue culture plates, the data was plotted again for (C) hMSCs and
(D) hAFS cells. DNA increased with time indicating cellular proliferation. Data is
presented as mean ± standard error of mean. p < 0.05 is considered significantly different.
(* - significantly different than the other cell type at same time point; # - significantly




























































































Osteogenic differentiation of hMSCs and hAFS cells: ALP activity 
The osteogenic differentiation of the cells was first investigated by analyzing the 
ALP activity of the cells (Figure 3.4). ALP is a membrane-bound enzyme that hydrolyzes 
phosphate esters, which results in inorganic phosphate being available for incorporation 
into mineral deposits [224]. There was significant increase in the ALP activity of both 
cell types with time, on plates as well on nanofiber meshes, suggesting osteogenic 
differentiation. On tissue culture plates, ALP activity peaked at day 7 for MSCs, whereas 
for AFS cells it increased slowly but continuously up to day 28 (Figure 3.4 A). 
Interestingly, the maximum ALP activity of the hAFS cells was greater than the hMSC 
peak. On the nanofiber meshes, hMSCs demonstrated a similar earlier rise in ALP 
activity, on day 14, compared to day 28 for hAFS cells (Figure 3.4 B). The ALP activity 
of the hMSCs was significantly greater than that of hAFS cells on all time points other 
than day 1. The ALP response on meshes is delayed compared to that on the plate, as 
seen by the later increase in ALP activity. Interestingly, the ALP activity of hMSCs on 
meshes was sustained longer than plates, with the maximum value on meshes at day 28 
greater than that observed on plates at day 7 (p<0.05). 
Osteogenic differentiation of hMSCs and hAFS cells: matrix mineralization 
The osteogenic differentiation of the cells was further investigated by quantifying 
and staining the calcium deposits and by analyzing the chemical nature of the deposited 
mineral by FTIR spectroscopy. An ANOVA on the calcium deposited by the cells 
revealed that both cell type and the culture surface had a significant effect on the calcium 
levels (Figure 3.5 A). Under osteogenic stimulation, all groups demonstrated increased 
calcium deposition, compared to growth media, indicating that cells are able to 
differentiate to an osteoblastic phenotype on the surfaces. Calcium levels in the hMSC 
growth media groups were negligible. hAFS cells deposited a higher amount of calcium 
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than hMSCs on both plates and meshes. Also, both cell types deposited more calcium on 
meshes compared to plates. 
FTIR spectroscopy was used to characterize the composition of the mineral that 
was deposited by the cells on the nanofiber meshes under osteogenic stimulation (Figure 
3.5 B). To distinguish the peaks associated with the mineral from the peaks associated 
with the PCL mesh, an acellular piece of PCL mesh was also scanned [225]. The cellular 
samples displayed amide I/II peaks at 1655 and 1550 cm-1, a carbonate peak at 870 cm-1, 
and a doublet split phosphate peak at 560 and 605 cm-1, which were not seen in the 
acellular mesh. There was also a peak at 1050 cm-1 in the cellular samples, but it 
overlapped with a PCL mesh peak. These peaks are the signature of a carbonate-
containing, poorly crystalline hydroxyapatite, the form of mineral that is found in native 
bone. This suggests that both hMSCs and hAFS cells deposited mineral that possessed 
the characteristic bands of physiological mineral. 
Samples were stained with calcein to visualize the presence of calcium on the 
nanofiber meshes. The calcein staining demonstrated the presence of extensive calcium-
containing mineral nodules, which were uniformly distributed on the meshes, as seen by 
the green fluorescence (Figure 3.6 A). This was the case in both the hMSC and hAFS cell 
osteogenic groups, whereas the growth media groups stained minimally. Quantification 
of the fluorescence revealed that more mineral was deposited by the hAFS cells 


















































































Figure 3.4. ALP activity. The osteogenic differentiation of the cells was evaluated by
measuring the alkaline phosphatase (ALP) activity of cell lysates on (A) tissues culture
plates and (B) nanofiber meshes. ALP activity increased for both cell types with time,
suggesting osteogenic differentiation. p < 0.05 is considered significantly different. (* -
significantly different than the other cell type at same time point; # - significantly
different than a previous time point for same cell type; $ - significantly different than
hMSC peak on plate at day 7). 
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Figure 3.5. Calcium quantification and FTIR analysis. (A) The mineralization of the
constructs was assessed by measuring the calcium deposited by cells. Both cell types
deposited calcium in osteogenic media, indicating an osteoblast phenotype. p < 0.05 is
considered significantly different. (# - significantly different than growth media; * -
significantly different than other cell type on same surface; $ - significantly different than
plate with same cell type). (B) The chemical composition of the mineral was analyzed by
Fourier transform infrared (FTIR) spectroscopy. The annotated peaks are the signature of
a carbonate-containing, poorly crystalline hydroxyapatite, indicative of physiologic




























































1800 1600 1400 1200 1000 800 600
 51
 
Figure 3.6. Calcein staining. Constructs were stained with calcein to visualize the
presence of the mineral deposits. (A) The osteogenic samples stained with calcein,
illustrating that cells had deposited mineral uniformly on the nanofiber meshes. Images
were taken at 10X magnification. Scale bar indicates 200 µm and applies to all images.
(B) The calcein staining was quantified by measuring the fluorescence using a plate
reader. The data revealed greater mineralization by AFS cells. p < 0.05 is considered
significantly different. (* - significantly greater than MSC osteogenic media; # -























Nanofiber mesh as a cell delivery vehicle 
As a preliminary evaluation of the nanofiber mesh for cell delivery, AFS cells 
were seeded on nanofiber meshes and wrapped around cylindrical collagen scaffolds in 
vitro. The constructs were cultured for two weeks and then stained with the Live/Dead® 
staining kit. In the cell-seeded scaffold, we observed that more cells were present at the 
periphery of the scaffold, even though cells were seeded throughout (Figure 3.7 A). We 
also detected a large number of dead cells in the interior of the scaffold. When the cell-
seeded mesh was wrapped around a collagen scaffold, we found that numerous cells had 
migrated off the mesh onto the collagen scaffold and had high viability (Figure 3.7 C and 
D). The majority of cells were located close to the peripheral surface. Interestingly, we 
noted that the top surface was completely covered with cells (Figure 3.7 D). This implies 
that the cells were able to migrate at least 2 mm from the edge, where the mesh was 
present, to the center of the top surface. A few cells were also seen in the interior of the 
scaffold, more than 500 µm away from the peripheral surface (Figure 3.7 D). The mesh 
was completely confluent with cells indicating that only a subset of cells migrates from 
the mesh onto the scaffold (Figure 3.7 E). 
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Figure 3.7. Cell-seeded nanofiber meshes for in vitro delivery. (A) To investigate the use
of nanofiber meshes for cell delivery, AFS cells were seeded on nanofiber meshes and
wrapped around a 3-D collagen scaffold for 2 weeks in vitro. For comparison cells were
seeded throughout the scaffold. (B) - (E) Three-dimensional confocal images of the
live/dead stained scaffold and mesh. The projections of the 3-D images are shown. The
surface and top views are views of the 3-D image looking from the top. The side view is
the view of the 3-D image looking from the side. The green box indicates the area and
view being analyzed. (B) The collagen scaffold with cells seeded throughout had more
cells on the exterior with numerous dead cells in the interior. (C) When a cell-seeded
mesh was wrapped around the scaffold, cells migrated on to the peripheral surface of the
scaffold and displayed high viability. (D) Top and cross-sectional surfaces of scaffold
wrapped with cell-seeded mesh. Cells also colonized the top surface of the scaffold and
migrated more than 500 µm into the scaffold from the mesh. (E) The seeded mesh was
confluent with cells. Images were taken at 10X magnification. Scale bar indicates 200 µm






In this study, we investigated the function of two kinds of stem cells, hMSCs and 
hAFS cells, on electrospun nanofiber meshes. Both cell types were able to attach, 
colonize and undergo robust osteogenic differentiation on the meshes. This indicates that 
the nanofiber mesh is a scaffold membrane capable of supporting vital osteoprogenitor 
and osteoblast functions. Other groups have also reported the ability of nanofiber meshes 
to promote differentiation of osteoblasts [192, 226] and MSCs [213, 227]; however a 
quantitative and more thorough analysis of the matrix mineralization has been missing. 
We utilized a sensitive calcium assay based on the Arsenazo III dye to quantify the extent 
of matrix mineralization [218, 228]. The mineral deposited on the nanofiber meshes was 
confirmed to be biological in nature by FTIR spectroscopy, indicating that the process 
was cell-mediated. Finally, we used calcein staining to visualize and semi-quantify the 
mineral deposits on the mesh. Another advantage of the calcein stain is that it can be used 
for continuous monitoring of the in vitro matrix mineralization process [219, 220]. 
Although acellular approaches to bone reconstruction using scaffolds and 
osteogenic growth factors have shown moderate clinical success, the delivery of 
osteogenic cells may be required for patients with a reduced local supply of responsive 
osteoprogenitor cells. For successful clinical translation of cell based bone defect repair, a 
cell source needs to be identified that is readily available, propagated easily, has high 
osteogenic potential, and will be accepted by the recipient immune system. Both hMSCs 
and hAFS cells possess a number of these characteristics. MSCs have been studied 
extensively, especially for bone regeneration, and preclinical studies have shown their 
ability to repair bone defects in vivo [125, 126]. A number of human clinical trials have 
shown variable, but encouraging results of hMSC therapy, including the treatment of 
graft-versus-host disease, myocardial infarction, osteogenesis imperfecta and large bone 
defects [229, 230]. However, hMSCs are known to progressively lose their stem cell 
properties during expansion, limiting the total number of cells available for therapy, and 
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limited viability following transplantation remains a significant challenge [231]. One of 
the objectives of this study was to compare the osteogenic capacity of this widely-used 
adult stem cell with a more novel fetal stem cell source, the hAFS cells. AFS cells have 
been demonstrated to be capable of extensive self-renewal, and therefore can be 
expanded to large numbers and still maintain their multipotency [132, 134, 209, 210]. 
The colonization kinetics of hMSCs and hAFS cells on nanofiber meshes was 
found to be similar, suggesting comparable proliferation rates when seeded at a high 
density of 20,000 cells/cm2. On tissue culture plates there were more hMSCs than hAFS 
cells on day 28, but this was due to the pelleting and recolonization by the hMSCs. hAFS 
cells demonstrated a later rise in ALP activity than the hMSCs on both plates and meshes, 
perhaps due to their primitive nature. ALP is a membrane-bound enzyme that plays an 
important role in matrix mineralization [224]. ALP activity is one of the earliest markers 
of osteogenic differentiation and rises as the osteoprogenitors commit to the osteoblast 
lineage. It peaks in the matrix maturation phase and decreases as mineralization 
progresses [232, 233]. However, ALP is expressed by other differentiated cells as well 
[234, 235], and therefore it is important to simultaneously analyze other osteogenic 
measures, such as matrix mineralization. At four weeks, hAFS cells deposited 
significantly more mineral than hMSCs on both plates and meshes, as demonstrated by 
calcium quantification and calcein staining. Thus we observed that, while the rise in ALP 
activity of the hAFS cells occurs later than in hMSCs, the hAFS cells mineralize more 
robustly after 4 weeks. This indicates that the kinetics of ALP activity and matrix 
mineralization are differentially regulated for these two different cell types. Our results 
demonstrate that hAFS cells have high osteogenic potential, even at the late passage 
numbers we have used. In addition, unlike human embryonic stem cells (hESCs), hAFS 
cells have shown an absence of tumor formation in vivo [132]. This suggests that the 
hAFS cells may be a feasible cell source for the repair of bone defects. They may be 
especially useful in the case of patients whose cells are not amenable for autologous 
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transplantation due to disease or advanced age. Another advantage of the AFS cells is 
that they are suitable for convenient off-the-shelf allogeneic cell delivery, as long as the 
major histocompatibility complex of donor and recipient are matched. This would reduce 
the time and cost of delivering the cell therapy and may result in improved clinical 
acceptance. 
Woo and coworkers have recently reported that a nanofibrous scaffold made by a 
modified solvent casting method resulted in improved expression of osteoblast phenotype 
versus a solid-walled scaffold [236]. We compared cell function on the nanofiber meshes 
with that on tissue culture plastic. Compared to tissue culture plastic, there is delayed 
initial attachment and proliferation on the meshes. However by two weeks, the cells on 
the meshes catch up with those on the plates and there is no significant difference 
between the groups. The cells, especially the hMSCs, did not lift off the nanofiber mesh 
surface, as was seen on plates. This difference in cell attachment could to due to changes 
in cell adherence, material and topographic properties or ECM deposited on the nanofiber 
mesh surface. Despite the initial lag in colonization on meshes compared to that on 
plates, we observed enhanced mineralization on meshes by both the cell types at four 
weeks. This suggests that the ECM-mimetic morphology of the nanofibers provides an 
environment conducive for matrix maturation. In a recent paper, Smith et al. 
demonstrated that the use of nanofibers resulted in a greater degree of embryonic stem 
cell differentiation, compared to films and tissue culture plates [237]. This study also 
provides support for the use of nanofiber meshes as an improved in vitro cell culture 
model surface that better recapitulates the in vivo environment of cells.  
Cell survival following delivery is a critical issue in the development of cell-based 
strategies, especially for thick tissues such as bone. The lack of initial vascularity in bone 
defects limits the transport of nutrients to and waste products from the center of the 
defect. Therefore, if cells are seeded throughout a three dimensional scaffold and placed 
at the defect site, cells located at the center of the scaffold may not survive [137-140]. 
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Delivery of cells on the periphery of bone defects via a tissue engineered periosteum may 
be an effective approach to enhance cell survival by the presence of a neighboring 
vasculature. With time, as a continuous vasculature is established at the center, the cells 
may migrate towards the center due to an improved transport environment. Recently 
Zhang reported that engraftment of bone morphogenetic protein-2 (BMP-2) producing 
BMSCs using gelfoam wrapped around nonvital allografts improved allograft 
incorporation and repair [141]. Our results indicate the electrospun nanofiber mesh 
possesses characteristics suitable for supporting cell function. In addition its thickness 
can be controlled to obtain a membrane suitable for creating a tissue engineered 
periosteum. To begin preliminary investigations into cell delivery, we asked the question: 
will cells migrate off the mesh and populate a three dimensional scaffold in vitro? We 
observed that the cells migrated off the mesh and colonized the scaffold within two 
weeks, traveling as far as 2 mm. In addition to the migration, part of the colonization is 
probably due to cell proliferation. Interestingly, we noticed better viability of the cells in 
the scaffold when they were delivered on the mesh compared to when they were seeded 
uniformly in the scaffolds. These results suggest that a cell-seeded nanofiber mesh may 
be an effective method to deliver cells to bone defects and maintain high viability. Future 
work will determine whether these effects are also observed in vivo. 
In conclusion, we demonstrated that two types of stem cells, hMSCs and hAFS 
cells, are able to attach, colonize and undergo robust osteogenic differentiation on 
electrospun nanofiber meshes. hAFS cells displayed a delayed ALP increase, but 
deposited significantly more mineral compared to hMSCs. Cell-seeded nanofiber meshes 
were effective in colonizing three dimensional scaffolds in an in vitro model. These 
results indicate that the electrospun nanofiber mesh supports osteoprogenitor cell function 
and may be useful as a medium for cell delivery for the repair of bone defects in vivo. In 
addition, this study provides support for the use of nanofiber meshes as a model surface 
for cell culture experiments.  
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CHAPTER 4  
NANOFIBER ORIENTATION AND SURFACE 
FUNCTIONALIZATION MODULATE HUMAN MSC 
INFILTRATION AND OSTEOGENIC DIFFERENTIATION 
Introduction 
 Biomaterial-based implants offer a robust therapeutic strategy to improve tissue 
regeneration and construct integration [238]. Acellular approaches for tissue 
regeneration, in which the implanted biomaterial recruits endogenous cells for repair, are 
more feasible than cell-based therapies for deployment in clinical practice [239-242]. 
This is due to the technical challenges of cell delivery and survival, and the commercial 
difficulties associated with the manufacturing and storage of cells and obtaining 
regulatory approval. For purely biomaterial-based therapies to be effective, the 
biomaterial is usually required to function as both a scaffold and a biologically active 
agent to provide specific molecular signals for regulating cellular response [115, 165]. 
The rational design of the material structure and composition is therefore essential for 
implant success. 
 Electrospun nanofiber meshes are a unique type of scaffold with structural 
features that, at least by scale, resemble the extracellular matrix (ECM). In addition, they 
exhibit large surface area and high porosity, making them suitable as a scaffold for 
guiding tissue regeneration by host cells [98, 191, 214, 243]. For example, in the case of 
a large diaphyseal bone defect, the nanofiber mesh may be able to provide cues for 
progenitor cells from the periosteum and marrow space to migrate into the defect region 
and deposit mineralized matrix. In a previous study, we demonstrated that nanofiber 
meshes made from a synthetic polymer are able to support the attachment, colonization 
and osteogenic differentiation of progenitor cells (Chapter 3). Synthetic polymers, 
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however, lack biological ligands, and are not capable of directing intracellular signaling 
and response. Nanofiber meshes have also been fabricated from natural materials like 
collagen and fibrinogen [187, 195, 197], but these are limited by poor mechanical 
strength and handling characteristics for in vivo applications [199]. Approaches that 
incorporate bioactive molecules within a synthetic polymer backbone may provide an 
optimal combination of biological activity and mechanical integrity. 
 Tremendous advances have been made in imparting biofunctionality to synthetic 
materials by coating them with ECM components. These biomimetic material surfaces 
present adhesion motifs to engage the cell signal transduction machinery for directing 
cellular response and tissue repair [115, 116]. Though adhesive proteins such as type I 
collagen, fibronectin and laminin have been immobilized on material surfaces, these 
approaches are limited by protein purification and processing issues, and a potential host 
immunogenic response [108-111]. In addition, the multiple adhesion domains in a full-
length protein may trigger conflicting intracellular signals, leading to suboptimal tissue 
repair. Therefore, there is a great need to develop peptides that mimic specific domains of 
natural proteins. These ECM-mimetic peptides can be synthesized and purified with 
relative ease, and furthermore, can be designed to trigger a specific cellular response 
[244-248]. One such peptide that has been recently investigated is a triple-helical, 
collagen-mimetic oligopeptide containing the glycine-phenylalanine-hydroxyproline-
glycine-glutamate-arginine (GFOGER) domain from residues 502-507 of the α1(I) chain 
of type I collagen [249, 250]. It has been shown that the interaction of this adhesion motif 
with α2β1 integrin mediates osteoblast adhesion, differentiation and matrix mineralization 
[117, 118]. This has been exploited to enhance the adhesion and osteogenic 
differentiation of progenitor cells and improve implant integration, by coating surfaces 
with the GFOGER peptide [120, 121, 251]. This technique utilizes simple adsorption of 
the GFOGER peptide on implant surfaces in physiologic conditions, which may be 
advantageous for clinical translation. 
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 Another set of guidance strategies consists of topographical cues to influence 
cellular responses. It is now accepted that surface morphology, including roughness and 
texture, modulates cellular response. For instance, titanium implants with rough 
microtopographies reduced cell number, increased differentiation and enhanced implant 
integration [252-255]. The electrospinning process can be easily adapted to obtain fibrous 
matrices with varying structure. Fiber alignment, especially, has generated significant 
interest due to the fact that a number of native and regenerating tissues display an ordered 
architecture. Studies have shown that alignment of fibers along a particular direction 
affects cellular attachment and morphology as well as matrix deposition [208, 256, 257]. 
Neurites grown on aligned nanofibers display contact guidance and improved migration 
[258, 259]. However, the effect of fiber alignment on human MSCs (hMSCs) function 
needs to be investigated. In addition, the combined effect of nanofiber mesh  orientation 
and surface composition has not been studied extensively. 
 The purpose of this study was to investigate the effect of nanofiber 
functionalization and orientation on hMSC function, in order to identify conditions that 
best support bridging of bone defects by osteoprogenitor cells. Nanofiber meshes were 
functionalized with the GFOGER peptide to improve cell adhesion and osteogenic 
differentiation. An oriented topography was obtained by electrospinning aligned 
nanofibers in order to enhance cellular migration. We developed an in vitro model to 
examine hMSC infiltration on top of nanofiber meshes, and isolated the contribution of 
cell proliferation versus migration. The individual and combined effects of nanofiber 
functionalization and orientation on hMSC function were investigated. We hypothesized 
that functionalizing nanofiber surfaces with the GFOGER peptide and aligning nanofiber 
orientation will modulate cellular behavior in vitro. In addition, we assessed the efficacy 




Materials and Methods 
Electrospinning and nanofiber mesh characterization 
 Nanofiber meshes were made by electrospinning, and characterized as described 
elsewhere (Chapters 3 and 5). Briefly, a 12% (w/v) solution of poly (ε-caprolactone) 
(PCL) was made in a 90:10 volume ratio of hexafluoro-2-propanol 
(HFP):dimethylformamide (DMF) (Sigma-Aldrich, St. Louis, MO). A 3 mL syringe 
(Becton-Dickinson, Franklin Lakes, NJ) was filled with the PCL solution and fitted with 
a 22 gauge blunt-end needle (Jensen Global Inc., Santa Barbara, CA). The syringe was 
placed on a syringe pump (Harvard Apparatus, Holliston, MA), which was adjusted for a 
flow rate of 0.75 mL/hr. To create a nanofiber mesh with random fiber alignment 
(random nanofiber mesh), a flat copper plate was placed at a distance of 20-23 cm from 
the needle tip. To obtain meshes with fibers aligned along the same direction (aligned 
nanofiber mesh), they were collected on a mandrel rotating at ~2500 rpm and placed 8-10 
cm from the need tip. The syringe needle was attached to the positive end of a high 
voltage power supply (Gamma High Voltage Research, Ormond Beach, FL), and the 
collector was grounded to create the electrostatic field required for electrospinning. After 
applying a voltage of 13-20 kV, the polymer solution was ejected from the needle 
towards the collector and deposited as nano-scaled fibers. The fibers were collected for 
45-60 minutes to obtain meshes with sufficient thickness for cell culture experiments.  
 The nanofiber meshes were sputter coated with gold (Quorum Technologies, East 
Granby, CT) and their morphology visualized by Scanning Electron Microscopy (SEM; 
Hitachi HTA, Pleasanton, CA). A custom MATLAB® (The MathWorks Inc., Natick, 
MA) program was used to calculate the individual fiber diameter from the SEM images. 
The alignment of the fibers in aligned nanofiber meshes was quantified by measuring 
fiber angle relative to the direction of rotation, using the Image-Pro software (Media 
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Cybernetics, Inc., Bethesda, MD). In the case of random nanofiber meshes, the angles 
were measured with respect to an arbitrarily set line. 
GFOGER peptide preparation and nanofiber surface coating 
 The peptide, GGYGGGPC(GPP)5GFOGER(GPP)5GPC, was synthesized by the 
Emory University Microchemical Facility (Atlanta, GA) as described previously [251]. 
This peptide contains the GFOGER motif, where O refers to hydroxyproline. The 
purified peptide was lyophilized as a trifluoroacetic acid (TFA) salt. The peptide was 
reconstituted at a concentration of 10 mg/mL in a 0.1% TFA solution containing 0.01% 
sodium azide (NaN3). The stock solution was diluted to 50 µg/mL in phosphate-buffered 
saline (PBS, Mediatech Inc., Manassas, VA). Nanofiber mesh samples were sterilized by 
ethanol evaporation, wetted with 70% ethanol and rinsed with excess PBS. The samples 
were then passively adsorbed with GFOGER by submerging them in the dilute GFOGER 
solution for 2 hours at room temperature or overnight at 4°C. For comparison, samples 
were also coated with a 50 µg/mL purified rat type I collagen (Trevigen Inc., 
Gaithersburg, MD) solution or left uncoated in PBS. After rinsing again with PBS to 
remove any unbound peptide, the samples were ready for analysis or cell seeding. 
Analysis of GFOGER surface coating 
 The GFOGER adsorbed on the surface of the nanofibers was visualized and 
quantified using a biotinylated version of the GFOGER peptide. Biotin was conjugated to 
the carboxyl end of the peptide using the EZ-Link® Amine-PEG3-Biotin kit (Pierce 
Biotechnology), and the unreacted biotin was removed by dialysis. To visualize the 
presence of the peptide on the nanofiber surface, the GFOGER coated nanofiber mesh 
samples were incubated with 10 µg/mL fluorescein conjugated NeutrAvidin® (Molecular 
Probes, Eugene, OR) for 30 minutes at room temperature in the dark. After rinsing with 
excess PBS, images were taken on an inverted fluorescence microscope (Axio 
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Observer.Z1, Carl Zeiss, Thornwood, NY) using a FITC filter. The saturation of the 
surface by GFOGER was investigated by incubating meshes with varying GFOGER 
concentrations of 0-50 µg/mL. To quantify the amount of the biotinylated GFOGER 
peptide adsorbed on the nanofiber surface, an ELISA was performed using an anti-biotin 
antibody. Non-specific adsorption of the antibody was first blocked by immersing the 
nanofiber meshes in 0.25% heat denatured serum albumin with 0.0005% Tween-20, 1 
mM EDTA, and 0.025% NaN3 in PBS for 1 hour at 37oC. The meshes were then 
incubated with an anti-biotin antibody (diluted 1:2000) conjugated to alkaline 
phosphatase (clone BN-34, Sigma-Aldrich) for 1 hour at 37oC. An alkaline phosphatase 
substrate, 4-methylumbelliferyl phosphate, was used at a concentration of 60 µg/mL in 
diethanolamine buffer (pH 9.5) to measure the amount of bound antibody. After 
incubating the meshes with the substrate solution for 1 hour at 37oC, the fluorescence was 
read on a plate reader (HTS 7000, Perkins-Elmer, Waltham, MA) at an excitation of 360 
nm and emission of 465 nm. 
Human mesenchymal stem cell (hMSC) culture 
 The Center of Gene Therapy at Tulane University kindly provided the hMSCs. 
The isolation of the cells has been described previously by Sekiya and co-workers [216]. 
Briefly, bone marrow aspirates were taken from the iliac crest of normal adult donors, the 
nucleated cells were isolated with a density gradient and only the cells that adhered to the 
plate after 24 hours were cultured further. Passage 1 cells frozen in 1 mL aliquots were 
shipped us. To expand a culture, the cells were thawed and plated at a density of 50 
cells/cm2 in αMEM (Invitrogen), supplemented with 16% FBS (Atlanta Biologicals, 
Atlanta, GA), 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine 
(Invitrogen). This is termed the hMSC growth media. After the cells reached a 
confluency of ~70%, they were harvested with 0.25% trypsin–EDTA (Invitrogen), 
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counted, and either expanded again or seeded on nanofiber meshes. Passage 2-3 hMSCs 
were used in all experiments. 
Investigating cell infiltration on nanofiber meshes in an in vitro model 
 Rectangular samples (8 mm  12 mm) were cut from random and aligned 
nanofiber mesh sheets, sterilized and coated with GFOGER or collagen, or left uncoated 
in 24-well tissue culture plates, as mentioned above. A 0.9 mm wide sterile stainless steel 
strip was then placed on the nanofiber mesh to create a region without cells (Figure 4.1). 
For aligned nanofiber meshes, the strip was placed perpendicular to the fiber orientation. 
Samples were submerged in 800 µL of hMSC growth media, after placement of a dead 
weight on the edges to prevent them from floating. hMSCs were then seeded on the 
nanofiber mesh samples at a density of 40,000 cells/cm2 in 200 µL of hMSC growth 
media. After 24 hours, the strip was removed, and the cell infiltration into the gap was 
observed at various time points.  
 Cell infiltration was analyzed by staining the nuclei with 4',6-diamidino-2-
phenylindole (DAPI, Molecular Probes). Some samples were, in addition, stained with 
rhodamine phalloidin (Molecular Probes) to visualize the cell alignment. After samples 
were taken down, they were rinsed with PBS and fixed with 4% formaldehyde for 10 
minutes. The samples were then incubated in 0.05% Triton-X (Sigma-Aldrich) for 5 
minutes, rinsed in PBS and incubated in 5 units/mL rhodamine phalloidin for 20 minutes. 
After a PBS rinse step, the samples were incubated in 5 µg/mL DAPI for 5 minutes. 
Samples were finally washed in excess PBS to remove any unbound dye, and images 
were taken on an inverted fluorescence microscope (Carl Zeiss). The DAPI images were 
further processed using ImageJ (U. S. National Institutes of Health, Bethesda, MD) to 
count the cell nuclei, and thereby quantify cell number. Three fields of view along the 
gap were analyzed for each sample, and the mean cell number per field is presented, 
 65
along with the standard error of the mean. To investigate the number of cells attached on 
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Figure 4.1. Schematic of cell infiltration model. A stainless steel strip is placed on the
nanofiber mesh sample before seeding to create a cell-free region. After 24 hours, the
strip is removed and cell infiltration into the gap is observed by fluorescence
microscopy. 
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Role of cell proliferation in the cell infiltration model 
 To investigate whether cell proliferation influences the infiltration of cells on 
nanofiber meshes, mitomycin C was used to block proliferation. Mitomycin C, which is a 
known inhibitor of cell proliferation, cross links the strands of DNA, thereby inhibiting 
DNA replication [260, 261]. The effect of mitomycin C on hMSC proliferation was first 
studied on tissue culture plates (Figure 4.7 A). hMSCs were plated at a density of 20,000 
cells/cm2, and after 24 hours, they were incubated with 10 µg/mL mitomycin C for 60 
minutes. Control samples remained in culture media. Cell proliferation was assessed 
using 5-bromo-2’-deoxyuridine (BrdU) labeling, according to the manufacturer’s 
instructions (FLUOS, Roche Diagnostics, Mannheim, Germany). Forty eight hours after 
cell seeding, the cells were incubated in hMSC growth media containing 10 µM BrdU for 
24 hours in the incubator. Cells were fixed with an ethanol based fixative for 45 minutes, 
and denatured with 4 M HCl for 20 minutes to allow for antibody access. After 
neutralizing the pH with PBS, the cells were incubated with a monoclonal anti-BrdU-
antibody conjugated with fluorescein for 45 minutes at 37°C. The cells were finally 
stained with DAPI for the total number of cells and analyzed using fluorescence 
microscopy, as mentioned above. Nine fields were examined in a 3 3 grid pattern, and 
the number of BrdU positive cells along with the DAPI stained cells were counted. Data 
are presented as the BrdU and DAPI cell counts, as well as the proportion of BrdU 
positive cells. 
 The effect of mitomycin C was next studied in the cell infiltration model on 
nanofiber meshes (Figure 4.8 A). Cells were seeded on rectangular nanofiber mesh 
samples at a density of 40,000 cells/cm2, as above. Twenty four hours post seeding, 
mitomycin C was added to the media at a final concentration of 10 µg/mL, and incubated 
for 60 minutes. The media was slowly aspirated, fresh media was added and the stainless 
strip was removed. After a further 48 hours, the samples were taken down, stained with 
DAPI and analyzed for cell infiltration into the gap. 
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Osteogenic differentiation and total DNA content on nanofiber meshes 
 Random and aligned nanofiber mesh samples were coated with GFOGER, 
collagen, or left uncoated. hMSCs were seeded on circular mesh samples (diameter: 12 
mm), cut using biopsy punches (Acuderm, Ft. Lauderdale, FL), at a density of 20,000 
cells/cm2. Four days after seeding, the hMSC growth media was replaced with osteogenic 
media, which consists of the hMSC growth media supplemented with 10 nM 
dexamethasone, 6 mM β-glycerol phosphate, 50 µg/ml ascorbic acid 2-phosphate and 50 
ng/ml L-thyroxine (Sigma-Aldrich). Media was changed every 3-4 days and the samples 
were cultured for 3 weeks. The samples were analyzed for DNA content, alkaline 
phosphatase (ALP) activity and calcium deposition, as described previously (Chapter 3). 
Briefly, cells were lysed by freeze-thawing three times. The cell extract was used to 
measure DNA amount by the PicoGreen® dsDNA Quantitation Kit (Molecular Probes) 
and ALP activity by the use of p-nitrophenyl phosphate. The calcium content of a 
separate set of mesh samples was determined by using the dye Arsenazo III, after 
overnight incubation in 1 N acetic acid. 
Assessment of GFOGER coated nanofiber meshes in vivo 
 The effect of GFOGER coating in vivo was investigated using a segmental bone 
defect model described previously [74]. Nanofiber meshes were used to create tubular 
implants, having a diameter of approximately 5 mm and a length of 13 mm, without any 
perforations (Chapter 5). The mesh tubes were coated with 50 µg/mL GFOGER 
overnight at 4°C, while control samples were left in PBS. Female Sprague-Dawley rats 
aged 13 weeks were used for this study. Both femurs were stabilized by fixation plates, 
and 8 mm segmental defects were created in the mid-diaphyses. Nanofiber mesh tubes 
were rinsed with PBS, and implanted in the defect, such that the periphery of the defect 
was covered with nanofiber mesh with the center empty. 
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 Radiographs were obtained at 4 and 12 weeks, and ex vivo µCT analysis was 
performed at 12 weeks to detect bone formation. Torsional testing was performed on 
extracted femurs at 12 weeks to test their biomechanical properties. Histological analysis 
consisted of embedding in glycol methacrylate (GMA), obtaining 5 µm sections, and 
staining with H&E. 
Data analysis 
 Data were analyzed using ANOVA and Tukey’s tests for pairwise comparisons. 
Whenever required, the raw data was transformed using a natural logarithmic 
transformation to make the data normal and the variance independent of the mean [221]. 
Student’s t-test was used for 2-sample comparisons, where it was appropriate. Other 
statistical tests that were performed for specific comparisons are mentioned in the results 
section. The significance level for the above analyses was set at p<0.05. Minitab® 15 
(Minitab Inc., State College, PA) was used for all statistical analysis. 
Results 
Nanofiber mesh morphology and alignment 
 PCL nanofiber meshes were produced by electrospinning and characterized by 
analyzing SEM images. Interconnected, non-woven fibers that were mostly bead-free 
were obtained (Figure 4.2). The resulting nanofiber mesh is a porous structure, but due to 
the multiple fiber layers, the effective pore size appeared to be less than 2 µm, much less 
than hMSC dimensions. A flat stationary collector was used to obtain random nanofiber 
meshes with no dominant fiber orientation. The mean and median fiber diameters for 
random meshes were found to be 168.0 nm and 122.8 nm respectively. The distribution 
of fiber diameters indicated that the highest frequency occurred for fibers between 75 nm 
to 125 nm, with 90% of the fibers between 50-300 nm. To obtain aligned nanofiber 
meshes, a rotating mandrel was used to orient the fibers along the direction of rotation of 
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the mandrel surface (Figure 4.3 A). In this case, the mean and median fiber diameters 
were observed to be 256.4 nm and 227.4 nm. The fibers of the aligned meshes were 
found to be significantly larger in diameter than those in the random meshes (Mann-
Whitney test; p<0.001). The angle of the fibers with respect to an arbitrary line was 
measured to quantify fiber alignment (Figure 4.3 B). Though there is a moderate spread 
in the orientation of the fibers, a preferred fiber direction was observed, with 89% of the 
fibers between -45 to 45°. For random meshes, this metric was calculated to be only 52%. 
Using a Z test for proportions, the alignment was found to be significantly higher in the 
case of aligned meshes (p<0.0001). hMSCs seeded on aligned nanofiber meshes 
exhibited a polarized morphology along the preferred fiber direction, while in the case of 
random nanofiber meshes, the cells did not display any regular orientation (Figure 4.3 C). 
GFOGER coating of nanofiber meshes 
 The collagen-mimetic peptide: GGYGGGPC(GPP)5GFOGER(GPP)5GPC, 
containing the GFOGER motif, was synthesized by stepwise solid-phase procedures. The 
amino acid sequences adjacent to GFOGER enable formation of a stable right-handed 
triple helical configuration (Figure 4.4 A), which is required for cell adhesion [249, 262, 
263]. The GFOGER peptide was passively adsorbed on the surface of nanofiber meshes 
at a concentration of 50 µg/mL. The adsorbed peptide was visualized by coating the 
meshes with a biotinylated GFOGER peptide and incubating in a fluorescein conjugated 
NeutrAvidin®. The images revealed that the peptide coated the individual fibers 
uniformly over the entire mesh area (Figure 4.4 B). An ELISA was performed to quantify 
the amount of the GFOGER peptide adsorbed on the nanofibers with varying peptide 
concentration. The saturation curve indicated that the relative surface density increased 
with increasing peptide concentration, with the surface being saturated at a concentration 
of approximately 20 µg/mL (Figure 4.4 C). The peptide concentration at which the 
surface is 50% saturated, was calculated to be 3.45 µg/mL. For all further experiments, a 
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peptide concentration of 50 µg/mL was used to ensure saturation of the surface for 






































Figure 4.2. Nanofiber mesh morphology. (Top) A representative SEM image of a
nanofiber mesh at 10,000X magnification illustrates smooth bead-free fibers. (Bottom)
The fiber diameter histogram reveals that the fibers were in the nanometer range. The







































































Figure 4.3. Fiber and cell alignment on nanofiber meshes. (A) SEM images of random
and nanofiber meshes at 2000X magnification. (B) The fiber angle was measured from
the SEM images and the distribution plotted to assess the fiber alignment. Fibers had a
preferential orientation in the aligned mesh only. (C) hMSCs were seeded on random
and aligned nanofiber meshes, and the cell alignment was observed by staining with
rhodamine phalloidin. Images are at 10X magnification. hMSCs aligned along the fiber




Figure 4.4. GFOGER coating of nanofiber meshes. (A) Space filling model of the
triple helical GFOGER peptide (courtesy Dr. Andres J. Garcia, Georgia Tech). (B)
Biotinylated GFOGER was passively adsorbed on nanofiber meshes, and the coating
visualized using fluorescein conjugated NeutrAvidin®. (C) The amount of GFOGER
























Cellular infiltration on nanofiber meshes 
 An in vitro model was developed to study the effect of GFOGER coating and 
fiber alignment on cellular infiltration on top of nanofiber meshes. A cell-free region was 
created on the mesh, and the infiltration of hMSCs into this gap was examined by 
analyzing the DAPI stained images. To observe baseline infiltration, we first performed 
the experiments with uncoated, random nanofiber meshes (Figure 4.5 A). We verified 
that a cell-free region was generated in day 0 samples. The mean gap width was found to 
be 0.874 ± 0.02 mm, which was slightly less than the width of the stainless steel strip (0.9 
mm). The number of cells in the gap were counted on days 0, 3, 4 and 5. The cell count in 
the gap was found to be negligible on day 0. The quantification of cell infiltration 
revealed that there were significantly more cells in the gap on days 3 and 4 compared to 
day 0, and on day 5 compared to days 3 and 4 (p<0.05). The gap was not completely 
confluent with cells, even at day 5, indicating a slow infiltration rate on the uncoated and 
random nanofiber meshes. To investigate whether GFOGER coating had a significant 
effect on cell attachment efficiency, we counted the cells that attached outside the gap on 
day 0. The cell counts were observed to be equivalent in both the uncoated and GFOGER 
coated groups, indicating that GFOGER coating did not modify the cell attachment 
efficiency (Figure 4.5 B). This implies that both sets of samples start with comparable 
number of cells on the gap border. 
 The ability of GFOGER coating and fiber alignment to enhance cellular 
infiltration in this model was next studied on day 2 after strip removal. Some samples 
were coated with collagen to compare to the collagen-mimetic GFOGER peptide. The 
DAPI images revealed that the gaps on the GFOGER coated meshes were completely 
confluent with cells (Figure 4.6 A). Aligned and collagen coated meshes displayed 
moderately more cell infiltration than random and uncoated meshes, respectively. The 
cell numbers were determined in two regions: the entire gap and the middle-third of the 
gap. The middle-third region of the gap was analyzed as a more stringent measure of 
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cellular infiltration. Analysis of the cell counts indicates that both coating and fiber 
alignment had a significant effect on cell infiltration in both the regions (Figure 4.6 B). In 
the entire gap region on random meshes, GFOGER coated samples displayed higher cell 
numbers, compared to both uncoated and collagen samples. On the aligned meshes, both 
GFOGER and collagen coated samples had higher cell counts than the uncoated samples. 
Fiber alignment enhanced cell infiltration on uncoated and collagen coated samples. 
However, this effect was not seen on the GFOGER coated meshes, probably due to the 
fact that the gap was saturated with cells, even on the GFOGER coated, random meshes. 
Analysis of the middle-third region of the gap revealed that the cell counts displayed the 
following order for both random and aligned meshes: GFOGER > Collagen > Uncoated. 
Fiber alignment enhanced the cell infiltration on both uncoated and collagen coated 
samples, similar to the observation in the entire gap. 
Effect of cell proliferation on the infiltration of cells on nanofiber meshes 
 The cell infiltration observed on nanofiber meshes could be due to the migration 
and/or proliferation of hMSCs. To assess the contribution of cell proliferation, we 
blocked proliferation by treating the cells with mitomycin C, a known inhibitor of cell 
proliferation, 24 hours after seeding. We verified that mitomycin C was able to inhibit 
proliferation of hMSCs on tissue culture plates by staining with BrdU, a marker of cell 
proliferation (Figure 4.7). The results demonstrate that 48 hours after mitomycin 
incubation, the number of proliferating cells (seen with BrdU staining) decreased, thereby 
reducing the total number of cells (seen with DAPI staining) at this time point. In the 
absence of mitomycin C, the proportion of proliferating cells during the 24 hour period 
was 84.1%. This proportion decreased significantly to 6.4% in the presence of mitomycin 
C, indicating that mitomycin C blocked proliferation in almost all hMSCs. 
 The effect of inhibiting cell proliferation on the infiltration of hMSCs on 
nanofiber meshes was next investigated. hMSCs were seeded on nanofiber meshes, with 
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a stainless steel strip placed on top, and allowed to attach for 24 hours (Figure 4.8 A). 
The cells were incubated with mitomycin C for 60 minutes, and the strip was removed. 
After 48 hours of strip removal, the samples were stained with DAPI and analyzed for 
cell infiltration (Figure 4.8 B). The analysis of both the entire gap and the middle-third 
gap regions revealed that in the absence of mitomycin C, both GFOGER coating and 
fiber alignment enhanced cell infiltration, as observed before. With mitomycin C 
incubation, the overall cell infiltration decreased, indicating that cell proliferation 
contributed significantly to the infiltration. In the presence of mitomycin C, only the 
aligned, uncoated mesh samples had a significantly higher cell count than the random, 
uncoated mesh samples, in the entire gap region. In contrast, in the middle-third of the 
gap, the random, GFOGER-coated samples demonstrated significantly higher infiltration 
than the random, uncoated samples. Furthermore, the aligned, uncoated group displayed a 
higher cell count than the random, GFOGER-coated group. These results suggest that 
both cell proliferation and migration contribute to the observed cell infiltration on 
meshes, and that proliferation has a larger influence on infiltration due to GFOGER 
coating, compared to fiber alignment. 
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Figure 4.5. Kinetics of cell infiltration on uncoated random nanofiber meshes. (A) The
cells in the entire gap were examined on days 0, 3, 4 and 5 after strip removal by DAPI
staining. The cell number was quantified by counting the nuclei, and revealed a slow
infiltration rate. A middle-third gap region was defined for later studies. Scale bar is 1
mm and applies to all images. (B) The cells attachment efficiency was investigated by
quantifying the number of cells that attached outside the gap on day 0. There was no
effect of GFOGER coating on cell attachment efficiency. * indicates significantly
greater than cell number on day 0. # indicates significantly greater than cell number on
days 3 and 4. Significance was set at p<0.05. 
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Figure 4.6. Effect of coating and fiber alignment on cell infiltration at 48 hours after
strip removal. (A) Images of DAPI stained nanofiber mesh samples illustrating the
differences in the degree of cell infiltration. Scale bar is 1 mm and applies to all images.
(B) The number of cells present in both entire gap as well as the middle-third of the gap
was counted to quantify cell infiltration. ANOVA revealed that both GFOGER coating
and fiber alignment enhance cell infiltration. * indicates significantly greater than
uncoated with same fiber orientation. ** indicates significantly greater than collagen
with same fiber orientation. $ indicates greater than random orientation with same
coating. Significance was set at p<0.05. 
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Figure 4.7. Effect of mitomycin C on hMSCs proliferation on tissue culture
plastic. (A) Time-sequence of steps in this experiment. Cells were incubated with
mitomycin C 24 hours post-seeding to block proliferation, and proliferation was
assessed by BrdU staining that ended 48 hours after mitomycin C incubation. (B)
The number of BrdU and DAPI stained cells were counted in a 3 3 grid pattern.
Data are presented as the BrdU and DAPI cell counts, as well as the proportion of
BrdU positive cells. MMC: mitomycin C. * indicates significantly less than
without MMC (p<0.05). (C) BrdU and DAPI images (10X) illustrating that cell
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Figure 4.8. Role of cell proliferation in the cell infiltration model. (A) Time-sequence of
steps in this experiment. After seeding, cells were allowed to attach for 24 hours,
following which they were incubated with mitomycin C and the stainless strip was
removed. Samples were taken down 48 hours after strip removal. (B) The cell counts
demonstrated that blocking proliferation resulted in reduced infiltration, indicating that
both proliferation and migration contribute to cell infiltration. MMC: mitomycin C. *
indicates significantly greater than random uncoated with same MMC condition (p<0.05).
$ indicates significantly greater than random GFOGER with same MMC condition
(p<0.05). 
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Influence of nanofiber coating and alignment on total DNA content and osteogenic 
differentiation 
 Cells were seeded on circular nanofiber meshes and cultured in either hMSC 
growth or osteogenic media up to 21 days. This culture system does not involve the use 
of a stainless steel strip, and the cells are uniformly distributed on the mesh. First, the 
effect of GFOGER coating on changes in cell number was studied by measuring the 
amount of DNA extracted from the samples at days 4 and 7. The results demonstrate that 
GFOGER coating increased the amount of DNA in osteogenic media samples at both 
days 4 and 7, suggesting an improved proliferation rate (Figure 4.9). GFOGER coating 
did not have a significant effect on amount of DNA in growth media. The effect of 
coating and fiber alignment on DNA content in osteogenic media was investigated at a 
later time point of 21 days. ANOVA revealed that coating had an overall significant 
effect on amount of DNA, but there were no significant individual differences between 
the groups (Figure 4.10 A). 
 The influence of nanofiber coating and alignment on the osteogenic 
differentiation of hMSCs in osteogenic media was studied by measuring the ALP activity 
and calcium deposition. Analysis of the ALP activity data revealed that both coating and 
fiber alignment had a significant effect on ALP activity, and that the GFOGER-coated 
samples displayed an overall higher ALP activity than the uncoated and collagen coated 
groups (Figure 4.10 B). In the case of random nanofiber meshes, the GFOGER group 
also demonstrated significantly higher ALP activity than the uncoated and collagen 
groups, whereas, on aligned meshes, the GFOGER group displayed significantly higher 
activity than the collagen group only. Fiber alignment was found to reduce the ALP 
activity, in the case of GFOGER- and collagen-coated samples. 
 Under osteogenic stimulation, hMSCs deposited calcium on the nanofiber 
meshes, indicative of an osteoblast phenotype (Figure 4.10 C). GFOGER coating 
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significantly enhanced calcium deposition on both random and aligned meshes, compared 
to uncoated meshes. In addition, on random meshes, GFOGER-coated samples 
demonstrated significantly higher calcium deposition than collagen-coated samples. 
Collagen coating increased calcium levels only in the case of aligned meshes. Fiber 
alignment did not have an overall significant effect on calcium deposition, though a 
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Figure 4.9. Early effect of GFOGER coating on hMSC number. DNA amount was
quantified as a measure of cell number on days 4 and 7, in growth and osteogenic
media. GFOGER coating increased DNA amount in osteogenic media at both days 4
and 7. * indicates significantly greater than uncoated in the same group. 
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Figure 4.10. Effect of coating and fiber alignment on cell number and osteogenic 
differentiation of hMSCs in osteogenic media. Cells were seeded on circular nanofiber 
mesh samples and cultured in osteogenic media for 21 days.  (A) DNA amount. No 
significant differences were seen in the amount of DNA between groups. (B) Alkaline 
phosphatase (ALP) activity. Samples coated with GFOGER demonstrated increased ALP 
activity, whereas those with aligned fibers displayed a reduction in ALP activity. (C) 
Calcium deposition. GFOGER coating enhanced calcium deposition by hMSCs on 









































































Assessment of GFOGER coated nanofiber meshes in vivo 
 To investigate the ability of GFOGER coated nanofiber meshes to enhance bone 
formation in vivo, tubes made from nanofiber meshes were coated with the GFOGER 
peptide, or left uncoated, and implanted around segmental bone defects created in rat 
femurs. Radiographs at 4 and 12 weeks displayed new bone formation near the ends and 
the periphery of the defect (Figure 4.11). However, none of the defects were bridged 
completely. The results of the µCT analysis and torsional testing at 12 weeks revealed no 
significant differences between the two groups, indicating that coating nanofiber mesh 
tubes with GFOGER did not enhance bone formation in this model (Figure 4.12). The 
cross sectional views of the µCT images illustrated some bone formation along the 
nanofiber mesh tube and at the native bone boundary. However, capping of defect ends 
was observed, and presence of bony tissue was not evident at the defect center. 
Histological analysis of the defect area confirmed capping of the defect ends with newly 
formed bone (Figure 4.13). A combination of newly formed bone, fibrous tissue and 














Figure 4.11. Radiographs of femurs implanted with nanofiber mesh tubes at 4 and 12
weeks. Specimens in both groups displayed new bone formation near the ends and the
periphery of the defect. None of the defects were bridged completely. 
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Figure 4.12. µCT analysis and mechanical testing of extracted femurs at 12 weeks. (A)
Regenerated bone volume from µCT analysis. GFOGER coating did not have a
significant effect on bone volume. (B) Failure strength was calculated by measuring
the maximum torque in torsional testing. No significant differences were seen between
the groups. (C) Cross sections of µCT images reveal capping of defect ends and some
















































Figure 4.13. Histological analysis with H&E staining at 12 weeks. The defect in both
groups contains a combination of newly formed bone (nb), fibrous tissue (ft) and
marrow (m). The regenerated bone is limited to the defect ends with capping of the




 In this study, we developed bioactive nanofiber meshes with ordered topography 
for enhancing tissue repair. Nanofibers were functionalized with passive adsorption of the 
collagen-mimetic GFOGER peptide, and the nanotopography was patterned by aligning 
nanofiber orientation. The effects of these parameters on the migration, proliferation and 
osteogenic differentiation of hMSCs were studied. Our results indicate nanofiber surface 
functionalization and orientation modulate cellular behavior, individually and in 
combination. GFOGER coating and fiber alignment enhanced hMSC infiltration on 
nanofiber meshes. Both cellular proliferation and migration contributed to the observed 
infiltration, with proliferation exerting a larger influence on infiltration due to GFOGER 
coating, compared to fiber alignment. In contrast, only GFOGER coating enhanced the 
osteogenic differentiation of hMSCs. 
 The infiltration of hMSCs into a gap region on top of nanofiber meshes was 
studied in vitro using a modified version of the scratch wound healing assay, which is 
performed frequently to study migration on tissue culture plastic [261, 264]. Cell 
infiltration was investigated because it is an important initial step in recruiting 
endogenous progenitor cells for tissue repair in vivo. In addition to analyzing the entire 
gap region, we also measured cell infiltration in the middle-third area of the gap to isolate 
cells that infiltrated farther as a more stringent measure of infiltration. It is possible that 
some of the cells located just inside the gap boundary may be there simply due to the 
division of cells outside the gap, rather than due to an active response to nanofiber 
surface modification.  
 The functionalization of nanofiber surface with GFOGER resulted in the largest 
elevation of hMSC infiltration (as much as a 16-fold increase), higher than both collagen 
coating and fiber alignment. Whereas cells did not completely occupy the gap region on 
uncoated meshes even after 5 days, the gap in the GFOGER coated samples was 
confluent with cells, just after 2 days. To investigate whether the groups started with 
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comparable number of cells at the gap boundary, we measured the cell attachment 
efficiency at 24 hours, the time of strip removal. It was observed that this was indeed the 
case, with no difference detected between the numbers of cells outside the gap. It is also 
interesting to note that GFOGER coating displayed a significantly larger effect on cell 
infiltration compared to collagen coating, even though their effects on cell adhesion has 
been shown to be equivalent previously [251]. 
 The alignment of fibers along a preferred direction enhanced hMSC infiltration 
into the gap along this direction. Collagen coating and fiber alignment displayed a 
synergistic effect on cell infiltration. Fiber alignment did not add to the infiltration in the 
GFOGER coated groups. However, this was probably because the gap in the GFOGER 
coated samples was already confluent with cells, even on random meshes, and there was 
no additional room for cells to infiltrate. Patel and coworkers reported a similar 
synergistic effect of fiber alignment and protein immobilization on fibroblast infiltration 
on nanofiber meshes [265]. Though individual fibers were not perfectly oriented along a 
single direction, the cells that attached to the meshes aligned themselves along the 
preferred direction. This contact guidance may explain the improved infiltration of cells 
into the gap. Contact guidance due to fiber alignment has been reported previously in 
studies published by Bashur et al. and Yang et al., where they observed an increase in cell 
spreading and aspect ratio on aligned meshes [257, 266]. The fiber diameter in the case of 
aligned meshes was found to be higher than that in random meshes (256.4 nm vs. 168.0 
nm). This was probably due to differences in the electrostatic fields between the 
stationary and rotating collector setups. Though different configurations of the rotating 
mandrel were attempted, it was not possible to get similar fiber diameters while 
maintaining good fiber alignment. It is possible that the difference in fiber diameter may 
contribute to the observed differences in cell behavior on aligned nanofiber meshes. 
However, the fibers are still in a narrow submicron range, and the cells may not be able 
to sense the differences in fiber diameter. This hypothesis is supported by studies that 
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have reported insignificant differences in cell function with varying fiber diameters 
within the submicron range [192, 266]. 
 The observed infiltration of cells on nanofiber meshes occurs either due to the 
physical migration of individual cells, or due to cell proliferation, or a combination of 
both. To isolate the individual contributions, we blocked proliferation by incubating the 
cells with mitomycin C. In the absence of proliferation, the infiltration dropped in all 
groups, indicating that the infiltration on nanofiber meshes is dependent, at least to a 
certain extent, on cell proliferation. Part of the reduction in total cell numbers could be 
explained by a decrease in the viability of hMSCs due to mitomycin C; however there is 
some evidence in the literature that this is not the case [267]. The reduction in infiltration 
was especially high for the GFOGER coated samples, in which the improvement in 
infiltration was abolished, when measured in the entire gap region. In the middle-third 
gap region however, GFOGER coating still enhanced cell infiltration, indicating that at 
least some of the positive effects of GFOGER coating on infiltration are due to cell 
migration. This also suggests that the cell counts in the middle-third gap region are a 
more sensitive measure of cell migration than those in the entire gap. Compared to the 
GFOGER samples, the aligned meshes were less affected by the inhibition of 
proliferation, and demonstrated more infiltration in both the gap regions. Overall, these 
results suggest that both migration and proliferation contribute to the hMSC infiltration 
that was observed on nanofiber meshes. Kark et al. reported similarly that the gap closure 
on tissue culture plates, by rat MSCs in response to platelet releasate, was due to the 
combined effects of migration and proliferation [261]. The mode of infiltration on 
GFOGER coated samples appears to be more dependent on proliferation, whereas it is 
more dependent on migration in the case of aligned meshes. 
 The mechanisms for the improved cellular infiltration on GFOGER coated 
nanofiber meshes are likely related to the adhesive properties of the collagen-mimetic 
GFOGER peptide. It is now clear that the GFOGER hexapeptide, which is a sequence in 
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the α1(I) chain of type I collagen, is a major binding site for the α2β1 integrin [249, 263]. 
The α2β1 integrin is abundantly expressed in a wide variety of cells, including MSCs 
[268]. Since the engagement of integrins with ECM molecules regulate adhesion related 
functions of cells, which include migration and proliferation, it is plausible that the 
GFOGER-α2β1 integrin interaction may be driving the infiltration on nanofiber meshes  
[269-272]. Senger et al. demonstrated that blocking the α2β1 integrin by a soluble 
antibody resulted in ~40% inhibition of endothelial cells migration toward type I collagen 
[273]. In addition, Reyes and coworkers have reported that cell adhesion was greater and 
specific to the α2β1 integrin, when titanium surfaces were coated with GFOGER, 
compared to uncoated, RGD coated and even serum coated samples [121]. Finally, the 
GFOGER peptide has been shown to promote formation of mature integrin-mediated 
focal adhesions, an important event for post-adhesion intracellular signaling [251].  
 The effects of the mesh design parameters on the proliferation and differentiation 
of hMSCs on nanofiber meshes were also investigated. Proliferation was studied 
indirectly by determining the DNA content as a measure of cell number. However, this 
provides only a snapshot of the number of cells at any time point, and any changes in 
DNA content could be due to differences in cell attachment, viability and proliferation 
rate. Since the cell attachment (Figure 4.5) and viability (data not shown) were not 
significantly affected by mesh design, the DNA amount may be interpreted to be largely 
determined by the proliferation rate. The quantification of DNA amount in the first week 
of culture indicated higher DNA content on the GFOGER coated meshes in osteogenic 
media, suggesting an early enhancement of proliferation by GFOGER. However, by 21 
days, there was no significant effect of GFOGER coating on DNA content. 
 The osteogenic differentiation of hMSCs on nanofiber meshes was evaluated by 
measuring the ALP activity and the calcium deposition. ALP is a membrane-bound 
enzyme that hydrolyzes phosphate esters during mineralization, and is considered a 
marker of early osteogenic differentiation [224]. On the other hand, calcium deposition is 
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a final measure of matrix mineralization. GFOGER coating enhanced both the ALP 
activity and calcium deposition, indicating that the peptide is able to differentiate hMSCs 
to an osteoblast-like phenotype. The GFOGER-α2β1 integrin interaction has been 
implicated in mediating osteoblast adhesion, differentiation and matrix mineralization 
[117, 118]. Reyes and coworkers have previously reported the osteogenic differentiation 
of immature osteoblasts and rat MSCs when cultured on GFOGER coated surfaces [120, 
121]. They demonstrated that the peptide triggers signaling pathways that result in the 
upregulation of Runx2/Cbfa1, a transcriptional activator essential for osteogenic 
differentiation [120, 274-276]. In contrast to GFOGER coating, fiber alignment did not 
have an overall positive effect on osteogenic differentiation, and in some groups resulted 
in a reduction in ALP activity and calcium deposition. This may be due to the cells being 
more migratory on aligned meshes. 
 The in vivo results indicated that GFOGER coating of nanofiber mesh tubes did 
not enhance the repair of segmental bone defects. Defects in both the uncoated and the 
GFOGER coated groups displayed a moderate amount of new bone formation; however, 
none of the defects were bridged with bony tissue. Unsurprisingly, the biomechanical 
properties were also found to be much less than that of native bone (failure strength <0.05 
N-m compared to 0.31 N-m). Histological analysis revealed that the native bone ends 
were capped with newly formed bone, with the defect center occupied with fibrous tissue. 
Taken together with our other in vivo data (Chapter 5), these results suggest that when 
nanofiber mesh tubes are placed alone in large diaphyseal defects with the center left 
empty, they are not able to provide the structure necessary for complete defect bridging. 
Previous results have demonstrated the in vivo efficacy of the GFOGER peptide for 
implant osseointegration [121]. In addition, Wojtowicz et al. recently reported that 
GFOGER coating of three-dimensional scaffolds, with honeycomb architecture, 
enhanced bone formation in a similar segmental defect model [277]. It is possible that in 
our system, the GFOGER peptide may present an insufficient osteogenic signal for a 
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robust healing response, because it is available only on the defect periphery along the 
mesh tubes. In fact, Wojtowicz et al. reported that bone formation was sensitive to 
scaffold surface area, with reduced surface area resulting in the suppression of the 
GFOGER effect [277]. This suggests that nanofiber mesh tubes may not be an 
appropriate scaffold for providing GFOGER coated surfaces for the repair of large 
diaphyseal defects. Augmenting the GFOGER coated mesh tubes with another 
biomaterial inside the tubes may be an effective strategy for diaphyseal defect healing, 
and this needs to be explored further. 
 In conclusion, this study demonstrates that nanofiber orientation and surface 
functionalization modulate hMSC infiltration and osteogenic differentiation. Coating 
nanofibers with the collagen-mimetic peptide GFOGER enhanced the migration, 
proliferation and osteogenic differentiation of hMSCs, likely by engaging the α2β1 
integrin receptor. GFOGER coated nanofiber meshes were unable to functionally repair 
large diaphyseal bone defects in vivo, and modifications in the scaffold configuration 
would be needed for improved delivery of the peptide. Fiber alignment increased cell 
migration on nanofiber meshes along the direction of fiber orientation due to contact 
guidance, but did not demonstrate a positive effect on osteogenic differentiation. Overall, 
these results indicate that such design strategies modulating nanofiber orientation and 




CHAPTER 5  
A NOVEL HYBRID SYSTEM FOR GROWTH FACTOR DELIVERY 
PROMOTES FUNCTIONAL REPAIR OF LARGE BONE DEFECTS 
Introduction 
 Autologous and allogeneic bone grafting are the most widely used treatment 
modalities for fracture non-unions and large bone defects [45, 49]. However, these 
techniques are associated with a number of drawbacks, including the limited graft 
material available for autografts and the high failure rate of allografts [53, 55, 56]. These 
limitations have stimulated the search for improved techniques for bone repair, and tissue 
engineering/regenerative medicine (TE/RM) strategies have demonstrated significant 
potential in developing bone graft substitutes [75, 76]. These approaches promote tissue 
repair by providing a combination of physical and biochemical cues through structural 
scaffolds and biologics [64, 65, 77]. 
Much of bone TE/RM research is focused on the use of three-dimensional 
scaffolds having adequate strength to support in vivo loading [74, 91, 278]. However, 
structural scaffolds usually do not provide an optimal environment for cellular function 
and suffer from slow resorption kinetics, thereby impeding functional restoration of the 
damaged tissue. We previously demonstrated, for example, that poly (L,DL, lactide) 
scaffolds infused with recombinant human bone morphogenetic protein 2 (rhBMP-2) 
promoted bone ingrowth but failed to fully restore the mechanical properties of long bone 
defects [74]. Thin, two-dimensional membranes have been used to promote bone repair 
by placing them along the periosteal surface to demarcate the osseous from the non-
osseous region [92-95]. This technique, termed guided bone regeneration, has been 
applied successfully in the dental field to regenerate lost alveolar bone [175, 176]. 
However, few previous studies have investigated the use of polymer membranes in the 
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treatment of large defects in load bearing bones, and none have quantitatively evaluated 
the restoration of limb function [179, 181, 184]. 
Electrospun nanofiber meshes have recently emerged as a new generation of 
scaffold membranes, possessing a number of features suitable for tissue regeneration [90, 
98]. They have fibers of the same size-scale of extracellular matrix (ECM) components 
and a large surface area, which may improve cellular attachment, morphology, migration 
and function. Nanofiber meshes have been shown to support osteogenic differentiation of 
progenitor and stem cells in vitro [192, 214, 279, 280], and have been tested in calvarial 
defect models in vivo [96, 193]. However, their efficacy in guiding long bone 
regeneration in vivo remains to be investigated. 
Though a scaffold provides a template for guiding bone regeneration, biologic 
factors such as cells, growth factors or genes are typically required to effectively fill 
challenging bone defects [74, 125]. Osteoinductive growth factors like rhBMP-2 have 
demonstrated some clinical success for bone healing, but large doses are needed [101, 
241]. Delivery systems that provide sustained release and improved local retention may 
provide efficacy at lower protein dose, thereby minimizing complications and making the 
therapy more cost effective [61, 63, 143, 147]. Alginate hydrogels, made from brown 
algae derived polysaccharides, have been established as a scaffolding material [105] and 
a spatiotemporal delivery vehicle for a wide range of proteins [170-172]. Though 
mammalian cells lack receptors for alginate polymers, the alginates can be covalently 
coupled with adhesion peptides to promote cellular attachment [173]. In addition, the 
degradation rate of these hydrogels can be increased by Gamma-irradiation, resulting in 
lower molecular weight polymers. These modified alginates have been demonstrated to 




The primary objective of this study was to develop and test a hybrid growth factor 
delivery system for bone repair that utilizes an electrospun nanofiber mesh and injectable 
alginate hydrogel. To test this system, we evaluated its ability to deliver rhBMP-2 for the 
repair of critically-sized segmental bone defects in vivo. For control group comparisons, 
we also examined the ability of the nanofiber mesh alone, and in combination with 
alginate hydrogel, to heal the bone defects without rhBMP-2. Finally, the effect of a 
perforated nanofiber mesh design on bone repair was investigated. We hypothesized that 
rhBMP-2 delivery in the nanofiber mesh/alginate system would promote bone ingrowth 
and fully restore the mechanical properties of 8 mm segmental bone defects in the rat 
model. We further hypothesized that the perforated nanofiber mesh design would 
accelerate bone ingrowth due to enhanced early defect vascularization. We tested our 
hypothesis in an in vivo test bed model that utilizes quantitative techniques to assess 
differences in bone and vascular regrowth and restoration of mechanical function. 
Materials and Methods 
Fabrication of nanofiber mesh tubes 
Poly (ε-caprolactone) (PCL) pellets (Sigma-Aldrich, St. Louis, MO) were 
dissolved in a 90:10 volume ratio of hexafluoro-2-propanol (HFP):dimethylformamide 
(DMF) (Sigma-Aldrich) to obtain a  12% (w/v) polymer solution. DMF was first slowly 
added to HFP to prevent excessive heat generation, and mixed well on a stir plate for 5 
minutes. The PCL pellets were then added to the solvent solution, and gently stirred for 
16-24 hours. The solution was visually inspected to ensure a homogeneous and clear 
solution. The polymer solution was loaded in a 3 mL syringe (Becton-Dickinson, 
Franklin Lakes, NJ), and a 22 gauge blunt stainless steel needle (Jensen Global Inc., 
Santa Barbara, CA) was attached to the syringe end. The syringe was mounted on a 
syringe pump (Harvard Apparatus, Holliston, MA) set at a rate of 0.75 mL/hr. The fibers 
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were collected on a flat copper plate (McMaster-Carr, Atlanta, GA) which was placed at 
a distance of 20-23 cm from the needle end. Fibers were electrospun for 5 hours at a 
voltage of 13-20 kV, supplied by a high voltage power supply (Gamma High Voltage 
Research, Ormond Beach, FL), to obtain a thick sheet of nanofiber mesh. The residual 
solvent from the meshes was allowed to evaporate by placing them in a dessicator 
overnight. The morphology of the nanofiber meshes was examined using a Scanning 
Electron Microscope (SEM; Hitachi HTA, Pleasanton, CA) after gold coating using a 
sputter coater (Quorum Technologies, East Granby, CT). The diameter of the fibers were 
quantified by analyzing the SEM images (at 7000magnification) using a custom 
MATLAB® (The MathWorks Inc., Natick, MA) code. 
  The nanofiber meshes, as fabricated above, were used to create tubular implants. 
Rectangular samples measuring 13 19 mm were cut from a mesh. In some samples, 
perforations spaced approximately 1.5 mm apart were made in the mesh using a 1 mm 
diameter biopsy punch (Miltex Inc., York, PA). The rectangular mesh samples were 
wrapped around a steel mandrel (McMaster-Carr) to form a tube having a diameter of 
approximately 5 mm and 13 mm length. The overlapping edges of the mesh were secured 
together by using UV glue (DYMAX Corporation, Torrington, CT), which was cured 
with a LED spot curing lamp (DYMAX Corporation). The nanofiber mesh tubes were 
then rinsed twice in 70% alcohol (VWR, West Chester, PA), and sterilized by 
submerging in 200 proof ethanol (Sigma-Aldrich) and allowing the ethanol to evaporate 
overnight. After the samples had dried completely, they were pre-wetted with sterile 70% 
ethanol for 30 minutes. After aspirating the 70% ethanol, the mesh tubes were rinsed 
three times with excess phosphate-buffered saline (PBS; Mediatech Inc., Manassas, VA), 




Preparation of alginate hydrogel with and without growth factors 
Irradiated RGD-modified alginates were prepared as described previously [174]. 
Briefly, MVG sodium alginate (FMC Biopolymer) was subjected to a 5 Mrad dose of 
gamma irradiation. This reduces the molecular weight of the polymer leading to a faster 
degradation rate, which makes it more appropriate for in vivo studies [105]. The 
irradiated alginates were then covalently coupled with G4RGDASSP peptide sequences 
(Commonwealth Biotechnologies, Richmond, VA) at a density of 2 sequences per 
polymer chain using standard carbodiimide chemistry [281]. The resulting RGD-alginates 
were sterile filtered, lyophilized and stored at -20°C. 
To prepare hydrogels, the RGD-alginates were reconstituted in α-MEM to obtain 
a 2.5% (w/v) solution. Lyophilized rhBMP-2 (R&D Systems, Minneapolis, MN) was 
reconstituted in 0.1% rat serum albumin (RSA; Sigma-Aldrich) made in 4 mM HCl, at a 
concentration of 200-µg/mL. The alginate solution was then mixed with either the 
rhBMP-2 solution at a ratio 5:1 (700-µL alginate solution @2.5% (w/v) with 175-µL 
rhBMP-2 @200-µg/mL or 0.1% RSA). This results in a 2% (w/v) alginate solution 
containing 40-µg/mL rhBMP-2. The rhBMP-2 containing alginate solution was cross-
linked with a calcium sulfate (Sigma-Aldrich) slurry (0.21 g CaSO4 per 1 mL deionized 
water) at a ratio of 25:1 (35 µL of CaSO4 with 875 µL of alginate/rhBMP-2 solution). 
The mixing was performed in two 1-mL syringes (Becton-Dickinson, Franklin Lakes, 
NJ) coupled with a syringe connector (Cole-Parmer, Vernon Hills, IL) with Luer-Lok 
fittings to minimize air bubbles. Another set of hydrogels was prepared without rhBMP-2 
by substituting the rhBMP-2 solution with the carrier (0.1% RSA) alone. The alginate 
solutions were allowed to gel in the syringes for 30 minutes at room temperature and then 
transferred to 4°C. The hydrogels were kept at 4°C overnight and used in surgery the 
following day. Aseptic conditions were maintained in all the above steps, including 
handling of the exterior of the syringe. 
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rhBMP-2 release kinetics 
RGD-alginate solutions containing rhBMP-2 were cross-linked with a calcium 
sulfate slurry as above, and immediately injected into custom designed molds containing 
4 mm diameter wells. The alginate solutions were allowed to gel for 30 minutes at room 
temperature, producing cylindrical plugs measuring 4 mm in diameter and 8 mm in 
length. Each cylindrical alginate plug contained 500-ng rhBMP-2. Following a brief rinse 
in 0.1 M CaCl2 (Sigma-Aldrich), the samples were incubated at 37°C in 1-mL PBS 
containing calcium and magnesium ions. At specific time points through day 21, the 
entire buffer solution was collected and replaced with fresh 1-mL PBS. On days 0 and 21, 
alginate plugs were dissolved by immersing in 8-mL and 2-mL, respectively, of 2% (w/v) 
sodium citrate (Sigma-Aldrich) for 30 minutes at room temperature. The amount of 
rhBMP-2 present in the collected PBS and sodium citrate solution was quantified using 
an ELISA kit (R&D Systems), following the manufacturer’s instruction. 
Surgical procedure and analysis 
An established critically-sized, femoral segmental defect rat model was used in 
this study. All surgical procedures were approved by the Institutional Animal Care and 
Use Committee (IACUC protocol #A05041) at the Georgia Institute of Technology. The 
rat model and surgical technique has been described previously [74]. Briefly, bilateral 8 
mm segmental defects were created in the mid femoral diaphyses of 13-week old female 
Sasco Sprague-Dawley rats. Prior to defect creation, the femora were stabilized by 
modular fixation plates consisting of a polysulfone plate and two stainless steel plates 
(Figure 5.1 E). This is a more challenging segmental defect model compared to the 5-6 
mm defect models that are used most frequently in the field. Nanofiber mesh tubes were 
placed around the adjacent bone ends such that the tube lumen contained the defect and 
there was an overlap of 2.5 mm with the native bone ends at each end of the tube. In 
some groups, 125-µL pre-gelled 2% alginate with or without 5-µg rhBMP-2 was injected 
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in the tube lumen using a 22g needle (Jensen Global Inc.). As it is a soft hydrogel, the 
pre-gelled alginate is ejected from the needle in a continuous thin filament shape and fits 
compactly inside the tube. The tubes used for one of the groups had 1 mm diameter 
perforations to enhance vascular invasion during the repair process. The four groups 
(n=6-8) were as follows (Table 5.1): (I) Mesh alone, (II) Mesh with alginate, (III) Mesh 
with alginate containing rhBMP-2, (IV) Perforated mesh with alginate containing 
rhBMP-2. The groups were assigned to the right and left limbs to evenly distribute pairs 
of groups and obtain a balanced experimental design. After surgery, the animals were 
allowed to recover and move freely. For pain relief, the animals were injected with 0.03 
mg/kg buprenorphine subcutaneously every 8 hours for the first 48 hours and 0.01 mg/kg 
buprenorphine for the next 24 hours. Radiographs and in vivo micro-computed 
tomography (µCT) images were obtained at 4 and 12 weeks after surgery to evaluate 
bone healing. The rats were euthanized at 12 weeks and femora were extracted for 
mechanical testing. Histological analysis was performed on femora extracted at 4 and 12 
weeks. 
Table 5.1. The four groups utilized in the in vivo study, with the implant conditions in 
each group. 
Group # Nanofiber mesh tube Perforations Alginate rhBMP-2 
I + – – – 
II + – + – 
III + – + + 
IV + + + + 
2-D radiographs and 3-D in vivo µCT imaging 
At 4 and 12 weeks after implantation, two-dimensional radiographs (Faxitron 
MX-20 Digital, Faxitron X-ray Corp., Wheeling, IL) of the femur were taken to 
qualitatively assess bone regeneration and defect bridging. For the quantitative evaluation 
of bone formation, in vivo µCT was performed at the same time points. The rats were 
anesthetized by isoflurane and placed in an in vivo µCT system (Viva-CT, Scanco 
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Medical, Bassersdorf, Switzerland). The femoral defect region was scanned at a 38.5-µm 
voxel resolution, a voltage of 55-kVp and a current of 109-µA. The radiotranslucent 
polysulfone plate does not interfere with µCT scanning and therefore allows longitudinal 
evaluation of bone ingrowth. To obtain a consistent volume of interest (VOI) between 
animals and to avoid including the native bone ends, only the central 4 mm of the 8 mm 
defect was analyzed in vivo by drawing circular contours. A Gaussian filter (sigma = 1.2, 
support = 1) was used to suppress noise in the VOI, and a global threshold corresponding 
to a density of 270.3 mg hydroxyapatite/cm3 was applied to obtain the regenerated bone 
volume. This threshold was selected by the visual inspection of individual scan slices to 
detect newly formed bone and to exclude soft tissues, the polysulfone fixation plate and 
the nanofiber mesh tube. The volume and density of the segmented bone was noted. In 
addition, the density map was calculated in the segmented bone volume, and presented as 
a pseudo color-scaled image. 
Torsional testing 
The freshly extracted femora at 12 weeks were wrapped in gauze moistened with 
PBS, and stored at -20°C. Just before testing, samples were thawed in PBS and the 
majority of soft tissues adjacent to the bone removed. The ends of the femur were 
embedded in end blocks using Wood’s metal (Alfa Aesar, Wood Hill, MA) and aligned 
using a custom fixture. The polysulfone plate was then detached from the metal plates to 
enable loading of the bone. The potted femur was loaded into holding brackets mounted 
on a Bose ElectroForce system (ELF 3200, Bose EnduraTEC, Minnetonka, MN) fitted 
with a 2 Nm torsional load cell. The samples were rotated to failure at a rate of 3° per 
second under displacement control, and the torque and rotation were recorded. Maximum 
torque was calculated by locating the failure torque, which occurred within the first 15° 
for bridged defects. Samples that did not bridge displayed a gradual increase in torque 
and the absence of a sharp failure point, due to soft tissue stretching. For these samples, 
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the failure torque was measured in the first 60° to avoid analyzing the forces generated 
due to the stretching of soft tissues. Stiffness was calculated by finding the slope of the 
straight line fitted to the linear portion of the torque-rotation plot before failure. 
Histological analysis 
One representative sample from each group was selected for histological 
evaluation at 4 and 12 weeks. The extracted femora were fixed in 10% neutral-buffered 
formalin for 48 hours. They were dehydrated in a series of alcohol solutions of increasing 
concentrations, infiltrated with methyl methacrylate (MMA), and embedded by 
polymerizing the MMA. Ground sections, 50-80 µm thick, were generated using a 
EXAKT Grinding System (EXAKT Technologies, Oklahoma City, OK). The sections 
were stained with Sanderson’s Rapid Bone Stain [282] and a van Gieson counter stain 
(SURGIPATH Medical Inc., Richmond, VA, USA). This stain permits the detection of 
bone (pink), muscle (blue green) and cells (blue). 
Analysis of vascularity during bone regeneration 
The vascular regrowth at the defect area was investigated at 3 weeks post-surgery 
by using a modified version of the µCT–based angiography technique developed in our 
laboratory [278, 283]. After induction of anesthesia using isoflurane, a 25 gauge catheter 
was introduced into the abdominal aorta and 250 units (0.25 mL of 1000 units/mL) 
heparin were injected. The rat hind limb vasculature was cleared with PBS, fixed with 
10% neutral buffered formalin and cleared again with PBS using a peristaltic pump 
(Masterflex, Cole-Parmer). The rats were euthanized by an overdose of isoflurane before 
the formalin perfusion. A radiopaque, lead chromate based contrast agent (Flow Tech, 
Carver, MA) was then injected and allowed to polymerize for at least two hours. The 
femur along with its musculature was excised carefully, fixed in 10% neutral buffered 
formalin for 48 hours, and decalcified for 2 weeks using a formic acid based solution 
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(Cal-Ex II, Fisher Scientific). The samples were rinsed in PBS and stored in 10% neutral 
buffered formalin until imaging. They were imaged in a µCT system (Viva-CT, Scanco 
Medical) at a 21.5-µm voxel size. Two VOIs were defined to analyze the vessels inside 
the defect and adjacent to the defect. The images were globally thresholded based on X-
ray attenuation to segment the contrast-filled vasculature from surrounding tissues. 
Statistical analysis 
Data were analyzed by analysis of variance (ANOVA) conducted in Minitab® 15 
(Minitab Inc., State College, PA). Pairwise comparisons were made using the Tukey 
multiple comparison procedure. The normality of the residuals was evaluated by the 
Anderson-Darling normality test. To detect the presence of any pattern in the residual 
distribution, they were plotted against fitted values. To maintain the constancy of error 
variance and normality of error terms, data were transformed according to the Box-Cox 
procedure, wherever required [221, 222]. To investigate the effect of time on sequential 
in vivo µCT data, paired t-tests were performed. A p-value < 0.05 was considered 
statistically significant. All data are shown as mean ± standard error of mean (SEM). 
Results 
Nanofiber mesh tube characterization and placement 
The nanofibers obtained by electrospinning were observed to be smooth and 
bead-free (Figure 5.1 A). The fibers ranged in diameter from 51 nm to 974 nm with 82% 
of the fibers between 50 nm and 150 nm. The mean and the median fiber diameter were 
found to be 154 nm and 107 nm respectively. After 5 hours of electrospinning, the mesh 
was found to be approximately 300-400 µm thick. This thickness was sufficient to 
provide a bending stiffness that prevented collapse of the mesh in solution. The thick 
nanofiber meshes were able to be wrapped tightly around a steel mandrel, and glued to 
form a tube (Figure 5.1 B and C). Due to the fast curing time of the UV glue, it was 
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localized to the overlapping edges and did not seep to the rest of the mesh. The perforated 
meshes held the tubular structure well, and the holes accounted for 10% of the total 
surface area of the mesh tube. The nanofiber mesh tubes were deformed slightly to place 
them around the native bone ends of the segmental defect, but they regained their original 
shape due to the elasticity of the mesh. The overlapping ends and the surrounding 
musculature resulted in the tubes being stably located around the defect for the duration 
of the study (Figure 5.1 D and E). In some samples that were taken down after one week, 
the alginate was found to be still present inside the tube lumen, even in perforated tubes, 
with hematoma formation at the bone ends (Figure 5.1 F). 
Alginate release kinetics 
The in vitro release of rhMBP-2 from alginate hydrogel plugs was monitored over 
a period of 21 days (Figure 5.1 G). After dissolving the alginate plugs on day 0, 275.5 ± 
15.6 ng rhBMP-2 was detected in the resulting solution, indicating that the functional 
encapsulation percentage was 55.1%. Of the amount encapsulated, 25.8% (71.2 ± 3.8 ng) 
was released in the buffer solution in active form by day 21. The majority of the release 
took place within the first 7 days (98.6% of total released). We also assayed for the 
amount of rhBMP-2 retained in the gels by dissolving them at day 21, and found that 
9.9% (27.2 ± 3.3 ng) of the encapsulated amount was still present in the gels. It is 
possible that the binding of some of the rhBMP-2 molecules to the alginate fibers masks 
the antibody binding site. This subset of rhBMP-2 molecules would not be detected by 












































Figure 5.1. Nanofiber mesh tubes and alginate hydrogel for surgery. (A) SEM image
of electrospun nanofiber mesh illustrating the smooth and bead-free nano-scaled
fibers. (B) Hollow tubular implant without perforations made from nanofiber
meshes. (C) Tubular implant with perforations. (D) Implants in segmental bone
defect. Modular fixation plates are used to stabilize the femur. A nanofiber mesh
tube is placed around the 8 mm defect. In some groups, alginate hydrogel, with or
without rhBMP-2 is injected inside the hollow tube. (E) Picture of defect, after
placement of a perforated mesh tube. The alginate inside the tube can be seen
through the perforations. (F) A specimen was taken down after 1 week and the mesh
tube was cut open. The alginate was still present inside the defect, with hematoma
present at the bone ends. (G) Alginate release kinetics over 21 days in vitro.
Sustained release of the rhBMP-2 was observed during the first week. 
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Radiographs 
Two-dimensional radiographs were taken at 4 and 12 weeks for qualitative 
assessment of bone healing (Figure 5.2). Radiographs at the early time point of 4 weeks 
indicated that Groups I & II (Table 1) specimens had small amounts of bone formation, 
originating from the cut native ends and extending somewhat along the periphery. Group 
I samples were implanted with a nanofiber mesh tube alone, whereas Group II contained, 
in addition, alginate hydrogel inside the mesh tube. On the other hand, samples from 
Groups III and IV, in which 5-µg rhBMP-2 was delivered within alginate, demonstrated 
significant infiltration of mineralized tissue throughout the defect. Group IV specimens 
that were implanted with the perforated mesh tube exhibited the most robust 
mineralization. Group IV demonstrated the highest bridging rate (5/8) at the 4 week time 
point, whereas the remaining 3/8 defects were nearly bridged. Group III had none 
bridged, but 3/6 defects were nearly bridged. At 12 weeks, Groups I and II had still not 
achieved osseous union in any specimen, with most of the bony tissue formed on the 
periphery. In contrast, all specimens in Groups III and IV were completely bridged with 
densely packed bone. 
In vivo µCT imaging 
Animals were scanned in an in vivo µCT system at 4 and 12 weeks for 
quantifying bone formation (Figure 5.3). The three-dimensional µCT images revealed 
that new bone formation in Groups III and IV occurred throughout the cross-section of 
the defect, whereas it appeared predominantly at the native bone margins and the 
periphery in Groups I and II (Figure 5.3 A). The analysis of regenerated bone volumes 
indicated that Groups III and IV (Table 1) had significantly more (a; p<0.05) bone 
formation in the defect compared to Groups I and II, at both time points (Figure 5.3 B). 
At 4 weeks, Group IV, implanted with the perforated mesh, had significantly more (b; 
p<0.05) bone formation than Group III, which contained the mesh tubes without holes. 
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However at 12 weeks, there was no difference in bone volumes between Groups III and 
IV. There was a significant increase in bone volumes with time in Groups I (p = 0.048), 
III (p < 0.001) and IV (p = 0.001), but not in Group II (p = 0.08). Group III (37.65 ± 2.22 
mm3) samples demonstrated the greatest increase in bone volume between 4 and 12 
weeks, followed by Group IV (20.02 ± 2.96 mm3). Compared to these two groups, 
Groups I (3.96 ± 1.40 mm3) and II (2.09 ± 0.80 mm3) had significantly less bone 
accumulation during the same period. 
The density of the newly formed bone within the defect was also calculated at 4 
and 12 weeks (Figure 5.3 C). At 4 weeks, Groups I and II contained higher density bone 
than Groups III and IV (b and c respectively; p<0.05). Group IV samples demonstrated a 
density higher than Group III, at both 4 and 12 weeks (b; p<0.05). There was a significant 
increase in density with time for all groups from 4 to 12 weeks. 
Biomechanical properties 
Torsional testing was performed on extracted femora at 12 weeks to test their 
biomechanical properties (Figure 5.4). Age-matched non-operated femora were also 
tested to obtain properties of native intact bone. The maximum torque and stiffness in 
torsion was calculated from the torque-rotation data. Groups III and IV had significantly 
higher (a; p<0.01) maximum torque and stiffness compared to Groups I and II, as did the 
intact bone. There was no significant difference between Groups III and IV. However, 
compared to the intact bone, only Group IV samples had statistically equivalent 
maximum torque and stiffness, whereas Group III samples had significantly lower 
properties (b; p<0.05). The mechanical properties for Group IV were on average 









Figure 5.2. Representative radiographs at 4 and 12 weeks. Defects in Groups I and II
demonstrated small amount of bone formation, and did not bridge, even after 12 weeks.
At week 4, defects in Groups III samples were infiltrated with considerable bony tissue,
while Group IV samples exhibited the most robust mineralization. All samples in
Groups III and IV were bridged with densely packed bone at week 12. 
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Figure 5.3. µCT analysis of bone regeneration at 4 and 12 weeks. (A) µCT images
illustrate that defects in Groups III and IV were filled with newly formed bone, while
those in Groups I and II possessed limited new bone at the native bone ends and the
defect periphery. (B) Quantification of regenerated bone volume revealed that the
rhBMP-2 groups (Group III and IV) had significantly more bone formation than the
groups without rhBMP-2 (Groups I and II), at both 4 and 12 weeks. Perforations in the
nanofiber mesh tubes accelerated bone formation at 4 weeks (Group IV > Group III).
(C) Mean density of regenerated bone. At week 4, samples in Groups I and II
demonstrated higher density than the other two groups. Density of Group IV samples
was higher than those in Group III, at both time points. (a – significantly different than
Groups I and II; p<0.05); (b – significantly different than Group III; p<0.05). 
 








































I: Mesh alone II: Mesh+Alginate
III: Mesh+Alginate+BMP IV: Perforated-mesh+Alginate
+BMP
Week 4 Week 12 Week 4 Week 12




Figure 5.4. Mechanical properties of femora at 12 weeks. (A) Maximum torque and
(B) torsional stiffness. Mechanical properties in Groups III and IV were significantly
higher than in Groups I and II. Compared to intact bones, Group III samples had
significantly lower properties, whereas Group IV samples were statistically equivalent.
(a – significantly different than Groups I and II; p<0.01); (b - significantly different
than Group III; p<0.05). (I) Mesh alone, (II) Mesh with alginate, (III) Mesh with
















































































Ground MMA sections were stained and analyzed for examining the regenerated 
tissue (Figure 5.5 A and B). The nanofiber mesh tube was partially degraded due the 
MMA processing steps, but is still seen to be located around the defect. In Groups I and 
II, very little mineralized tissue was observed in the defect site at 12 weeks, similar to the 
radiographic and µCT results (Figure 5.5 A: I and II). The defects in these specimens 
were sparsely populated with fibrous tissue. The new bone formation was limited to the 
proximity of native bone ends and along the mesh tube. The end of the defects remained 
disconnected, with the capping of the native ends with bony tissue. The sections from 
Groups III and IV revealed extensive mineral deposition and bony bridging of the defects 
in these groups (Figure 5.5 A: III and IV). The newly formed bone was observed to be a 
combination of immature woven bone and mature lamellar bone. There was good 
continuity of the newly mineralized matrix with the native bone ends. Group IV, in 
particular, demonstrated the presence of a higher amount of lamellar bone, better 
integration at the native bone interface and development of marrow-like tissue. The dark 
areas correspond to undegraded alginate and the partially degraded mesh. The higher 
magnification images of Groups III and IV indicated the presence of osteocytes 
embedded in lacunae and osteoblasts lining the new bone surfaces (Figure 5.5 B). 
Histological analysis performed at 4 weeks revealed no evidence of cartilage tissue 
formation or endochondral ossification, indicating direct, intramembranous bone 
formation within the alginate gel (data not shown). The density maps obtained from the 
µCT indicate good correlation with histology sections (Figure 5.5 C). In addition, Group 
IV appeared to contain higher density mineralized tissue, which was distributed in a 
tubular pattern, similar to that of native cortical structure. 
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Figure 5.5. Histological analysis at 12 weeks. (A) Ground sections were stained with
Sanderson’s rapid bone stain at 12 weeks (4X magnification). Defects in Groups I and
II were sparsely populated with fibrous tissue, with the native ends capped with bony
tissue. Defects in Groups III and IV had extensive bone deposition throughout the
defect, with Group IV samples demonstrating better integration with the native bone.
(B) Higher magnification section, representative of the newly formed bone in Groups
III and IV (10X magnification). White arrows point to osteocytes embedded in
lacunae. Black arrows point to osteoblasts lining the bone surface. Scale bar is 100
µm. (C) Density maps obtained from the µCT analysis at 12 weeks indicate good
correlation with histology sections. The color scale to the right correlates to the
attenuation of bone. Red color indicates higher density bone (higher attenuation),
whereas green color represents lower density bone (lower attenuation). Compared to
Group III, Group IV samples contained higher density bone, distributed along the
native cortices. (I) Mesh alone, (II) Mesh with alginate, (III) Mesh with alginate
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Animals implanted with the rhBMP-2 containing Groups III and IV were 
euthanized at 3 weeks post-implantation, and their hind limb vasculature perfused with a 
radiopaque contrast agent. The femur and the surrounding soft tissues were imaged using 
µCT to quantify vascular ingrowth at an early time point preceding bone regeneration. 
Contours were drawn to define two VOIs. The first VOI included only the volume inside 
the defect region, whereas the second contained both the defect and the periphery of the 
defect, termed the total VOI (Figure 5.6). The analysis of the vasculature revealed the 
presence of vessels, both inside and outside the defect. The majority of the vascularity 
was observed in the periphery, as indicated by the significantly larger vessel volume in 
the total VOI (a; p<0.001). There were no significant differences in vascular volume 





Figure 5.6. Vascular ingrowth at defect site at 3 weeks. Only Groups III and IV were 
included in this experiment. The defect VOI contains only the defect volume, whereas
the total VOI contains the periphery of the defect in addition to the defect. The vascular
volume was found to be significantly higher in the total VOI compared to the defect 
VOI. No significant differences were observed in the presence of perforations. Scale
bar is 1 mm and applies to all images. Peri. – periphery of defect. (a – significantly 
different than the defect VOI; p<0.001). (III) Mesh with alginate containing rhBMP-2, 
(IV) Perforated mesh with alginate containing rhBMP-2. 
 





















































The treatment of large osseous defects remains a challenge for orthopaedic 
surgeons. We have developed a novel growth factor delivery technique for the functional 
repair of large bone defects using an electrospun nanofiber mesh tube and alginate 
hydrogel. Tubular scaffolds constructed from nanofiber meshes were placed around 
segmental defects. Alginate hydrogel containing 5-µg rhBMP-2 was injected into the 
tubes and constrained within the defect site by the mesh tube. Our results demonstrate 
that this technique results in substantial bone formation and complete defect bridging. 
Importantly, samples implanted with both perforated mesh tube and rhBMP-2 containing 
alginate had statistically equivalent biomechanical properties to those of intact age-
matched femora, indicating functional restoration of the limb function. 
The majority of scaffolds proposed for bone reconstruction are structural scaffolds 
designed to support in vivo loads and provide a three-dimensional framework for cell 
attachment. They are examples of “hard scaffolds”, usually made from slowly 
hydrolyzing polymers or ceramics with unpredictable degradation [65, 87, 125]. Though 
they provide a structure for tissue growth, it is difficult to fine-tune their degradation rate 
to match the rate of tissue formation. Oest et al. reported that the use of such a scaffold 
hindered complete bone restoration by occupying space and confining the bone formation 
to the pores and the periphery of the scaffold [74]. The use of structural scaffolds also 
precludes the use of the intramedullary pin for limb fixation, a technique frequently used 
by orthopaedic surgeons. In addition, the regular geometric shape of these scaffolds made 
them unsuitable to be placed inside fractures, which usually have irregular edges. Thin 
scaffold membranes have also been used for bone repair in a procedure termed guided 
bone/tissue regeneration [175, 179]. In this technique, the membranes are positioned on 
the periosteal surface to provide a structure for bone formation. It has been argued that 
while 3-D scaffolds support the ingrowth of cells and tissue, the 2-D membranes may 
also protect the defect from soft tissue ingrowth and guide cell migration from the 
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periosteum [92, 182]. Since the membranes are placed on the periphery of the defect, 
they retain space for bone deposition throughout the defect. However, when a large mass 
of bone is lost, repopulating the entire defect with cells would be a challenge due to the 
presence of a large void. 
Hydrogels are a class of highly hydrated materials that enable cellular and tissue 
infiltration with relative ease [164]. Alginate hydrogels are an example of such a “soft 
scaffold” that can deployed using minimally invasive procedures, conform to the shape of 
the defect and be manipulated by cells during tissue regeneration [165]. In addition, they 
can be used for sustained delivery of osteoinductive growth factors, a typical requirement 
for healing large defects. The primary concern with hydrogels is their inadequate 
mechanical stiffness, which causes them to deform easily under load. 
In this study, we present a novel hybrid technique that utilizes both a nanofiber 
mesh membrane and an alginate hydrogel. The mesh tubes prevent soft tissue 
invagination into the defect and create a space for tissue regeneration. In addition, they 
potentially guide the migration of progenitor cells along the periosteal surface, and retain 
the osteogenic factors within the defect site. However, nanofiber mesh tubes, alone or in 
presence of alginate hydrogel without rhBMP-2, were not sufficient to bridge the 8 mm 
segmental defects in rat femora. Without the presence of the osteoinductive protein, the 
center was only sparsely populated by cells and bony tissue capped the ends of the defect. 
This is not surprising, since previous studies have demonstrated the need for a biologic 
stimulus for effective bone regeneration in this challenging model [74, 278]. A series of 
studies have been performed to investigate the ability of polymer membranes to heal 
segmental diaphyseal defects [92, 181, 182, 284]. Pineda et al. implanted porous 
polylactide membranes thermoformed into tubes in 1-cm defects in the rabbit radius, and 
observed bridging with new endosteal bone generation from the native bone ends [182]. 
However, in more challenging defects in the sheep tibia, bone grafting or a vascularized 
periosteal flap was needed, in addition to a membrane, to heal the defect [93, 183]. 
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In contrast, we found significantly higher bone formation with the sustained 
release of rhBMP-2 from the alginate hydrogel. All defects in the rhBMP-2 groups 
(Groups III and IV) were bridged by 12 weeks with densely packed, cell mediated 
mineralized tissue. This suggests that the release of rhBMP-2 is able to attract 
osteoprogenitor cells into the defect from the adjacent periosteum, marrow and 
vascularized tissues, and induce them to undergo osteogenic differentiation. The release 
of proteins from alginate occurs due to a combination of diffusion and gel degradation. It 
is interesting to note that after 21 days, at least 10% of the functionally encapsulated 
rhBMP-2 was still present in the alginate, though the amount of the protein released at 
this time point was negligible. This suggests that a portion of the protein binds to the 
alginate polymer, which at later time points may be available to the invading cells. It has 
been reported that alginate can reversibly bind proteins like BMP-2 through heparin-
binding domains [285]. The binding of the protein to alginate could be an advantage, as 
this is thought to enhance the biological activity of the protein, perhaps by protection 
from premature degradation [286], and maintain a spatial cue during the tissue 
regeneration process. The RGD functionalized alginate used in this study also supported 
the robust penetration of osteogenic cells and tissue resulting in functional restoration. 
The presence of perforations in nanofiber mesh tubes accelerated early bone 
formation and defect bridging. The utilization of in vivo µCT scanning techniques 
permitted the sequential scanning of animals at multiple time points, and revealed that 
perforations in mesh tubes enhanced bone formation at 4 weeks. However, by 12 weeks, 
the group without perforations (Group III) had comparable bone volume to the group 
with perforations (Group IV). The differences in the bone deposition rate between 4-12 
weeks could be attributed to the fact that at week 4, Group IV defects were almost filled 
with newly formed bone, whereas Group III defects still exhibited substantial space for 
bone formation. Compared to Group III, the density of the newly formed bone was 
significantly higher in Group IV. Also, only Group IV femora demonstrated functional 
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restoration of biomechanical properties. These results indicate that perforations in the 
nanofiber mesh tube expedited bone formation, resulting in advanced bone remodeling 
and improved mechanical properties. Gogolewski and coworkers used a perforated 
membrane along with autologous bone graft for treating segmental defects in sheep 
tibiae, and concluded that the perforations improved bone regeneration by enhancing 
graft survival [93, 183]. They hypothesized that the perforations allow sufficient 
vascularization to develop, while limiting soft tissue ingrowth. 
There are two potential mechanisms that mediate the acceleration of bone 
formation due to perforations in our hybrid delivery system. The perforations may 
enhance invasion of vascularity or improve osteoprogenitor cell migration from the 
surrounding soft tissues into the defect region. We initially hypothesized that perforations 
improve vascular invasion, and employed a µCT-based technique to quantitatively assess 
the vascularity in the early stages of bone regeneration [287]. However, our results 
indicated that the perforations did not have a significant effect on vascularity at the defect 
site. In addition, it was seen that only a fraction of the total vessels were present inside 
the defect. It is possible that the scan resolution was too low to detect the 
microvasculature in the developing bone [288]. The lack of differences in vascular 
regrowth due to the perforations suggests that the acceleration of bone formation was due 
to improved osteoprogenitor cell migration into the defect.  
The current clinical technique for rhBMP-2 delivery involves soaking a collagen 
sponge with rhBMP-2 solution, which primarily relies on the adsorption of the protein to 
collagen [241]. Numerous sustained delivery systems are being currently developed from 
natural and synthetic materials for reducing the high rhBMP-2 dose required clinically 
[91, 100, 289-292]. For example, Johnson et al. obtained the sustained release of rhBMP-
2 without a large burst release by utilizing lipid-based microtubes [289]. A gelatin 
hydrogel engineered for the sustained released of rhBMP-2 resulted in the repair of a 
large ulnar defect [293]. On the other hand, Rizzi and co-workers reported that the 
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physical linkage of rhBMP-2 to a recombinant protein-poly(ethylene glycol) hydrogel 
prevented optimal bone healing of murine cranial defects [169]. This was attributed to the 
inability of the bound rhBMP-2 to be released to provide a chemotactic signal and the 
insufficient degradation of the hydrogel matrix. By providing a sustained and localized 
release of rhBMP-2 and permitting robust cell infiltration, the hybrid alginate/nanofiber 
mesh system creates an environment conducive for bone regeneration. The 5-µg dose 
utilized in this study is in the lower range of what has been reported (2-20 µg) in similar 
models [74, 91, 294, 295]. For example, in a 8 mm rat segmental defect model, 20-µg of 
rhBMP-2 delivered on inactive dimineralized bone matrix was required for defect 
bridging [294]. Future studies will compare our hybrid system with the clinically used 
rhBMP-2 delivery technique to determine the effect of alginate/nanofiber mesh delivery 
on bone repair. 
In conclusion, a novel hybrid growth factor delivery system was presented in this 
study. This system resulted in complete bony bridging of challenging segmental bone 
defects in a rat model. Perforations accelerated the deposition of mineralized tissue, and 
resulted in functional repair, by perhaps improving osteoprogenitor cell migration into the 
defect. The mesh tube alone, or in combination with alginate hydrogel, did not generate a 
strong repair response. The sustained delivery of rhBMP-2 via alginate hydrogel was 
required for substantial regeneration to occur. These results indicate that this hybrid 
technique may be clinically useful for bone regeneration in the case of fracture non-
unions and large bone defects. 
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CHAPTER 6  
DELIVERY OF BONE MORPHOGENETIC PROTEIN WITHIN 
NANOFIBER MESH/ALGINATE ENHANCES SEGMENTAL BONE 
DEFECT REPAIR 
Introduction 
 Large bone defects caused by trauma, tumor resection or disease present a 
significant clinical problem. Current treatments include autologous and allogeneic bone 
grafting, and more recently ceramic and composite substitutes for these [45, 48, 49]. 
Autologous bone grafting remains the gold standard for bone healing because of the rich 
biologic environment it provides, but this treatment modality is limited by the amount of 
graft material available [49, 53]. Furthermore, morbidity of the donor site is a serious 
drawback [52]. Structural allografts have been used as an alternative, but are unable to 
support revascularization and remodeling, and therefore are associated with a high rate of 
complications [54-56]. Bone graft substitutes, made from ceramics or polymers, suffer 
from limited bioactivity, and usually need to be supplemented with osteogenic cells or 
bone graft material [51]. There is, therefore, a tremendous need to find alternatives to 
these treatment options, and biomimetic materials and molecules, which can recruit 
endogenous progenitor cells and provide osteogenic cues, represent a new and promising 
class of therapies for bone repair. 
 The role of bone morphogenetic proteins (BMPs) in bone formation has been 
studied extensively (for reviews, see [19, 29]). BMPs are necessary for fetal tissue 
development as well as for fracture repair [30, 31, 296, 297]. BMPs are present primarily 
in native bone tissue, and serve to attract progenitor cells to the defect site and promote 
their osteogenic differentiation. In the last decade, recombinant human bone 
morphogenetic protein-2 (rhBMP-2) and rhBMP-7 have been approved by regulatory 
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bodies worldwide for spinal fusion, oral-maxillofacial applications and the treatment of 
certain fractures, [101, 241]. However, challenges remain due to the suboptimal delivery 
vehicles, poor spatiotemporal dosage control, short protein half-life, and the cost-
restrictive supraphysiologic concentrations required to initiate cellular responses [63, 
143, 147]. Currently, osteoinductive proteins are delivered in solution on a purified type I 
collagen matrix. However, high doses (3.5 – 12 mg) are required for obtaining a 
substantial healing response. The high doses have resulted in complications arising due to 
diffusion of the BMP away from the defect site [60, 61, 144], and the high cost has 
prevented this treatment from being used routinely [62, 63]. 
 Due to the limitations of the current BMP delivery technique, numerous 
biomaterial-based sustained delivery vehicles are being developed to improve protein 
pharmacokinetics in vivo [289, 290, 293, 298]. Spatial distribution of the protein is also 
important to maximize efficacy and minimize side effects. In a previous study, we 
demonstrated that a hybrid BMP delivery system using an electrospun nanofiber mesh 
tube and alginate hydrogel results in the functional repair of large bone defects (Chapter 
5). In this technique, a nanofiber mesh tube is used to cover the defect region and RGD-
functionalized alginate hydrogel that contains BMP is injected inside the tube. The 
alginate provides sustained availability of the growth factor and supports cell infiltration 
into the defect space, while the nanofiber mesh aids in retaining the hydrogel and growth 
factor within the defect site. 
 The purpose of this study was to compare the hybrid nanofiber mesh/alginate 
BMP delivery technique with the clinical standard of BMP delivery on collagen matrix. 
In addition, the role of the nanofiber mesh tube as a spatial constraint was investigated. 
Our hypotheses were that BMP delivery within alginate hydrogel would enhance bone 
formation, and that the mesh tube would aid in the spatial retention of the regenerated 
bone. To test this hypothesis, we evaluated the structural and biomechanical properties of 
the regenerated bone in a challenging rat segmental defect model. 
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Materials and Methods 
Nanofiber mesh tube fabrication and alginate preparation 
Nanofiber meshes were made by electrospinning and formed into tubes as 
described in Chapter 5. Briefly, a 12% (w/v) solution of poly (ε-caprolactone) (PCL) was 
made by dissolving the polymer in a 90:10 volume ratio of hexafluoro-2-
propanol:dimethylformamide. The following parameters were used during 
electrospinning: flow rate: 0.75 mL/hr; voltage: 13 kV; collector distance: 17 cm; needle 
gauge: 22. Fibers were collected for 6 hours to obtain nanofiber meshes having a 
thickness of approximately 300-400 µm. Perforations measuring 1 mm in diameter and 
spaced approximately 1.5 mm apart were made in rectangular 13 19 mm mesh samples 
using a biopsy punch. The mesh samples were wrapped around a steel mandrel and glued 
using UV glue (DYMAX Corporation, Torrington, CT) to form hollow tubular implants 
having a diameter of approximately 5 mm and 13 mm length. 
Medical grade alginate, MVG (FMC Biopolymer, Philadelphia, PA), was 
irradiated with a 5 Mrad dose of Gamma irradiation, and covalently coupled with RGD-
containing G4RGDASSP peptide sequences. Alginate hydrogels, encapsulating 33.33 
µg/mL rhBMP-2, were prepared in 1 mL syringes at a concentration of 2% (w/v) by 
crosslinking the alginate with calcium sulfate slurry (Chapter 5). For one of the 
experimental groups, the hydrogels were made in the form of cylindrical plugs ( 5 mm; 9 
mm length) by using a custom built mold. 
Animal model and bone regeneration analysis 
A previously described segmental defect animal model [74] was employed to 
compare three different rhBMP-2 delivery methods. Briefly, femora of 13 week old 
female Sasco Sprague-Dawley rats were stabilized with custom fixation plates. Bilateral 
8 mm segmental defects were created in the mid femoral diaphyses with an oscillating 
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saw under irrigation. A 5 µg dose of rhBMP-2 was delivered to each defect in one of 
three different ways shown in Table 6.1. In Group I, a collagen scaffold ( 5 mm; 9 mm 
length) was soaked with 150 µL of 33.33 µg/mL rhMBP-2 solution for 15 minutes, and 
implanted in the defect. The collagen scaffolds were obtained from a fibrous collagen 
sheet (average pore size 61.7 µm, 93.7% pore volume, Kensey Nash, Exton, PA). Group 
II implants consisted of a cylindrical scaffold ( 5 mm; 9 mm length) made from alginate 
containing 5 µg rhBMP-2. In Group III, perforated nanofiber mesh tubes were placed 
around the defect, and injected with 5 µg rhBMP-2-containing alginate using a 22g 
needle. 
Radiographs and µCT images of 8-10 samples per group were obtained at 4 and 
12 weeks to assess bone formation. Radiographs were also taken at 2 weeks to assess 
early differences between groups. In addition to the volume of newly formed bone at 
each time point, µCT data was processed to obtain mean density, connectivity density 
and temporal changes in volume of the regenerated bone. Based on the two dimensional 
scan slices, an appropriate threshold was selected at each time point to detect new bone 
formation. 
Torsional testing was performed on extracted femurs at 12 weeks using a Bose 
ElectroForce system (ELF 3200, Bose EnduraTEC, Minnetonka, MN) to test their 
biomechanical properties. Maximum torque and failure angle were measured at the 
failure point from the torque-rotation data, and the work to failure was calculated using 
these values. Torsional stiffness was calculated by fitting a straight line to the linear 
portion of the curve before failure. Histological analysis was also performed at 12 weeks 
by embedding decalcified femurs in glycol methacrylate (GMA) and staining 5 µm 





Data are presented as mean ± standard error of mean (SEM). Data were analyzed 
using ANOVA and Tukey’s tests for pairwise comparisons (significance set at p<0.05). 
When data were not normal, the nonparametric Mann-Whitney test was used to compare 
between groups. Minitab® 15 (Minitab Inc., State College, PA) was used for all statistical 
analysis. 
Table 6.1. Experimental groups 
Group Description 
Group I Collagen scaffold + 5µg rhBMP-2 
Group II Alginate scaffold + 5µg rhBMP-2 
Group III Perforated nanofiber mesh tube + Alginate + 5µg rhBMP-2 
Results 
Radiographs 
 The radiographs at the early time point of 2 weeks illustrated that, while 
considerable new bone deposition was evident in the collagen scaffold group (Group I), 
the alginate groups (Groups II and III) demonstrated comparatively less bone formation 
(Figure Figure 6.1). In contrast, the radiographs at 4 and 12 weeks revealed that the 
alginate groups exhibited higher amount of bone, though there was substantial bone 
regeneration in all groups at 4 weeks and bridging of all defects after 12 weeks. In 
addition, there were differences in the distribution and density of bone deposition among 
groups. Group I samples appeared to have more trabecular-like bone that was not as 
densely packed as the other two groups. Group II demonstrated mineral deposition both 
within and outside the defect, suggesting some alginate scaffold displacement or protein 
diffusion. In contrast, samples in Group III exhibited consistent localization of dense new 
bone formation inside the defect.  
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Figure 6.1. Representative radiographs at 2, 4 and 12 weeks. At 2 weeks, Group I
specimens possessed more bony tissue in the defect than Groups II and III. However, at
4 and 12 weeks, Group II and III defects demonstrated qualitatively higher bone
formation. All defects in the three groups were bridged with bony tissue by 12 weeks.
The newly formed bone in Groups II and III appeared more densely packed that Group I.
Note that the new bone formation was better contained within the defect in Group III,
with the nanofiber mesh tube. (I) Collagen scaffold + rhBMP-2, (II) Alginate scaffold +
rhBMP-2, (III)  Perforated nanofiber mesh tube + Alginate +  rhBMP-2. 
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µCT analysis 
 The three-dimensional µCT images obtained in vivo at 4 and 12 weeks were 
consistent with the radiographs (Figure Figure 6.2). The collagen scaffold group (Group 
I) demonstrated substantial bone formation in the defects by 4 weeks. Specimens in the 
alginate scaffold group (Group II) exhibited a fragmented distribution of mineralized 
tissue, with substantial bone formation occurring outside the defect region. In contrast, in 
the presence of a nanofiber mesh tube (Group III), new bone formation was confined 
within the defect region and displayed a continuous distribution. 
 µCT analysis determined that the amount and distribution of regenerated bone 
was significantly affected by the rhBMP-2 delivery method. Two volumes of interest 
(VOI) were defined for the quantitative analysis of bone distribution. The central VOI 
corresponds to an interior cylindrical volume that captures the defect. The total VOI 
contains the entire volume of mineralization, in and around the defect, including the 
irregular bone formation outside the defect. At both 4 and 12 weeks, the alginate delivery 
groups (Groups II and III) had significantly more bone formation than the collagen 
delivery groups (Group I) (Figure Figure 6.3 A). The bone volume in the central VOI at 4 
weeks was not significantly higher in Group II compared to Group I; however the p value 
was very close to significance (p=0.051). Although there was no difference between 
Groups II and III at 4 weeks, the central VOI analysis at 12 weeks revealed a significant 
increase in bone formation within the defect region associated with use of the nanofiber 
mesh tube (Group III). However, it was observed that the total bone volume at 12 weeks 
was not significantly different between Groups II and III. The change in bone volume 
between 4 and 12 weeks was calculated for each specimen (Figure Figure 6.3 B). This 
analysis demonstrated that Group III specimens had the largest increase in mineral 
accumulation between the two time points. 
 Mean density and connectivity density of the newly formed bone were evaluated 
at 4 and 12 weeks (Figure Figure 6.4). The results indicate that the mean bone density in 
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Group III specimens was significantly lower than those in Groups I and II, at both time 
points and in both VOIs. There was more than a 50% increase in the density of all groups 
between 4 and 12 weeks, indicating maturation of the mineralized tissue. At 4 weeks, the 
connectivity density in Group III was significantly higher than the other two groups, 
though there were no differences at 12 weeks. Finally, it was observed that the newly 
formed bone in the central VOI displayed higher connectivity density than that contained 
in the total VOI. 
Biomechanical properties 
 Biomechanical properties of the regenerated femurs were obtained from torsional 
testing at 12 weeks. The maximum torque was 58% higher for Group III (alginate + 
mesh) specimens, compared to Group I (collagen) specimens (Figure Figure 6.5). In 
addition, the torsional stiffness and work to failure of Group III specimens were 
significantly higher than those in Group I by 58% and 102%, respectively. Though the 
value of mean failure angle was largest in the case of Group III, there were no significant 
differences between the groups. Importantly, there were no differences in the 
biomechanical properties between Groups I (collagen) and II (alginate). There were no 
significant differences in any of the mechanical parameters between Groups II and III; 
however the mean values of all parameters were higher for Group III specimens. 
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Figure 6.2. Three-dimensional in vivo µCT images at 4 and 12 weeks. There was
evidence of ample bone formation in Group I samples by 4 weeks. Substantial bone
formation in Group II specimens occurred outside the defect. Group III specimens, with
a nanofiber mesh tube, demonstrated continuous cylindrical bone distribution within the
defect. (I) Collagen scaffold + rhBMP-2, (II) Alginate scaffold + rhBMP-2, (III)
Perforated nanofiber mesh tube + Alginate +  rhBMP-2.  





Figure 6.3. Quantitative µCT analysis of new bone volume. Groups II and III had
significantly higher bone formation than Group I at both time points. In addition at 12
weeks, Group III possessed more bone in the central VOI region than Group II,
consistent with the three-dimensional images. Group III also saw the largest increase in
the bone volume between 4 and 12 weeks. * indicates significantly different (p<0.05).
(I) Collagen scaffold + rhBMP-2, (II) Alginate scaffold + rhBMP-2, (III)  Perforated
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Figure 6.4. Mean density and connectivity density of the newly formed bone, obtained
from µCT analysis. Mean density was significantly lower in Group III, compared to the
other two groups at both time points, and in both VOIs. At week 4, connectivity density
was the highest in Group III specimens. * indicates significantly different (p<0.05). (I)
Collagen scaffold + rhBMP-2, (II) Alginate scaffold + rhBMP-2, (III)  Perforated
nanofiber mesh tube + Alginate +  rhBMP-2. 
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Figure 6.5. Biomechanical properties of regenerated femurs at 12 weeks. Group III
specimens demonstrated higher maximum torque, torsional stiffness and work to failure
than those in Group I. * indicates significantly different (p<0.05). (I) Collagen scaffold
+ rhBMP-2, (II) Alginate scaffold + rhBMP-2, (III)  Perforated nanofiber mesh tube +






































































































 This study quantitatively compares a novel hybrid BMP delivery system to the 
current clinical standard for challenging bone defect repair. Compared to delivery on a 
collagen matrix, rhBMP-2 delivered at the same dose via alginate hydrogel resulted in 
enhanced bone formation as early as four weeks. The addition of a perforated nanofiber 
mesh to spatially retain the BMP hydrogel resulted in an increased mineral accumulation 
between 4 and 12 weeks, leading to enhanced bone ingrowth into the defect region at 12 
weeks, compared to all other groups. Finally, biomechanical function was significantly 
improved following treatment with the hybrid nanofiber mesh/hydrogel delivery system, 
compared to collagen matrix delivery.  
 The amount and distribution of newly formed bone was influenced by the BMP 
delivery method. At two weeks, there appeared to a greater amount of mineral deposition 
with the collagen matrix delivery (Group I), compared to the alginate delivery (Groups II 
and III). However, by 4 weeks, the alginate groups demonstrated higher bone volume 
than the collagen matrix delivery, and this trend continued at 12 weeks. These results 
indicate that the kinetics of bone repair is dependent on the delivery system. This 
suggests that, whereas a majority of rhBMP-2 was released from the collagen matrix by 2 
weeks, protein retention at the defect site beyond 2 weeks was improved with alginate 
hydrogel delivery. This is consistent with other studies that report that less than 5% of 
rhBMP-2 is retained within a collagen sponge by 2 weeks in vivo [159, 160]. Addition of 
the nanofiber mesh tube to the alginate hydrogel did not enhance overall bone formation 
that was seen in the total VOI. However, the pattern of bone formation that was observed 
in the alginate group without the mesh tube (Group II) indicated substantial bone 
formation outside the defect region, which implies leakage of the hydrogel and/or protein 
to the surrounding area. Analysis of the central VOI, which excluded this abnormal bone 
formation, revealed that presence of the nanofiber mesh tube (Group III) indeed enhanced 
bone formation within the defect region. This indicates that the nanofiber mesh tube is 
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able to improve the spatial retention of rhBMP-2 within the defect by containing the 
alginate and/or the growth factor. 
 Differences due to the BMP delivery method were observed in mineral deposition 
rate, as well as mineral density and biomechanical properties of the regenerated bone. 
Mineral accumulation between 4 and 12 weeks was highest for specimens in the hybrid 
delivery group (Group III), even higher than the alginate group without the mesh tube 
(Group II). This suggests that presence of the nanofiber mesh tube improves localization 
of rhBMP-2 within the defect site for a longer time period. It is possible that the 
nanofiber mesh tube slows the protein diffusion away from the implant, by perhaps 
binding the protein through nonspecific interactions. In an in vitro study, we observed 
that overnight incubation of a nanofiber mesh sample with a model protein, ovalbumin, 
resulted in 90% of the protein bound to the mesh, which remained attached to the mesh 
even at 1 week (data not shown). As the surface area of the nanofiber mesh is relatively 
large, these interaction effects may have a substantial effect on protein retention. 
Alternatively, the nanofiber mesh tube may function by constraining and therefore 
compacting the BMP-containing hydrogel, which could improve the local retention at 
later time points. In contrast to mineral accumulation, the density of the mineralized 
tissue was lowest in Group III. This suggests that new, immature bone is still being laid 
down in Group III specimens at later time points, which lowers the overall bone density 
in this group. It should be noted that the density obtained from the µCT is the actual 
density of the bone tissue, and not the apparent density of the entire bone. This would 
explain the lower tissue density in Group III specimens, even though the regenerated 
bone in these specimens appeared denser in the radiographs. In spite of the lower tissue 
density, maximum torque, torsional stiffness and work to failure were significantly higher 
in Group III specimens, when compared to those in Group I. This indicates that the 
higher bone volume in Group III compensated for the lower mineral density in 
contributing to the biomechanical properties. It should be noted that the Group III 
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torsional properties exceeded those of age-matched intact femurs determined previously 
(Chapter 5). For example, the mean maximum torque of Group III samples was observed 
to be 0.44 Nm, whereas it was 0.31 Nm in the case of intact femurs. There were no 
significant differences in the biomechanical properties between Groups II and III; 
however the mean values were consistently higher for Group III specimens. This suggests 
that, although there was significantly higher mineralization in Group III inside the defect 
region, the bony tissue outside the defect in Group II contributed somewhat to the overall 
mechanical properties. 
 The connectivity of the regenerating bone was also affected by the protein 
delivery system. Connectivity density is a parameter used to analyze trabecular bone, and 
is a measure of the number of trabeculae in a unit volume [299]. Though regenerating 
bone does not consist of mature trabeculae, the direct mineralization induced by BMPs is 
initiated at discrete locations, which then develop connections as the mineralization 
progresses [13]. The connectivity obtained from the µCT analysis of regenerating bone is 
a measure of these connections. At 4 weeks, Group III specimens demonstrated the 
highest connectivity density, compared to the other two groups, indicating a more 
interconnected bone structure, perhaps because of the spatial guidance provided by the 
alginate hydrogel and the containment effect of the nanofiber mesh tube. Containment 
due to the mesh tube may have facilitated connection of the mineralized nodes formed 
during intramembranous ossification. There were no differences in connectivity density 
at 12 weeks, and the values were uniformly low. This could be due to the fact that as the 
defect fills with bony tissue, the discrete bone initiation centers merge to form a 
continuous volume, which would reduce the connectivity density. 
The results of this study demonstrate that delivery of rhBMP-2 via the hybrid 
nanofiber mesh/alginate system results in improved bone repair compared to delivery on 
a collagen matrix, the technique currently used by orthopaedic surgeons. This 
improvement may be due to the sustained delivery and spatial control achieved by the 
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hybrid system. It should, however, be noted that the processing of the collagen matrix 
used in this study is different than that of the absorbable collagen sponge (ACS) used in 
the clinic, and may affect the BMP delivery. Delivery of BMPs on collagen matrix has 
been shown to result in significant initial burst release, in the range of 40-90% [160]. 
Winn et al. reported that collagen sponges loaded with rhBMP-2 exhibited a continuous 
release for 2 weeks with a half life of 3-5 days in a rat ectopic model; however the long 
term release was not investigated [159]. They hypothesized that rhBMP-2 release from 
the collagen sponge is mediated by desorption of the protein from the collagen, 
degradation of the sponge and solubility of the protein. The binding of rhBMP-2 to 
collagen sponges has been found to be extremely sensitive to pH, suggesting that the 
interaction between collagen and rhBMP-2 is due to electrostatic forces [153]. As 
desorption and collagen degradation is expected to occur rapidly and unpredictably in 
vivo, this suggests that the growth factor may not be available at later time points, when 
delivered by this technique. The ability of alginate hydrogel to maintain sustained 
delivery of protein has been reported in a number of studies [74, 105, 172, 286]. In a 
previous in vitro release study, we observed that approximately 10% of the encapsulated 
rhBMP-2 remains attached to alginate after 3 weeks, though the amount released in the 
media was negligible at this time point (Chapter 5). This suggests that the protein binds to 
the alginate matrix and may be available to invading progenitor cells at later time points, 
which would mean that the function of the alginate hydrogel is more to improve long 
term availability than sustained release. Binding of the protein by alginate may be 
advantageous by protecting it from degradation [285, 286]. Our results also suggest that 
the nanofiber mesh tube may aid in containing the exogenous growth factor within the 
defect region. A couple of recent studies have highlighted the advantage of utilizing a 
‘container’ in retaining biologic factors at the defect site [94, 300]. For instance, Giardino 
et al. demonstrated that when a 400 µm thick poly-DL-lactide tube was utilized to 
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constrain dimineralized bone matrix and bone marrow stromal cells within segmental 
defects, it led to a significant increase in the thickness of newly-formed bone [94]. 
There are a number of drawbacks associated with the use of natural collagen for 
the delivery of rhBMP-2. The collagen matrix is typically obtained from an animal source 
and further crosslinked with formaldehyde to improve its mechanical properties. The risk 
of an immunogenic reaction to collagen or pathogen transmission to the host cannot be 
eliminated [161, 162]. Concerns also persist regarding the heterogeneity of the product, 
as it is derived from animals. In addition, the collagen processing steps such as 
crosslinking and sterilization have a large impact on the interaction of BMPs with the 
collagen matrix, and therefore on the release profile [83, 301]. Crosslinking reduces BMP 
binding; however uncrosslinked collagen degrades faster and leads to a rapid loss of the 
growth factor [301]. These contradictory requirements create challenges in developing an 
optimal delivery system. Finally, loss of the BMP solution when the collagen sponge is 
handled during surgery has to be considered. 
The delivery of BMPs on collagen matrix has been tested in a number of animal 
models of large bone defect repair; however high protein doses are typically required 
[302-306]. For instance, Cuomo et al. reported that delivery of 10 µg rhBMP-2 (double 
the dose used in this study) resulted in bony bridging of a 6 mm rat segmental defect 
[305], which is less challenging than the 8 mm defect we utilized. The injection of 5 µg 
rhBMP-2 in this study is equivalent to a 20 µg/kg dose, which is around 1/5th the clinical 
dose used in humans. It should be noted that sensitivity to rhBMP-2 varies with species; 
however our dose is still low compared to that used in similar models [74, 91, 294, 295]. 
By maintaining sustained and localized availability of rhBMP-2, the hybrid 
alginate/nanofiber mesh system could result in functional bone restoration at a lower 
dose, thereby reducing the cost and complications associated with collagen matrix 
delivery [60, 61]. In conclusion, this study provides promising evidence in a challenging 
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small animal model that spatiotemporal delivery strategies may enhance the therapeutic 
efficacy of BMP for repair of large bone defects. 
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CHAPTER 7  
SUMMARY AND FUTURE DIRECTIONS 
Overall Summary 
 Tissue engineering/regenerative (TE/RM) strategies have demonstrated great 
potential for the repair of bone defects. Such approaches typically involve the delivery of 
biological agents on a carrier scaffold. The function of the scaffold is to provide a 
template for cell guidance and tissue deposition, while biological cues induce a strong 
healing response. Biological agents such as stem and progenitor cells directly participate 
in the tissue regeneration process, and in addition may secrete factors that attract 
endogenous cells. Another set of TE/RM strategies rely solely on the recruitment of 
endogenous cells by the implant. These acellular strategies utilize soluble growth factors 
or biomimetic surfaces to attract and provide specific signals to local cells. The optimum 
combination of scaffolds and biologics may vary with different bone defects and patient 
populations. 
 The goal of this thesis was to investigate the potential of electrospun nanofiber 
mesh scaffolds for bone regeneration. Nanofiber meshes were utilized in a three-pronged 
approach. First, we validated their ability to robustly support osteogenic cell functions, 
including proliferation and matrix mineralization. We also demonstrated their efficacy as 
a cell delivery vehicle (Aim I; Chapter 3). Second, we investigated the effects of 
modulating nanofiber bioactivity and orientation on stem cell programming (Aim II; 
Chapter 4). Our results indicate that functionalization of nanofiber meshes with the 
collagen-mimetic GFOGER peptide enhanced the migration, proliferation and osteogenic 
differentiation of cells. Fiber alignment improved cell migration along the direction of 
fiber orientation. Finally, a nanofiber mesh based hybrid system for growth factor 
delivery was developed for bone repair and tested in a challenging animal model (Aim 
III; Chapters 5 and 6). The delivery of rhBMP-2 via this system resulted in the functional 
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restoration of limb function, and in fact proved more efficacious than the current clinical 
standard for rhBMP-2 delivery.   
Aim I: Nanofiber Meshes for Cell Culture and Delivery 
 The electrospinning techniques developed in Aim I of this thesis were utilized for 
the fabrication of nanofiber meshes in subsequent studies. In this Aim, we also validated 
the ability of nanofiber meshes to support vital osteogenic functions of two stem cell 
types. Finally, in an in vitro study, we demonstrated that a cell-seeded nanofiber mesh 
wrapped around a three-dimensional scaffold can effectively colonize the scaffold. 
Nanofiber mesh as a model cell culture surface 
 Our results provide support to the utilization of electrospun nanofiber meshes as a 
model cell culture surface in vitro. Tissue culture plastic is ubiquitously used for studying 
cell behavior in vitro. However, this culture surface is flat and inert, and does not 
resemble the in vivo ECM milieu that the cell interacts with. In fact, in our studies, cells 
frequently lifted off the tissue culture plastic implying a poor adherence to the surface. 
Cell culture substrates that are structurally closer to the in vivo environment would better 
allow cells to display their native behavior. For example, Matrigel, which is a basement 
membrane ECM secreted by mouse tumor cells, has found acceptance with researchers 
studying the differentiation and invasive activity of tumor cells [307]. Nanofiber meshes 
have fibers in the nanometer range, and scale-wise resemble collagen fibrils in native 
tissue [97]. They can also be manufactured from natural materials like collagen and 
fibrinogen to further imitate the ECM. In our studies, we observed that cells 
demonstrated improved adherence and mineralization on nanofiber meshes. Other studies 
have also demonstrated the advantages of using nanofibrous over flat surfaces in 
supporting cellular differentiation [236, 237]. Future studies could further characterize 
the osteogenic differentiation process on the nanofiber meshes versus tissue culture 
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plastic. This may involve, for example, analyzing differences in adhesion strength [262] 
and osteogenic gene expression [237] due to the culture surfaces. 
Nanofiber Mesh as a Cell Delivery Vehicle 
 The efficient delivery of exogenous cells to sites of injury is one of the main 
stumbling blocks in the commercialization of cell-based therapies. We have engineered a 
periosteum-like tissue by seeding a high density of cells on a nanofiber mesh. This tissue 
engineered periosteum has a cellular and a fibrous layer, much like native periosteum. 
When this construct was wrapped around a collagen scaffold in vitro, with cells facing 
the inside, some cells migrated on to the scaffold and populated it. Compared to the direct 
seeding method, we observed improved viability of cells on the scaffold when they were 
delivered on the nanofiber mesh construct. This may be due to the limited nutrient 
transport to the center of the three-dimensional scaffold, which would result in cell death. 
 The efficacy of the engineered periosteum to deliver cells in vivo needs to be 
investigated in further studies. One limitation of this method is that fewer numbers of 
cells can be accommodated on the nanofiber mesh surface, compared to seeding directly 
on three-dimensional scaffolds. For example, on a 15 10 mm mesh sample, a very high 
seeding density of 200,000 cells/cm2 still results in only 300,000 cells on the mesh. In 
contrast a 4 9 mm scaffold can easily hold 2-4 million cells. However, if a majority of 
the implanted cells inside the scaffold are not able to survive due to the initial lack of 
vascularity [137, 140], the number of cells surviving may turn out to be greater with the 
nanofiber mesh delivery. 
Aim II: Modulation of Nanofiber Mesh Design 
 Though the synthetic random meshes from Aim I supported the osteogenic 
activities of cells, we investigated whether they could be further improved by adding two 
design elements: a biomimetic surface and an oriented topography. First, nanofiber 
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meshes were coated with the collagen-mimetic adhesive peptide, GFOGER. The 
motivation behind this is the fact that the interaction of cells with the GFOGER motif via 
integrin receptors is a critical event in the osteogenic differentiation pathway. We also 
electrospun meshes with fibers aligned along a preferred direction with the expectation 
that the aligned fibers would provide contact guidance thereby improving cell migration. 
Our results are in line with our original conjecture, and demonstrate that GFOGER 
coating enhanced the migration, proliferation and osteogenic differentiation of cells, 
whereas fiber alignment improved cell migration. 
Mechanism of GFOGER action 
 The positive effects of GFOGER on cell function likely occur via the α2β1 
integrin. Future studies could delineate the molecular mechanism of how GFOGER 
potentiates the migration and osteogenic differentiation of cells on nanofiber meshes. For 
example, by using an antibody against the α2 integrin, Reyes et al. demonstrated that the 
adhesion of osteoblast-like cells on GFOGER coated titanium surfaces was specific to the 
α2β1 integrin [121]. It would also be interesting to study the intracellular events that occur 
after the GFOGER-integrin engagement. 
Effect of fiber diameter, surface area and porosity 
 One confounding factor in studying the effects of GFOGER coating and fiber 
alignment was the difference in fiber diameters between random and aligned nanofiber 
meshes. We attempted to maintain similar diameters by changing various electrospinning 
parameters, but were unsuccessful. In addition to the differences in diameters, other 
parameters such as surface area and porosity may also have been affected by the fiber 
alignment. For example, differences in surface area would change the overall surface 
density of the adsorbed GFOGER and collagen, which could have a considerable effect 
on cell function. Unfortunately, it was not possible to calculate these parameters in 
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nanofiber meshes due to the lack of specialized equipment needed to make these 
measurements. Future experiments could further scrutinize the effects of fiber diameter, 
surface area and porosity on cell behavior. 
GFOGER immobilization on nanofiber surfaces 
 An improvement over the passive adsorption of GFOGER may be the 
immobilization of the peptide on the nanofiber surfaces through the primary amine 
terminal [251]. This would result in the peptide being orientated in a specific direction, 
making the cell recognition site highly accessible, and thereby improve peptide activity. 
In contrast, in the passive adsorption method that was utilized in this study, the peptide 
can adopt a range of orientations, some of which could mask the cell recognition site. The 
immobilization scheme would, in addition, prevent desorption of the peptide from the 
surface, which could result in longer term signaling. 
Promoting in vivo bone regeneration with nanofiber mesh tubes 
 Despite the substantial improvement in cell migration and differentiation in vitro, 
GFOGER coating did not enhance bone regeneration in vivo. GFOGER coated nanofiber 
mesh tubes did not result in the bridging of segmental bone defects. The likely 
explanation is that the nanofiber mesh tube alone is not able to provide the structure for 
bony bridging in this challenging 8 mm defect. With the inside of the defect kept empty, 
the cells from the periosteum and bone ends are perhaps not able to migrate to the defect 
center. As the hematoma is limited to the bone ends, there is a large void at the defect 
center that cannot support cell colonization. It is still surprising that improved mineral 
deposition was not seen even on the surface of the GFOGER coated tubes.  
 It is possible that smaller defects (5-6 mm) may see a benefit simply due to a 
nanofiber mesh tube. Guided bone regeneration of diaphyseal defects solely by the 
placement of membranes on the periosteal surface has been reported in literature, though 
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the defects have been relatively small [180, 182, 284]. A future strategy could involve the 
tethering of a growth factor like rhBMP-2 on the nanofiber mesh surface. The presence of 
this potent osteoinductive protein may generate a strong healing response despite the 
empty center. The binding of  rhBMP-2 to the nanofiber surfaces could be achieved by 
using di-NH2-PEG and heparin as linkers [265]. 
 The addition of a RGD conjugated alginate hydrogel inside the nanofiber mesh 
tube also did not result in defect bridging (Chapter 5). This implies that a strong 
osteogenic stimulus is required throughout the defect in this model. One approach future 
studies could take is the covalent conjugation of the GFOGER peptide with alginate, 
which would be injected inside a GFOGER coated tube. This would ensure the presence 
of the osteoinductive peptide at the defect interior and periphery. Another method for 
improving bone formation could be the placement of a GFOGER coated structural 
scaffold inside the nanofiber mesh tube. 
 Aim III: Nanofiber Mesh/Alginate Growth Factor Delivery System 
 From the in vivo studies in Aim II, it was clear that in order to repair a large 
diaphyseal bone defect, a scaffolding material containing a strong biologic stimulus 
would need to be present inside the nanofiber mesh tube. Therefore, a novel hybrid 
growth factor delivery system was developed in this study. This system consists of 
placing a nanofiber mesh tube around the bone defects, and injecting alginate hydrogel 
that contains rhBMP-2 inside the tube. The utilization of this system resulted in bony 
bridging of challenging segmental defects in vivo. However, a number of parameters need 
to be examined to optimize the repair process. 
The role of perforations in defect healing 
 A perforated mesh tube design resulted in the acceleration of bone formation over 
a non-perforated mesh tube. We originally hypothesized that this acceleration is due to 
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the improved vascular invasion of the defect site through the perforations. However, µCT 
analysis of the vascular ingrowth at the defect site at 3 weeks by using a radiopaque 
contrast agent did not support this hypothesis. In fact, very little vascularity was detected 
inside the defect volume at this time point. This is surprising as significant bone 
formation is observed by 4 weeks. In tissue development, the deposition of bony tissue is 
preceded by cell migration and condensation. It is possible that the cell migration in our 
system occurred, not via the vasculature, but due to the chemotactic attraction of rhBMP-
2. If true, this would also support the hypothesis that the perforations in the mesh 
enhanced the migration of progenitor cells from the surrounding soft tissues. Given that 
perforations in the mesh tube improved bone regeneration, it would be interesting to 
fabricate nanofiber meshes from a polymer which degrades faster than PCL, such as 
Poly(lactic-co-glycolic acid) (PLGA). The faster degradation of PLGA mesh tubes may 
enhance vascular ingrowth and/or progenitor cell migration into the defect. 
 It would be interesting to analyze the vascular ingrowth at a later time point, 
following substantial bone formation. This may also prevent the problem of contrast 
agent leakage that was observed in some samples, which occurred perhaps due to the 
immature vessels at the early time point. A resolution of 21.5 µm was utilized for the 
vascular analysis in order to maintain a balance between image resolution and 
computational power. It is possible that a higher resolution of 10 µm would permit better 
detection of the microvasculature. However it has been reported previously that the 
higher resolution did not significantly alter the vascular volume, though it affected other 
parameters like connectivity and vessel thickness [107]. 
Mechanical stimuli and tissue remodeling 
 The delivery of rhBMP-2 in the nanofiber mesh/alginate system resulted in the 
robust bridging of segmental bone defects by 12 weeks. In fact, almost the entire defect 
space was occupied by bony tissue, though there was some marrow development. Though 
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the mechanical properties exceeded those of intact femurs, the cortical structure of the 
femur diaphysis was not restored. This was not surprising considering that the 12 week 
time point is still short for significant remodeling events to occur. In addition, the 
continued presence of the stable fixation plate does not permit the mechanical loading of 
the bone, an important for remodeling. Other studies in our laboratory are being 
performed to provide mechanical stimuli in this model by utilizing compliant fixation 
plates [308]. To investigate the remodeling at late time points, we extended our 
observation period on a few animals (n = 3) up to 22 weeks. The radiographic images 
over the entire course of the study revealed that the majority of the new bone was 
deposited by 8 weeks, and no gross remodeling or resorption took place up to 22 weeks 
(Figure 7.1). To investigate whether the restored limb may be able to bear physiologic 
loads, we removed the polysulfone plate that stabilizes the defect at 22 weeks. We 
observed that not only did the limb not collapse after plate removal, but the animal started 
putting full weight on that limb and resumed normal ambulation a few weeks later. This 
indicates that in addition to regaining the original mechanical properties, the limb is fully 
functional again. This is a remarkable achievement and a first, in our laboratory at least. 
Surprisingly, even 4 weeks after the plate removal, there did not appear to be major signs 
of remodeling of the regenerated bone at the whole bone level, despite the existence of 
direct mechanical stimuli. Future studies could investigate this further using µCT to 
analyze any microstructural changes and at later time points after plate removal. 
Growth factor dosage 
 In all our in vivo studies with the nanofiber mesh/alginate system, a 5 µg dose of 
rhBMP-2 was selected to demonstrate the feasibility of this system. This dose is in the 
lower range of what has been reported in literature (2-20 µg). In addition, most rat 
femoral defects are 5-6 mm, less than the 8 mm defects used in this study. Previous 
studies in our lab have delivered 2 µg rhBMP-2 in alginate hydrogel, though they utilized 
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a slow degrading three-dimensional scaffold [107]. In addition to the partial bridging 
observed with this dose, comparisons of the torsional testing results with respect to the 
nanofiber mesh/alginate system indicate much lower mechanical properties. In view of 
the robust bridging observed in our studies, an important question is: what is the lowest 
dose of rhBMP-2 that can be delivered in the hybrid system while still obtaining 
consistent defect bridging? We have conducted a preliminary study (n = 1) in which a 
dose of 1 µg rhBMP-2 was delivered via the hybrid system. The results indicate that 1 µg 
rhBMP-2 was sufficient in robust bridging the defect (Figure 7.2). However, compared to 
the 5 µg dose, bone volume appeared to be lower. As the torsional properties of 
regenerated femurs with the 5 µg dose exceeded those of native femurs by approximately 
33%, the reduced bone volume at the 1 µg dose may still lead to properties equivalent to 
native femurs. Future studies could investigate this dose dependency, and establish the 
minimum rhBMP-2 dose required to be delivered through the hybrid system. If these 
studies can obtain consistent bridging with even 1 µg rhBMP-2, it will be the lowest dose 
reported in the literature for healing femoral diaphyseal defects [74, 91, 294, 295]. A 
lower dose of BMP than the 3.5-12 mg currently used in humans would decrease the cost 




Week 4 Week 12 Week 22
Week 26
(4 weeks after 
plate removal)
Week 8
Figure 7.1. Long-term observation of a regenerated femur. In a preliminary study, one
specimen was observed beyond the usual 12 weeks of observation. At 22 weeks, the 
polysulfone plate was removed to enable loading of the regenerated femur. The
specimen was observed for a further 4 weeks, up to a total of 26 weeks from the
original surgery. No significant change in bone volume or distribution is seen beyond
8 weeks, even after loading. The loaded femur did not collapse and remained intact. 
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Week 4 Week 12
1 μg rhBMP-2
5 μg rhBMP-2
Figure 7.2. Dependence of rhBMP-2 dose on segmental bone defect repair. In a
preliminary study, we investigated whether a lower dose of rhBMP-2 would lead to
defect bridging. A dose of 1 µg rhBMP-2 was sufficient in to heal the defect, though
the bone volume appeared to be lower than in the case of the 5 µg rhBMP-2 dose. 
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Growth factor delivery considerations 
 The performance of the alginate hydrogel in delivering rhBMP-2 in our studies 
warrants further discussion. In the in vitro release study, of the 500 ng rhBMP-2 that was 
added to the alginate, only 276 ng was recovered immediately after gelation, indicating 
that the functional encapsulation percentage was 55%. It is possible that the binding of 
some rhBMP-2 molecules to the alginate matrix prevents the detection of the protein by 
the antibody, even after dissolving the hydrogel. In this case, the actual encapsulation 
percentage will be higher than what the ELISA results suggest. An alternative 
explanation for the low encapsulation percentage in our studies could be the denaturation 
of the rhBMP-2 due to the high shear forces applied during the crosslinking step.  
 The binding of rhBMP-2 to alginate could also be part of the reason why only 
26% of the encapsulated protein is released to the buffer. A recent study estimated the 
total in vitro release of another protein, VEGF, from a similar alginate hydrogel to be 
40% of the total amount over 21 days [286]. It should however be noted that a 
radiolabeled VEGF was utilized in this study for protein detection, instead of an ELISA. 
This also brings into question the ability of the antibody based ELISA to detect alginate-
bound protein after its release into the buffer. The other potential reason for the low 
release percentage is that the remaining protein is denatured or degraded by the time it is 
released, and therefore not detected. Interestingly, we noted that 10% of the protein was 
found to be still present inside the hydrogel at 21 days. As the half life of rhBMP-2 in its 
free form is relatively short, this suggests that a substantial amount of the protein binds to 
the alginate matrix and is protected from degradation. This could explain why we obtain 
robust bone formation with the alginate/nanofiber mesh rhBMP-2 delivery at later time 
points, even though the encapsulation percentage was low and majority of the release 
occurred within the first week. It should be kept in mind though, that the release study 
was done in vitro, and may not correspond to the in vivo release due to differences in 
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numerous conditions. Future studies could investigate the in vivo retention of the protein 
at the defect site by using a radioactive label on the protein [159, 160]. 
 Due to the relatively low functional protein encapsulation percentage and the non-
optimal release kinetics of alginate, it may be replaced by another hydrogel in the hybrid 
system. Another drawback of alginate is inability to support cell-mediated remodeling 
and breakdown, even with RGD functionalization. Histological images revealed the 
continued presence of alginate in the defect at 12 weeks, even though the low molecular 
weight formulation we utilized degrades faster. This could be explained by the fact that in 
vivo degradation is highly dependent of the local environment, and the isolated alginate 
islands within the dense bone matrix remain trapped there. In fact, the gross observation 
of the newly formed bone reveals a granular consistency of the mineral, perhaps due to 
the presence of the residual alginate islands. Hydrogels constructed from biomaterials 
that have better cell compatibility and degrade faster, such as collagen and gelatin, may 
be used to replace alginate. For example, Tabata and coworkers have developed gelatin 
hydrogels for growth factor release, which have demonstrated in vivo degradation and 
release profiles suitable for tissue regeneration [67]. Another advantage of gelatin is its 
long history of clinical use.  
Delayed growth factor delivery 
 The timing of the growth factor delivery is another factor that future studies could 
investigate. It is well known that the first phase of the fracture healing process consists of 
an inflammatory response, which lasts for around one week. However, during this time, 
majority of the growth factor is released from the delivery system, despite the fact that 
the defect site is not yet ready for osteogenic activities. Therefore, a substantial portion of 
the exogenous growth factor is probably wasted, which would explain the 
supraphysiologic doses of BMPs needed to generate a strong repair response. The 
delayed delivery of BMPs to bone defects, after the subsidence of the inflammatory 
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process, could improve the healing efficiency by presenting the growth factor only when 
the injury site is ready to respond to it. The hybrid nanofiber mesh/hydrogel system is 
conducive to delayed delivery because the nanofiber mesh tube maintains space and 
prevents invagination of soft tissue in the defect, for at least 2 weeks. The growth factor-
hydrogel can be injected inside this space at the later time point using minimally invasive 
procedures. This delayed delivery system could result in a further reduction in the 
rhBMP-2 dose required for successful bone repair. This hypothesis is supported by the 
recent data reported by Betz et al., which demonstrate an improvement in segmental bone 
defect repair, when the percutaneous injection of adenoviral BMP-2 vector was delayed 
until 5 or 10 days after defect creation [309]. 
Conclusions 
 Though TE/RM approaches have demonstrated significant promise for bone 
regeneration, very little has been translated to clinical practice. The studies performed in 
this thesis have suggested novel techniques for improving the repair of clinically 
challenging bone defects. The central theme of our work consists of delivering bioactive 
molecules on electrospun nanofiber meshes. We have validated our approach in a 
challenging small animal model, and demonstrated that a hybrid nanofiber mesh/alginate 
delivery system performs better than the current clinical system for BMP delivery. Our 
results indicate that the delivery of BMP via the hybrid system may reduce the dose and 
side effects of BMP, thereby broadening the use of BMP based bone augmentation 
procedures. The utilization of a small animal model permitted quantitative µCT analyses 
of bone regeneration that enabled us to identify the best configuration for protein 
delivery. The hybrid system has to be tested next in a large animal model before initiating 
clinical trials. If proven successful in these studies, our protein delivery system has the 
potential to become the standard of care for clinically challenging bone defects, including 
large bone defects, open tibial fractures, and nonunions.  
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APPENDIX A 
NANOFIBER MESH PROTOCOLS 
A.1 Electrospinning Nanofiber Meshes 
Supplies 
– 5 ml Syringe 
– 22 Gauge needle tip  
– Solution: 12 w/v % PCL in 90/10 hexafluoro-2-propanol/dimethylformamide 
(HFP/DMF). Using a stir bar, start with mixing HFP and DMF (add DMF 
gradually). Then add PCL. Keep overnight. Use within 1-2 days. 
Procedure 
1. To change infuse rate: press “set” then “infuse rate” 
2. To change diameter: press “set” then “diameter” 
3. Put the plate at a certain distance from the surface 
4. Put the voltage source around the needle tip. 
5. Push the setup such that the needle goes inside. 
6. Put an aluminum foil paper so the mesh is deposited on it. 
7. Put a towel paper before you start up so the first spray will go on it. 
8. Click on run  
9. Once you see the solution coming out of the needle tip, click voltage on. 
10. Continue increasing the voltage until a drop forms at the needle tip and 
doesn’t drop. The drop should form a cone; if the drop is big, increase voltage. 
11. Check on the mesh every 1-2 hours to ensure drop is still the right size. 




Typical Electrospinning Parameters 
– Needle gauge: 22 
– Distance:  20-23 cm 
– Flow rate: 0.75 ml/hr 
– Voltage: 13-20 kV 
– Electrospinning time:  5-6 hours (gives thick enough mesh for surgery) 
 
A.2 Fabrication of Perforated Nanofiber Mesh Tubes 
Supplies 
– Thick mesh 
– Petri dish (10 cm) 
– Ethanol absolute (200 proof) 
– Biopsy punch (dia = 1 mm) 
– Steel mandrel (dia = 4.5 mm) 
– UV glue (Dymax 1187-M-VT) 
























           
2. Wrap the above rectangular piece of mesh around the steel mandrel over the 
longer edge to form a cylinder having an inner diameter of 4.5 mm and 13 mm 
length. Close the overlapping edge with the UV glue. Use a 25g needle to 
draw a line of UV glue on the edge, and cure it with the lamp. 
3. Wash the tubes in ethanol 2X and sterilize by ethanol evaporation overnight in 
petri dish. 
4. Add sterile 70% ethanol to the petri dish to wet the tubes. Keep for 30 
minutes. 
5. Wash 3X with excess of PBS. 










   1.5 mm 
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A.3 Nanofiber Mesh Sample Preparation and Cell Culture 
Fabricating nanofiber meshes and preparing samples for cell culture 
1. Electrospin meshes of desired thickness, alignment, and fiber diameter. We 
typically make meshes from poly (ε-caprolactone) (PCL). 
2. (Optional): Obtain SEM images of the meshes to confirm fiber diameter and 
alignment. 
3. Nanofiber meshes can be stored long term in a desiccator to minimize 
exposure to moisture. 
4. Cut the meshes to the desired size/shape using a ruler and scissors. The mesh 
can be placed face down, and the desired size/shape can be marked on the 
aluminum foil. Be careful not to put too much pressure on the mesh. Use 
another piece of foil on the bottom so that the mesh is resting on a smooth 
surface. If circular samples are required, a biopsy punch of appropriate 
diameter can be used. The biopsy punch allows for more accurate control of 
sample area, but thick meshes are somewhat difficult to punch out. We usually 
use either 1X1-cm rectangular samples or 12-mm diameter circular sample. 
5. To separate the mesh from the aluminum foil, immerse the meshes in 70/30 
(v/v) ethanol/water solution in a Petri dish. Reagent alcohol can be substituted 
for pure ethanol. Once wet with the solution, separate the mesh from the foil 
using fine tipped forceps. Touch the mesh only at the edges to minimize 
damage and indentation marks on the mesh. Thick meshes may have some air 








1. Transfer the meshes from the Petri Dish to sterile plates using forceps in a 
laminar flow hood. We use 24-well low cell attachment plates, so that the only 
surface the cells can attach to is the mesh. 
2. Submerge the meshes in 200 proof ethanol (in 24-well plates, 500 uL is 
enough).  
3. Let the ethanol evaporate completely in the hood overnight. After this the 
mesh is considered sterile. 
 
Cell seeding and culture 
1. After ethanol evaporation, the mesh will be dry. Submerge the meshes in 
sterile 70/30 (v/v) ethanol/water solution for 2-3 minutes. This will help wet 
the mesh before adding media – PCL is quite hydrophobic initially.  
2. Aspirate the ethanol/water solution. If the mesh samples tend to float in the 
well, place a sterile dead weight on the mesh edges to keep them on the 
bottom of the well. We use sterile stainless steel staples for this purpose. 
3. Wash the meshes at least three times with excess PBS to remove any residual 
ethanol. Leave the meshes submerged in PBS until cells are ready to seed. At 
this point, the meshes can be coated with collagen, fibronectin or any other 
adhesive molecule to improve cell attachment. 
4. Prepare culture media and cells.  
5. Aspirate the PBS and replace with desired amount of culture media (we use a 
total of 1 mL per well in 24-well plates – therefore we add 800 µL of media in 
this step and seed cells in 200µL in the next step).  
6. Seed cells at a density of 10,000-40,000 cells/cm2. We usually seed at a 
density of 20,000 cells/cm2 for differentiation studies. The area is based on the 
well bottom area and not the mesh area. Cells will sit on the well bottom 
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surface as well, but if low attachment plates are used, then they will be able to 
attach only to the mesh. 
7. Incubate for 2-4 days before any media change. We usually seed the cells in 
growth media and change to osteogenic media after 3-4 days. This is 
considered day 0 for osteogenic differentiation. 
8. Change media every 3-4 days or as required for the specific cells used. 
9. Take down samples for various assays between 0-5 weeks. We usually do 
DNA and ALP assays from 0-5 weeks, and calcium assays from 3-5 weeks. 
For the calcium assay, it is good to have an appropriate acellular or non-
mineralizing cell control to eliminate the possibility of non-cell mediated 
mineral deposition. FTIR can also be performed to evaluate physiologic 
nature of the deposited mineral. 
 
A.4 Infiltration Assay 
Fabricating and preparing meshes 
1. Electrospin meshes of desired thickness, alignment, and fiber diameter 
2. (Optional): Obtain SEM images of the meshes to confirm fiber diameter and 
alignment 
3. Cut the meshes to the desired size/shape using a ruler and scissor.  
4. To separate the mesh from the aluminum foil, immerse the meshes in 70/30 
v/v ethanol/water solution in a container (i.e. in a petri dish). Once wet with 
the solution, separate the mesh from the foil using forceps (be careful not to 






1. Transfer the meshes from the container to sterile plates (we use 24-well plates, 
non-TC) using sterile forceps in a sterile hood. 
2. Submerge the meshes in sterile 70/30 v/v ethanol/water solution (in 24-well 
plates, 500 uL is enough).  
3. Ethanol-dry the meshes in the hood overnight.  
 
Autoclaving 
1. Autoclave the required number of sterile stainless steel strips (we use 0.9 mm 
wide strips) and “holding strips” (we use stainless steel staples); one holding 
staple and one strip per mesh. Also autoclave forceps.  
 
Cell seeding and infiltration 
1. Submerge the ethanol-dried meshes in sterile 70/30 v/v ethanol/water solution 
for 2-3 minutes.  
2. Wash the meshes at least three times with excess PBS to remove any residual 
ethanol. Leave the meshes submerged in PBS until cells are ready to seed.  
3. Prepare culture media. 
4. Prepare cells.  
5. Aspirate the PBS and replace with desired amount of culture media (we use 1 
mL per well in 24-well plates).  
6. Place the holding staples on the meshes and the strips in the center of the 
meshes.  
7. Seed cells at 40,000 cells/cm2.  
8. Incubate for 24 hours.  
9. Remove the strip to create the region of no cells.  
10. Observe infiltration into the gap using DAPI staining.  
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APPENDIX B 
CELL FUNCTION ANALYSIS PROTOCOLS 
B.1 Extraction of DNA and ALP 
Collection of mesh samples 
1. Wash 3X with PBS on shaker plate. 
2. Pick mesh up with forceps and place in eppendorf tube containing 0.5 ml of 
0.05% Triton X-100/PBS. 
3. Store samples at -80C (or -20C) if needed, or continue with the lysis. 
 
Cell lysis 
1. Add plenty of dry ice to the bottom of an ice bucket.  
2. Add methanol to the bucket till it is 2-3 cm. above the dry ice, and allow the 
methanol to become cold for around 5 minutes. (Solution is cold enough when the 
contents of the tubes freeze within 3-5 minutes.) 
3. Immerse the rack with eppendorf tubes into the methanol for ~5 minutes making 
sure the methanol is just below the cap. 
4. Once the samples have frozen, remove them from the dry ice/methanol, and place 
them in a water bath containing water at room temperature. Allow samples to 
thaw completely. 
5. Vortex vigorously. 
6. Repeat steps #3-5 for a total of 3 freeze and thaw cycles. 




B.2 ALP Assay 
Solutions/Reagents 
REAGENT 
Recipe for working 
solution 
1. 2-Amino-2-Methyl-1-Propanol (AMP) 
      Stock: ct# A65182; liquid; MW 89.14; density     
      0.934 g/mL; in the dry chem. shelf 
      Working solution: 1.5 M balance to pH 10.25 with 
      HCl; store at 4C; good for 2 months 
7.18 mL/42.82 mL 
(3.59 mL/21.41 mL) 
(in DDI water) 
(pH to 10.25) 
2. Sigma 104 phosphatase substrate/p-Nitrophenyl  
      phosphate disodium hexahydrate (pNPP) 
      Stock: ct# 1040/ (new-P4744); crystalline; MW  
      371.14; in the PCR room freezer 
      Working solution: 20 mM; store at 4C;  
      protect from light; good for one month 
371.14 mg/50 mL 
(185.57 mg/25 mL) 
(in DDI water) 
(protect from light) 
3. MgCl2  
      Stock: ct# M4880; powder; MW-95.22; in the dry 
      chem. shelf 
      Working solution: 10 mM; store at 4C; good for  
      one week        
47.61 mg/50 mL 
(in DDI water) 
4. NaOH 
      Stock: 10 N 
      Working solution: 1 M; prepare 0.1mL/well;  
      prepare fresh each day; maintain at room              
      temperature  
2 mL/18 mL 
(in DDI water) 
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5. 0.05% Triton X-100 in PBS 
0.25 mL Triton X-
100 to 500 mL PBS 
6. Substrate working solution (AMP-pNPP-MgCl2) 
      Working solution: prepare fresh from above    
      solutions each day; 0.05mL/well (except   
      standards); maintain at room temperature 
Combine #1,#2 and 
#3 in a 1:1:1 ratio 
7.    p-Nitrophenol standard (pNP)  
       Stock: ct# N7660 (10 mM) 
       Working solution: 800µM (Maximum standard); 
       stored at 4C; protect from light  
 
80 µL/920 µL 
(in 0.05% Triton-X 
100 in PBS) 
 
Procedure 
1. Extract ALP by freeze/thawing (ALP-DNA extraction for mesh.doc), and store at 
-80C. 
2. Thaw extracted samples at room temperature, and put on ice. 
3. Dilute samples in 0.05% Triton X-100/PBS, if needed. 
4. Prepare pNP standards in microcentrifuge tubes as follows:  
a. Dilute 80 µL of 10 mM pNP standard in 920 µL of 0.05% Triton X-
100/PBS to get the 800 µM standard. 
b. Make an additional six serial dilutions in 0.05% Triton X-100/PBS, and 








5. Pipette 50 µL of each standard in triplicate in rows A-H columns 1-3 of a clear 
Costar 96-well plate. Do this in the dark to protect from light. 
6. Pipette 50 µL of each experimental sample in triplicate to the appropriate wells of 
the 96-well plate. 
7. Add 50 µL of substrate working solution to all the wells containing the standards 
and experimental samples. Use either the repeater or the multipipetor. 
8. Incubate at 37C for 1-3 hours. Watch for color change to yellow, and remove 
from incubator when color change is seen in majority of the wells. Note 
incubation time. 
9. Immediately add 100 µL of the NaOH solution to all the wells containing the 
standards and experimental samples, and read at 405 nm. 
 
Notes 
– If enzyme is present at a high concentration, it may need to be diluted. At high 
enzyme concentrations all the substrate may be used up, and a saturation point 
will be reached before the end of the assay. 
– All groups from one experiment need to be assayed at the same time to enable 
comparison. This is due to the fact that there may be subtle differences in the 
substrate working solution from lot to lot that may cause large differences in pNP 
produced in the same time period. 
pNP stds (µM, 
nmol/mL) 800 400 200 100 50 25 12.5 0 
Final pNP conc 
in 200 µl (µM) 200 100 50 25 12.5 6.25 3.125 0 





20 10 5 2.5 1.25 0.625 0 
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– By comparing the absorbance of the sample with the standards, we are able to 
find out how much pNP has been produced by the enzyme in our samples. The Y 
axis will be nmol of pNP produced by the enzyme (i.e. enzyme activity) in 500 
µL of sample. The ALP enzyme is stable for 48 hours at 4C, and a few months at 
-20C. 
B.3 DNA Assay 
Solutions/Reagents 
– PicoGreen dsDNA quantification kit (molecular probes cat# P11496) 
– PicoGreen dsDNA reagent 
– lambda DNA standard (100 ug/ml) 
– 20X TE buffer (200mM tris-HCL, 20 mM EDTA, pH 7.5) 
– 0.05% triton-X100 in PBS 





1. TE buffer  
        - 20X in kit; dilute to 1X 
        -  ~0.4mL/sample for dilution + ~10mL for standards 
          + PicoGreen reagent volume                
5 mL to 95 mL 
DNase-free water 
(2.5/47.5) 
2. PicoGreen dsDNA reagent 
       - dilute 1: 200 from kit; protect from light     
       - 0.1mL/well            
0.1 mL to 19.9 mL 
1X TE 
(0.05/9.95) 
3.   Lambda DNA standard 
       - 100 µg/ml in kit; dilute to 1 µg/mL    
0.015 mL to 1.485 




1. Extract DNA into solution (by proteinase K digestion, freeze thaw etc.). 
2. Thaw samples at room temperature. 
3. Dilute samples in 1X TE to get <1000 ng/mL (<130,000 cells/mL). (For 24-well 
studies, 1:10 has been an appropriate dilution. Pipette 40 µL of sample into 360 
µL of 1X TE.) 
4. Prepare lambda DNA standards (this will be enough for 3 plates only): 
µL of 1 µg/mL 
DNA 
1000 100 10 1 0 
µL of assay 
buffer 
0 900 990 999 1000 
DNA (ng/mL) 1000 100 10 1 0 
 
5. If available, prepare standards from a known amount of cell suspension (e.g. 
1e6/mL; enough for 3 plates): 
µL of  1e6 
cells/mL 
100 10 1 
µL of assay buffer 900 990 999 
Cells (cells/mL) 100,000 10,000 1,000 
 
6. Prepare PicoGreen working solution. This solution should be used within a few 
hours of its preparation. 
7. Pipette 100 µL of standards and samples in triplicate to a black Costar 96-well 
plate. 
 164
8. In the dark, add 100 µL of working reagent to all the wells containing the 
standards and experimental samples. Use either the repeater (with the 5mL tip) or 
the multipipetor. 
9. Incubate for 5 minutes at room temperature, protected from light. 
10. Read the plate using the Perkins-Elmer HTS 7000 fluorescent plate reader at an 
excitation of 485-nm, emission of 535-nm and manual gain of 60 using the 
HTSoft program.  Ensure that the reader is set for the Costar 96-well black plate 
(cos96fblk). 
Notes 
– Standards should be made up in the same solution that the assay samples are in. It 
is called the assay buffer in this protocol. For e.g. if the samples are in 0.05% 
Triton X-100, and I dilute them 1:10 in 1X TE, then make a 1:10 dilution of 
0.05% Triton X-100 in 1X TE, and use this to make the standards. This is because 
the fluorescence intensity can change due to the presence of these other 
compounds. 
 
B.4 Calcium Assay 
Solutions/Reagents 
– PBS 
– 1N acetic acid 
– Calcium reagent (Arsenazo III, Diagnostic Chemicals Limited # 140-24 (1L)) 
– Calcium standard (1 mg/ml) 
 
Procedure 
1. Wash samples 3X with calcium free PBS. 
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2. Remove samples from wells/plates and place in microcentrifuge tube with 500 
μL of 1N acetic acid. 
3. Vortex samples overnight in refrigerator. 
4. If needed, spin samples down in small centrifuge on maximum speed for 8-10 
minutes, and remove supernatant into fresh tubes. 
5.  Prepare standards (maximum 100 μg/mL, and 6 serial dilutions; in 1N acetic 
acid). 
6.   Pipette 25 µL of standards and samples in triplicate to a clear Costar 96-well 
plate. 
7. Add 300 μL of reagent to each well (dilute samples if color change is more than 
maximum standard). 
8. Incubate for 30 seconds at room temperature. 
9. Read samples on plate reader at 650 nm (color is stable for 30 minutes). 
 
Notes 
– For cells in plates, put acid in plate overnight at 4C. Next day use cell scraper to 
scrape off the cells, and transfer cells and acid to microcentrifuge tubes. Vortex 
samples overnight in refrigerator. 
– Store samples at -20C. 
– According to the reagent manual, when using 20µL of sample and 2 mL of 
reagent (1/100 ratio), the assay is linear up to 200µg/mL. The linearity will 
depend on the ratio of sample/reagent used. When using the ratio above, the 
relationship is linear for < 20 µg/mL, but a quadratic equation fits the standards 
very well. A fourth order polynomial equation fits the standards almost perfectly. 
– In the case of the ratio above, the saturation limit of the assay is ~175 µg/mL. 
– To figure out the dilutions required for each group, you can compare color change 
in 1-2 samples from each group with the standards using n=1.  
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B.5 Calcein Staining 
Solutions/Reagents 
– PBS without Ions (PBS-) 
– Calcein (Sigma # C0875-5G) 
– Make 1 mg/ml solution of calcein in PBS-. Not all calcein will go into 
solution. Mix well, and immediately dilute 1:10 in PBS- to get a 100µg/ml 
stock solution. Confirm that the pH is between 7.0-7.4. Sterile filter, wrap 
container with foil, and store at 4C. 
– bisBenzimide H 33342 trihydrochloride (Hoechst 33342) (Sigma # B2261-
500MG) 
– Make 10 mg/ml stock solution of the dye in DI water. Dilute 1:1000 in DI 
water to get a working solution of 10 µg/ml. 
 
Procedure 
1. On the take-down day, add calcein to the media such that the final concentration 
is 10 µg/ml. (for example, add 333µl of 100 µg/ml calcein to 3 ml media.) 
2. Incubate for 4 hours in the incubator. 
3. Wash 2X with PBS-. 
4. Fix cells with 10% neutral buffered formalin for 10 minutes. 
5. Wash 2X with DI water. 
6. Add 10 µg/ml Hoechst dye solution, and incubate for 30 minutes at room 
temperature. 
7. Wash 2X with DI water. 






– As an alternative to the 4 hour incubation, you can use 1 µg/ml calcein and 
incubate the cells for 24 hours. If continuous monitoring is required, 1 µg/ml 
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